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Preface
Atherosclerotic disease is the most common origin of cardiovascular disorders giving 
rise to the leading cause of death of adults living in the western world. Atherosclerosis 
is a complex ongoing disease starting early in the twenties and involving many risk 
factors ultimately leading to unstable atherosclerotic plaques, ischemia, infarction 
and eventually death. Treatment options are generally available and include drug 
therapy to influence features like hypercholesterolemia, diabetes and hypertension 
as well as prevention of thrombus formation. Interventions are also possible with 
percutaneus revascularization techniques or more invasively with bypass grafting 
of coronary or peripheral arteries. End stage atherosclerotic disease leading to 
permanent damaged solid organs as seen after massive myocardial infarction may 
require organ transplantation. 
Unfortunately the long term results of these interventions are compromised by 
renewed narrowing of either the former dilated lesion after percutaneus angioplasty 
(restenosis), the venous bypass graft (graft failure) or the smaller arteries in the solid 
grafts (transplantation arteriosclerosis). The linking factor between these different 
modalities is neointimal hyperplasia which is the major cause of restenosis, graft 
failure and transplantation arteriosclerosis. Although subject of study for several 
years the exact factors influencing neointimal hyperplasia are still not completely 
elucidated. Recent epidemiological associations and pathological evidence have 
suggested a role for micro-organisms like Cytomegalovirus and Chlamydia pneumoniae 
on the process of intimal hyperplasia. 
Whether these pathogens play a causal role or are just present as an innocent 
bystander has remained rather unclear and is subject of this thesis. In addition 
we investigated a novel therapeutic gene based approach of preventing intimal 
hyperplasia.
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General introduction
1. Cytomegalovirus
1.1. Characteristics of cytomegalovirus
The human herpesvirus family consists of nine members: herpes simplex virus 
types 1 (HSV-1) and 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus 
(EBV), cytomegalovirus (CMV), human herpesvirus 6 (variants A and B), human 
herpesvirus 7, and Kaposi’s sarcoma virus or human herpesvirus 8. CMV belongs to the 
betaherpesvirinae together with alphaherpesvirinae and gammaherpesvirinae one 
of the three subfamilies within the family of herpesviridae.The alphaherpesvirinae, 
HSV-1, HSV-2 and VZV are characterized by an extremely short reproductive cycle 
(hours), prompt destruction of the host cell, and the ability to replicate in a wide 
variety of host tissues. They characteristically establish latent infection in sensory 
nerve ganglia. The betaherpesvirinae, CMV and HHV-6 and HHV-7 have a restricted 
host range. Their reproductive life cycle is long (days), with infection progressing 
slowly in cell culture systems. A characteristic of these viruses is their ability to form 
enlarged cells, as exemplified by CMV. These viruses can establish latent infection 
in secretory glands, cells of the reticuloendothelial system, and the kidneys. The 
gammaherpesvirinae, EBV and HHV-8 have the most limited host range. They replicate 
in lymphoblastoid cells in vitro and can cause lytic infections in certain target cells. 
Latent virus has been demonstrated in lymphoid tissue (Roizmann 1992). 
1.2. Structure and replication of cytomegalovirus
The virus has a unique four-layered structure: a core containing the large linear 
double-stranded DNA genome of 229 kb with a molecular weight of 150-155×106 Da. 
The genome contains two unique segments, US (short) and UL (long), one internal 
repeat and two terminal repeat sequences enclosed by an icosapentahedral 
symmetric capsid with a diameter of 100-110 nm which is composed of 162 capsomers. 
The capsid is tightly surrounded by an amorphous protein coat called the tegument. 
Loosely surrounding the capsid and tegument is a glycoprotein-bearing lipid bilayer 
envelope derived from host cell membranes. Several host proteins have been found 
in the envelope, among them annexin and beta-2 microglobulin (Wright 1995, Grundy 
1987). 
CMV encodes for many proteins that are non-essential for virus replication but 
are important to establish life long persistence in its host (Chee 1990, Mocarski 2001, 
Griffiths 1997).During CMV infection virtally all cells of the body can be infected 
including: fibroblasts, endothelial cells, monocytes/macrophages, epithelial cells 
and smooth muscle cells. The virus behaves differently in different cell types. 
In some cells such as fibroblasts a fully permissive replication with production of 
infectious virus occurs while in other cells such as monocytes the infection is 
restricted to early events and no infectious virus is produced. Since it is known that 
fibroblasts are fully permissive cells for CMV replication these cells have been used 
as model to study the entry and replication of the virus. The virus enters these cells 
by attachment to extracellular heparan sulfate. When the viral envelope fuses with 
the host cell membrane, the nucleocapsid and the tegument proteins are released 
into the cytoplasm of the cell. The tegument contains proteins capable of trans-
activating viral genes. Transcription, genome replication, and capsid assembly 
occur in the host cell nucleus. In a productive infection genes are replicated in a 
specific order: (1) immediate-early (IE) genes, which encode regulatory proteins and 
act as trans-activators for many cellular promoters and (2) early (E), genes which 
encode enzymes for replicating viral DNA and in turn activate (3) late (L) genes, 
which encode structural proteins and proteins which play a role in the assembly of 
the virus. Assembly of the viral core and capsid takes place within the nucleus. The 
tegument and envelope are acquired as the virion buds out at the nuclear membrane 
and during transport out of the nucleus through the endoplasmic reticulum and the 
Golgi complex. Glycosylation of the viral membrane occurs in the Golgi apparatus. 
Mature virions are transported to the outer membrane of the host cell inside vesicles. 
Release of progeny virus is accompanied by cell lyses (Compton 1993, Mocarski 2001, 
Mettenleiter 2002, Homman-Loudiyi 2003).
A unique characteristic of the herpesviridae is their ability to persist in the host in a 
quiescent state or so called latent infection. Viral latency is defined as the persistence 
of the viral genome in the absence of production of infectious virions, but with the 
ability of the viral genome to reactivate under specific stimuli. All herpesviruses have 
the potential to establish latency in specific host cells, and the latent viral genome 
may be either extra-chromosomal or integrated into host cell DNA. HSV-1, HSV-2 and 
VZV all establish latency in the dorsal root ganglia. EBV virus can maintain latency 
within B lymphocytes and salivary glands, while CMV, HHV-6 and HHV-7 have relatively 
unknown sites of latency. Monocytes are responsible for dissemination of the virus 
and are also thought to be the predominant cell for latency (Taylor-Wiedema 1991). 
The precise cellular sites in which CMV is carried and the mechanisms regulating its 
latency and reactivation remain poorly understood. CMV can be transmitted by blood 
transfusion and leucocyte depletion reduces the risk of infection suggesting strongly 
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that one site of carriage of this virus was in the peripheral-blood compartment (Adler 
1983, de Graan-Hentzen 1989). By using highly sensitive polymerase chain reaction 
(PCR) strategies, a number of laboratories have demonstrated the presence of CMV 
DNA in the peripheral blood leukocytes of healthy individuals and it has now become 
clear that especially peripheral blood monocytes are a major site of of CMV carried 
in a true latent state, with little or no accompanying viral IE expression (Prosch 1999, 
Taylor-Wiedema 1991, Söderberg 1993). Wether there are other sites of latency or 
long term-carriage of CMV is still matter of debate. Especially vascular cells such as 
smooth muscle cells and endothelial cells have been suggested to be a reservoir of 
latent virus, perhaps providing support to the evidence that has linked CMV infection 
to atherosclerosis (Jarvis 2002, Hendrix 1990). 
1.3. Epidemiology and clinical presentation of cytomegalovirus infection
CMV is found universally throughout all geographic locations, and seroepi-demiological 
studies have demonstrated a high prevalence of antibodies against HCMV up to 50% 
till 85% of all individuals. The seroprevalence depends on socioeconomic state and in 
western countries the seroprevalence increases with 10% every decade resulting in a 
total prevalance of 85% by the age of 75 (Staras 2006). 
In adults transmission of CMV occurs from person to person mainly during sexual 
interplay or by contact with young children. Infection requires close, intimate 
contact with a person excreting the virus in saliva, urine, or other body fluids. 
CMV can be sexually transmitted and can also be transmitted via breast milk, 
transplanted organs and by blood transfusions. The immune status of the host is an 
important determinant in the clinical course of CMV infection. Most infections in 
immunocompetent individuals are subclinical although some persons may experience 
symptoms resembling infectious mononucleosis, with prolonged fever, nausea, 
fatigue, pharyngitis, mild hepatitis and occasionaly rash. Suggestive laboratory 
findings include atypical lymfocytosis, abnormal liver functions and thrombocytopenia 
(Klemola 1973, Jordan 1973). 
Although CMV is not associated with clinical apparent disease in non immuno-
suppressed hosts it may cause severe symptoms in immunosuppressed patients. In 
newborns severe infections with clinical findings as hepatitis, splenic enlargement 
and central nervous systems disease are reported. Infection of the developing fetus 
in utero (congenital infection) is characterized by high levels of replicating virus in 
many organs (Boppana 1997, Boppana 1992).
CMV infection is the most common congenital infection in humans. Between 1 
and 2% of the infants born are infected in utero and an additional 8 to 60% of the 
newborns become infected in the first months after birth mainly due to infection 
occurring during labor or breastfeeding. Infants and children who get CMV infection 
after birth have few, if any, symptoms or complications. When symptoms do appear, 
they are generally mild and include lung problems, poor weight gain, swollen glands, 
rash and jaundice. In rare cases newborns can have a life-threatening infection 
mostly acquired in utero during primary infection of the mother. Up to 30% of these 
infants become infected in utero if the mother is found to be CMV IgM seropositive 
or if IgG seroconversion is present. In this group 5 to 18% is symptomatic at birth 
resulting in a severe congenital CMV disease characterized by hepato-splenomegaly, 
prolonged jaundice, petechia and pneumonitis. Other consequences of intra-
uterine CMV infection are fetal growth retardation, pre-term birth and intra-uterine 
death resulting in a mortality of almost 30%. Survivors are confronted with a high 
morbidity of 80% and may suffer from severe neurological impairments including 
microencephalopathy, cerebral palsy, mental retardation, delayed psychomotor 
development and often sensor neural hearing loss. Many of these children require 
custodial care for life, with significant public health implications (Stagno 1982, 
Stagno 1983, Revello 2004).
CMV disease is a well-known cause of morbidity and mortality in people with 
weakened immune system as seen for example in solid organ and bone marrow 
transplant recipients and in patients with AIDS. The pathogenesis of CMV infections 
in these immunosuppressed hosts is related to the level of virus replication in several 
organs (Emery 1999, Gewurz 2001). 
The manifestation of CMV infection is not only dependent on the viral burden 
but a lot of variables, such as severity of immune suppression, past experience of 
the host with the virus (primary infection, donor seropositivity and recipient sero-
negativity), play a role in the pathogenesis. In transplant recipients the degree of 
major histocompatibility complex mismatch has also an influence on pathology of 
CMV disease. In general primary infection results more often in severe symptomatic 
CMV disease compared to re-infection. Symptoms also tend to be more pronounced 
in heart, liver and lung recipients compared to kidney transplant recipients, in whom 
immunosuppressive regimens are less rigorous. In addition to symptomatic CMV 
infections, CMV may predispose the transplant recipients to bacterial and fungal 
infections (Rubin 1990). CMV infections also play an important role in allogenic bone 
marrow transplant recipients. The loss of immune response in these patients has been 
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shown to lead to uncontrolled virus replication leading to massive and widespread viral 
dissemination. Especially the loss of T-cell reactivity is responsible for reactivation 
of CMV and for the development of disease (Reusser 1997). Reactivation of CMV in 
already seropositive recipients is common occurring in up to 65% of those patients 
(Miller 1986). In contrast to the high prevalence of CMV infection the frequency of 
serious CMV disease has been reported to be considerably lower, generally occurring in 
about 2 to 8% in bone marrow transplant recipients. Immunotherapy with CMV-specific 
CD8 T-cells provided passive protection in these patients (Walter 1995, Boeckh 2003). 
The most severe manifestations of CMV disease after bone marrow transplantation 
are interstitial pneumonia and less common gastrointestinal involvement leading to 
gastrointestinal haemorrhage and CMV hepatitis which may result in a high mortality 
rate of 80% despite antiviral treatment (Konoplev 2001, Enright 1993).
Virtually every HIV infected adult is CMV seropositive and shedding of infectious 
virus is common. Generalized infection with viraemia occurs frequently at low CD4+ 
T-cell numbers but the clinical presentation of CMV infection in immunosuppressed 
individuals differs between organ transplant recipients and AIDS patients. In the latter 
CMV commonly infects the retina of the eye (CMV retinitis) and cause blindness, but 
also gastrointestinal involvement, encephalitis and polyradiculopathy are frequently 
reported in these patients. Occurrence of CMV pneumonia results in a high fatality 
rate and is often complicated by other opportunistic pathogens, in particular 
Pneumocystis carinii, however the incidence of CMV disease seems to be declining 
since the introduction of highly active antiretroviral therapy (HAART) that include 
protease inhibitors (Accorinti 2006, Gross 1990, Schooley 1990).
Over the years an increasing amount of evidence emerged linking CMV to cardio-
vascular pathologies especially atherosclerosis. In 1987 a study was published showing 
a higher incidence of CMV antibodies in patients with severe atherosclerosis needing 
a surgical revascularisation than in control patients (Adem 1987). A more causal 
role of cytomegalovirus and atherosclerosis was suggested by Nieto and co-workers 
who showed in a cohort study a relation between the development of an aggraveted 
intimal-medial hyperplasia in the carotid artery and the presence of a higher amount 
of CMV antibodies 15 years earlier (Nieto 1996). Besides its role in atherosclerosis CMV 
is a significant post-allograft pathogen and contributes to more frequent rejection 
episodes, increased transplant related arteriosclerosis, and subsequent graft loss 
after cardiac transplantation (Grattan 1989). 
CMV has been also frequently associated with inflammatory bowel disease (IBD) 
especially in steroid treatment resistent cases (Adani 2001). In some cases, CMV 
infection is associated with a poor outcome but it is not clear which patients are 
more likely to be affected and in which stage of the disease. The use of anti-viral 
therapy in IBD may be benificial but still is controversial and an empirical study with 
controls is lacking (Kishore 2004, Kandiel 2006).
1.4. Treatment of Cytomegalovirus infection
No treatment is generally necessary for CMV infection in the healthy individual since 
the majority of infections resolve on their own. Before the introduction of specific 
antiviral drugs against CMV hyperimmune globulin was used to prevent CMV disease 
in transplant recipients. However CMV hyperimmune globulin has been found by 
some investigators to be ineffective in the treatment of CMV disease in solid-organ 
transplant recipients (Burdelski 1987). 
Nowadays ganciclovir treatment is the drug of choice used for patients with 
depressed immunity who have either sight-related or life-threatening illnesses. The 
orally applicable valine ester of ganciclovir: valganciclover is also frequently used 
(Curran 2001, Baldanti 1996, Matthews 1988). It is a prodrug which is phosphorylated 
to ganciclovir 5’-monophosphate by a protein encoded by the UL97 open reading frame 
of human CMV and then to the di- and triphosphate forms by host cellular kinases. The 
active drug inhibits viral replication by competing with deoxyguanosine triphosphate 
as a substrate for the enzyme DNA polymerase. The incorporation of ganciclovir 
triphosphate into the growing chain of viral DNA slows extension, thus inhibiting 
viral replication. Adverse effects of ganciclovir when administered to solid-organ 
transplant patients are less frequent than in bone marrow transplant recipients and 
AIDS patients. They include leukopenia, thrombocytopenia, anaemia, eosinophilia, 
bone marrow hypoplasia, haemolysis, nausea, infusion site reactions, diarrhoea, renal 
toxicity, seizures, mental status changes, fever, rash, and hepatocellular dysfunction 
(Buhles 1988, Pava 2004, European/Australian comparative study of efficacy and 
safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS, 
1995).
Other anti CMV drugs are foscarnet and cidofovir. They do not require a viral 
function for activity. Foscarnet or cidofovir can be given in patients with CMV resistant 
to ganciclovir, though foscarnet is not as well tolerated as ganciclovir. Foscarnet is an 
inorganic pyrophosphate analogue that does not need to be phosphorylated into an 
active form by viral or host cell enzymes. It selectively inhibits viral DNA polymerase 
and is virostatic (Ringden 1986, Baldanti 2004). 
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Cidofovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, a nucleotide 
analogue of dCMP, is a novel agent that has been introduced to the antiviral pharma-
copoeia (De Clercq 1987). Unlike ganciclovir, cidofovir does not require viral enzymes 
for activation. It is used almost exclusively for the treatment of CMV infection in 
patients with AIDS. A major drawback of cidofovir is its associated nephrotoxicity; this 
can be partially averted by the concurrent administration of probenecid. Neutropenia 
and constitutional reactions to probenecid may be encountered. 
Novel antiviral compounds such as benzimidazole, adefovir, and lobucavir might 
further improve the management of CMV infection (Zhou et al. 1997, Xiong et al. 
1997, Tenny et al. 1997). Moreover, antisense oligonucleotides complementary to RNA 
transcripts of IE genes provide a novel mechanism of inhibition for viral replication 
(Anderson 2004). 
Ultimately, control of CMV infection, particularly the devastating sequelae of 
congenital CMV disease, depends on immunization. The major target population for 
a CMV vaccine is women of childbearing age, in addition a vaccine can also be useful 
in controlling CMV disease in organ transplant recipients. A live attenuated vaccine, 
the Towne vaccine, showed promising results for prevention of CMV disease in studies 
involving renal transplant recipients. However, the Towne strain of CMV is poorly 
immunogenic, probably because it has been attenuated during the process of tissue 
culture passage (Plotkin 1994, Plotkin 2004). Newer technologies using recombinant 
chimeric viruses that represent genetic hybrids between Towne virus and a low-
passage clinical isolate, the Toledo strain, are currently under investigation as the 
next generation of live-virus CMV vaccines. Subunit vaccine approaches are also 
being explored. In these vaccines molecularly cloned eucaryotically expressed forms 
of the major immunogenic CMV envelope protein are used. Another approach is the 
vectored vaccine approach in a genetically engineered poxvirus vector, canarypox, is 
also under evaluation. In addition to gB, this approach targets the major CTL target, 
the UL83 gene product (Gonzol 2001, Berencsi 1996, Pass 1999). Although there is no 
doubt about the importance to have a CMV vaccine a lot of work has still to be done 
before a vaccine will be available.
2 Chlamydia pneumoniae
2.1. Characteristics of Chlamydia pneumoniae
Since 1989 Chlamydia pneumoniae (C. pneumoniae) has been recognized as the third 
species in the genus Chlamydia. C. pneumoniae was first isolated from the conjunctiva 
of a child in Taiwan in 1965 and was established as a major respiratory pathogen in 
1983 when it was isolated from the throat of a college student at the University of 
Washington (Grayston 1986). The family Chlamydiaceae consists of genus Chlamydia 
(C. trachomatis, C. suis and C. muridarum) and genus Chlamydia (C. pneumoniae, 
C. psittaci, C. abortus, C.  caviae, C. felis and C. pecorum) (Everett 1999). Three of 
these species are known to infect humans. C. trachomatis, which can cause urogenital 
infections, trachoma, conjunctivitis, pneumonia and lymphogranuloma venereum, C. 
psittaci, which can cause pneumonia (psittacosis) and C. pneumoniae. C. pneumoniae 
causes approximately 10% of community-acquired pneumonia and 5% of pharyngitis, 
bronchitis, and sinusitis. Most infections caused by C. pneumoniae however are sub-
clinical or are characterized by mild flu-like symptoms (Hammerschlag 2002, Kuo 
1995). 
2.2. Structure and replication of Chlamydia pneumoniae
Chlamydiae are small obligate intracellular pathogens and were once considered to be 
viruses. However, they contain DNA, RNA and ribosomes and make their own proteins 
and nucleic acids and are now considered to be true bacteria. They possess an inner 
and outer membrane similar to those of gram-negative bacteria (Cook 1994). 
The development of Chlamydia occurs in the cytoplasm of the cell. Chlamydia 
exists in two forms: a small (0.3-0.4 μm) transmissible form called elementary body 
(EB) and a larger intra-cellular metabolic form called reticulate body (RB) (Ward 
1988). The EB is metabolically inert and exists outside of cells. The ultrastructure of 
Chlamydiae is characterized by a peer-shaped EB. Chlamydiae do not contain a cell 
wall, but the outer membrane of the EB contains a number of cysteine containing 
proteins that are heavily cross-linked by disulfide bonds. This stabilizes its outer 
surface and enables it to survive outside a host. The genome of an EB is densely 
packed. This is facilitated by histone-like proteins that bind to the DNA and cause it to 
aggregate inside the EB. Infection of the host cells occurs by attachment of the peer-
shaped EB to the cell’s membrane, followed by invagination and endocytosis (Kuo 
1988). Inside the host cell the EB differentiates to a metabolic active RB which is the 
replicative form. In the RB, DNA is not bound to histones, and many more ribosomes, 
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mRNA and proteins are found. After two to four days RB mature into EB and cell 
lyses occurs giving rise to free EB able to infect other cells. C. pneumoniae is able to 
infect a diversity of cell types like macrophages, endothelial and smooth muscle cells 
(Gaydos 1996). 
2.3. Epidemiology and clinical presentation of Chlamydia pneumoniae 
infection
Transmission occurs from person-to-person by respiratory secretions. All ages are 
at risk. Seroprevalence of antibodies is common and increases with age (Grayston 
1992). Antibodies against C. pneumoniae are rare in children under the age of 5, 
but common in school-age children. At the ages of 7 and 8 years already 10% of the 
children have C. pneumoniae antibodies often without a history of clinical respiratory 
infections (Volanan 2003). In the United States, about 50% of adults have antibodies 
against C. pneumoniae Antibody prevalence continues to increase slowly to 70% to 
80% at ages 60 to 70 (Grayston 1986). Recurrent C. pneumoniae disease is common 
and may result from either repeated infections or persistence of the organism after 
unresolved infections. However the high incidence of C. pneumoniae infections and 
transient immunity observed after infection posses difficulties in differentiating 
between persistent infection and re-infection (Patnode 1990). 
C. pneumoniae is a well known cause of community acquired respiratory tract 
infections (Grayston 1993). The clinical symptoms of C. pneumoniae pulmonary 
infections are similar to those caused by most other respiratory pathogens; the 
main difference is the ability of C. pneumoniae to cause chronic complications. The 
spectrum of illness can range from asymptomatic infection to severe disease wherein 
subacute onset and pharyngitis are common. In young children C. pneumoniae is 
associated with upper respiratory tract infections like rhinitis, sinusitis and acute 
tonsillopharyngitis which left untreated may predispose to lower respiratory tract 
infections (Norman 1998, Esposito 2006). A biphasic pattern of disease is observed 
in adults, with pharyngitis resolving before bronchitis or pneumonia develops. 
Cough is very common and prolonged. Pneumonia is often relatively mild, although 
approximately 50,000 individuals are hospitalized with this illness in the U.S. every 
year. Recovery is often slow, even with antibiotic therapy and cough and malaise may 
persist for many weeks (Kauppinen 1995). 
In addition to these acute infections, C. pneumoniae is also associated with 
a range of chronic diseases that are characterized by persistent inflammation and 
scarring and may result in significant damage to the host. Here, C. pneumoniae seems 
to be present in a persistent state. Persistence is characterized by modified bacterial 
metabolism and morphology, as well as a reversible arrest of chlamydial development 
until reactivation takes place (Beatty 1994). In particular peripheral blood monocytes 
are able to harbour persistent C. pneumoniae which renders it relatively refractory 
to antibiotic treatment (Gieffers 2001). In cell culture, this persistent state can be 
induced by gamma interferon. C. pneumoniae is able to cause long-lasting changes 
in the expression of genes involved in anti-apoptosis, cell cycle control, and host cell 
metabolism in gamma interferon induced persistence (Eickhoff 2007). 
Unresolved respiratory C. pneumoniae infection or persistent chronic infection 
may contribute to the pathogenesis of several chronic inflammatory lung diseases, 
such as asthma and chronic obstructive pulmonary disease (Gencay 2001, Blasi 1993). 
In addition to pulmonary consequences, C. pneumoniae can also disseminate from 
the site of initial infection and has been associated with cardiovascular diseases 
like atherosclerosis myocarditis, vasculitis and myocardial infarction (Tong 1995, 
Ljungstrom 1997, Kuo 2003, Saikku 1988). Moreover presence of C. pneumoniae was 
detected in atherosclerotic lesions of coronary arteries as well as carotid arteries 
and lesion progression could be reduced with antibiotic treatment (Kuo 1993, Sander 
2002).
Besides cardiovascular diseases chronic C. pneumoniae infection has also been 
linked to late-onset Alzheimer’s disease and other clinical syndromes like erythema 
nodosum, sarcoidosis, multiple sclerosis and reactive arthritis (Balin1998, Yucescan 
2001, Hannu et al. 1999, Stratton 2006, Gaede 2002, Erntell 1989).
2.4. Treatment of Chlamydia pneumonia infection
C. pneumoniae infections are susceptible to antibiotics that inhibit protein synthesis 
such as tetracyclines, macrolides and quinolones. Doxycycline is the treatment of 
choice except in children younger than 9 years and pregnant women. Treatment 
should be continued for at least 10-14 days after defervescence. If symptoms persist, 
a second course with a different class of antibiotics is usually effective. Alternatives 
include erythromycin and newer macrolides such as azithromycin and clarithromycin. 
Newer macrolides are better tolerated than erythromycin. Shorter courses of 
the newer macrolides appear to be effective. Telithromycin is the first antibiotic 
in a new class called ketolides and is approved for C. pneumoniae pneumonia. 
Fluoroquinolones, including levofloxacin and more recent ones as gemifloxacin 
and moxifloxacin also have some activity, although less than that of tetracyclines 
or macrolides (Kauppinen 1995, Hammerschlag 1992, Miyashita 2002, Riog 2006). In 
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addition vaccines are curently under development and have been shown effective in 
animal models (Thorpe 2007).
3 Cytomegalovirus and Chlamydia pneumoniae in  
 arterial restenosis
3.1. Arterial restenosis
Coronary artery stenosis, resulting from advanced atherosclerosis, is commonly 
treated with percutaneous transluminal coronary angioplasty (PTCA) and stenting. 
Unfortunately, the initially high success rate is in 30-50% of all cases compromised 
in the long run by the problem of restenosis, a renewed narrowing of the formerly 
dilated vessel (Glagov 1994). Despite intensive investigation, the exact underlying 
pathological mechanisms and causal factors still have to be elucidated. Pathological 
processes underlying atherosclerosis and restenosis resemble but are not identical. In 
contrast to atherosclerosis, which is considered as an ongoing chronic inflammatory 
disease that develops over decades, restenosis is initiated by an acute mechanical 
injury to the vessel wall resulting in luminal narrowing within a period of several 
weeks to months (Schwartz 2002). Neointimal hyperplasia is a major factor in the 
restenosis problem, although other factors might be equally important (Tanaka 
1995). Additional factors include thrombus formation, intimal and medial dissections 
and elastic recoil of the arterial wall. Recent epidemiological studies indicated that 
infectious agents, like Helicobacter pylori, C. pneumoniae and CMV may increase 
the risk of restenosis after PTCA, although reported results have not always been 
consistent (Horne 2002, Anderson 1995, Patel 1995). Below, we will briefly discuss 
this possible role of both CMV and Cpn in restenosis.
3.2. Cytomegalovirus and arterial restenosis
In 1996, it was Epstein and co-workers who first reported that prior infection 
with CMV might be a strong independent risk factor for restenosis after coronary 
atherectomy (Zhou 1996). Additional evidence has been provided by Blum et al. who 
demonstrated that high antibody titers against CMV correlated with the prevalence of 
coronary artery disease and predicted post PTCA restenosis (Blum 1998). Even after 
aggressive ballooning with coronary stenting, patients with prior CMV infection had a 
smaller permissive lumen and a higher restenosis rate at six month after intervention 
(Mueller 2003). However, not always was CMV IgG seropositivity found to carry an 
increased risk of restenosis after stenting (Neumann, 2001, Schiele 2001). 
Concerning the underlying mechanisms, it has been speculated that angioplasty-
induced injury to the vessel wall reactivates latent CMV (Guetta 1997). Then, once 
reactivated, the virus causes excessive accumulation of SMCs in the developing 
neointima and thereby contributes to restenosis. Molecular mechanisms involved 
in this process may include including inhibition of p53 function (which could 
enhance SMC proliferation or inhibit apoptosis), an increase in cytokine expression 
and coagulability of CMV-infected endothelial cells with an increased platelet and 
monocyte adhesion or the substantial up-regulation of the beta-receptor of platelet-
derived growth factor in SMC with an increased proliferative activity following 
stimulation (Tanaka 1999, Speir 1994, Span 1991, Reinhardt 2005). Also the marked 
degradation of the extra-cellular matrix due to a reduction in collagen type I and 
fibronectin synthesis as well as the enhanced MMP-2 protein production and activity 
following CMV infection of SMC might be a factor in the augmented response to 
injury following eg balloon angioplasty (Reinhardt 2006). Importantly, the latter 
may facilitate migration of SMC to the lesion site which is interesting in view of the 
observation that the US28 gene product, a chemokine receptor encoded by CMV, is 
also able to stimulate SMC migration (Streblow 1999).
However, the importance of these predominantly in vitro findings may be limited 
for our knowledge regarding the underlying mechanisms of CMV-enhanced restenosis 
in vivo. Yet, in contrast to findings in atherosclerotic specimens, CMV DNA could not 
be demonstrated unequivocally in endarterectomy material from patients suffering 
from either coronary restenosis or progressive allograft coronary artery disease 
(Gulizia 1995, Kol 1995). This suggests that the presence of the virus in the vascular 
wall may not be a prerequisite as inflammatory and immune responses to chronic 
persistent CMV infection may be more important for the exaggerated response 
to vascular injury in CMV seropositives (Stassen 2006, 2008). This is supported by 
findings in animal models showing that CMV infection of immunocompetent adult rats 
increases the neointimal response to vascular injury despite the absence of virus in 
the vascular wall (Zhou 1999, 2000).
3.3. Chlamydia pneumoniae and arterial restenosis 
In contrast to its role in atherosclerosis, the effect of C. pneumoniae on restenosis 
has been less well established. Sero-epidemiological evidence has been provided by 
Hayashida et al., who showed the presence of anti C. pneumoniae IgG antibodies to 
be a strong independent risk factor for restenosis after percutaneous intervention 
(Hayashida 2002). These findings have been confirmed by others who demonstrated 
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pre-procedural seropositivity of anti C. pneumoniae IgA antibodies to be related with 
re-intervention, need for coronary artery bypass grafting, myocardial infarction, 
death and angina pectoris after the intervention, even when stents were used to 
prevent coronary intimal hyperplasia (Rahel 2004, Tanaka 2001). In addition, in 
patients with high C. pneumoniae antibody titres, roxithromycin reduced the rate of 
restenosis after coronary stent placement (Neumann 2001).
As already mentioned for CMV, the association between restenosis and the presence 
of C. pneumoniae in the vascular wall is scant. Although C. pneumoniae could be 
detected in 32% of all endatherectomy specimens taken from patients undergoing 
coronary artery bypass grafting, no associations with secondary lesions could be 
demonstrated (Radke 2001). Likewise, C. pneumoniae was also found in carotids 
plaques obtained from patients undergoing carotid endarterectomy. Yet, during a four 
year follow-up period no causal role for C. pneumoniae in restenosis or progression of 
carotid disease or mortality was seen in this patient group (Jahromi 2003). Therefore, 
more detailed studies regarding the possible role of C. pneumoniae in restenosis and 
intima hyperplasia are required. Unfortunately, until now no experimental studies 
are available investigating a possible causal relationship between C. pneumoniae and 
restenosis.
 
4 Cytomegalovirus and Chlamydia pneumoniae in venous  
 bypass failure
4.1. Venous bypass failure
Autologus saphenous vein grafts are commonly used for treatment of severe athero-
sclerosis via coronary artery bypass grafting (CABG) and infrainguinal bypass 
procedures in patients with critical limb ischemia. Although the initial results of 
these procedures are successful, the symptoms tend to recur due to degeneration 
and occlusion of the graft giving rise to 15-30% graft failure within one year and up to 
50% of all grafts being occluded 10 years after surgery (Fitzgibbon 1996). 
The main causes of venous graft failure are surgical trauma, intraoperative 
ischemia reperfusion injury, and implantation of a vein into the arterial circulation. 
In addition to surgical sequels, patients’ characteristics like insulin dependent 
diabetes, impaired left ventricular function and target vessel diameter have also 
been shown to negatively influence long term graft patency (Cho 2006, Cataldo 1993, 
Shah 2003). Saphenous graft failure can be considered as a tri-phase disease. Early 
graft failure occurs within the first months after surgery and is predominantly caused 
by thrombotic events often due to mechanical trauma during vein harvesting and is 
thought to be responsible for 20% of all failed grafts. Late graft failure tends to occur 
after several years and is caused by accelerated atherosclerosis (Paz 1993). These 
causes may be treated with currently available antiplatelet and lipid lowering drug 
therapy which has been proven to be successful in several clinical studies (Christenson 
2001). Intermediate failure of saphenous vein grafts is due to neointimal hyperplasia 
(IH), defined as the accumulation of smooth muscle cells (SMC) and extra-cellular 
matrix in the intimal component of the vein which is most prominent in the first 
year after surgery but can occur up to three years after CABG (Barboriak 1978). This 
process of graft occlusion involves the migration of medial vascular smooth muscle 
cells to the lumen of the graft were they transform into a more synthetic phenotype. 
Then, these cells will start proliferating as well as secreting extra-cellular matrix 
proteins. These processes will ultimately result in the formation of a neointima. It has 
been strongly suggested that IH is associated with extensive endothelial denudation 
and destruction of venous grafts, resembling to the response to injury as seen after 
PTCA often leading to restenosis of the denuded artery (Logerfo 1983). 
4.2. Cytomegalovirus and venous bypass failure
Whether the unresolved problem of venous coronary artery bypass graft occlusion 
is related to infection with C. pneumoniae and/or CMV has not been addressed 
extensively. Although multiple studies demonstrated a role for infectious agents, 
and in particular CMV, in atherosclerosis, restenosis and certainly in transplantation 
related vasculopathy, a possible contribution of CMV in venous bypass failure received 
only very limited attention so far and results have been inconclusive.
Bartels et al. demonstrated IgG CMV antibody titers, indicating prior CMV infection, 
to be present in 58.3% of the patients undergoing primary or repeated CABG. How-
ever, elevated IgM titers were not present and no CMV DNA could be detected by 
quantitative PCR in coronary desobliterated (dissecting the atherosclerotic cylinder 
from the adventitial layer of the coronary artery) samples or occluded aorto-coronary 
venous grafts obtained during re-operation (Bartels 2000). In addition, they failed to 
detect presence of CMV DNA in native saphenous veins used for CABG (Bartels 1999).
Experimental studies could have addressed the question whether infections contribute 
to venous bypass failure in a more detailed way. However, to our knowledge studies 
focusing on a relationship between CMV and venous bypass failure in an experimental 
model are missing. They are important to further elucidate a possible involvement of 
a pathogen in the process of restenosis.
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4.3. Chlamydia pneumoniae and venous bypass failure
In contrast to CMV the relationship between C. pneumoniae and venous graft failure 
has been more a subject of study. Bartels et al. were able to detect C. pneumoniae 
DNA in 25% of occluded vein grafts obtained from patients undergoing re-operations 
although they observed no differences regarding histopathological changes or 
proliferation rate of neointimal smooth muscle comparing C. pneumoniae positive 
and negative occluded vein grafts (Bartels 1999). Additionally they observed a strong 
correlation between elevated C. pneumoniae IgG titers and the presence of C. 
pneumoniae in occluded vein grafts (Bartels 2000). Similar data were shown by Zorc 
et al., suggesting an etiological role for C. pneumoniae in arterial bypass failure (Zorc 
2005). Whether presence of C. pneumoniae in patients undergoing cardiac surgery 
increases changes of clinical sequela remains disputable. Zamorano et al. were unable 
to show a significant increased risk of subsequent death, recurrent intervention and 
myocardial infarction in patients with unstable angina who harboured C. pneumoniae 
in the coronary artery atherosclerotic plaques prior to CABG (Zamaro 2003).
Although presence of C. pneumoniae antibodies in patients with venous bypass 
failure has been reported in literature, again no experimental studies have been 
published yet shedding light on a possible causal relationship. One could however 
speculate that mechanisms resembling those previously discussed in the interplay 
between C. pneumoniae and restenosis may play a similar role in venous bypass 
failure. In vitro C. pneumoniae is able to infect endothelial cells, SMC, and 
macrophages. Infection in all these cell types can be persistent giving rise to a 
continuous state of activation (Gaydos 1996). For example C. pneumoniae is able 
to induce a permanent state of activation in SMC leading to induction of secretion 
of interleukin 6, tumor necrosis factor alpha (TNFα), interleukin-1-beta (IL-1β) and 
basic fibroblast growth factor (Rödel 2000). These pro-inflammatory cytokines play 
an important role in the process of atherosclerosis but may also be of importance in 
venous bypass failure. Indeed in a prospective study involving 99 patients raised pre-
operative IL-6 levels have been shown to be associated with both early graft occlusion 
and late cardiovascular events after CABG (Hedman 2007). Furthermore, IL-6 is able 
to induce the production of C-reactive protein (CRP), which is able to stimulate 
endothelial and smooth muscle cell proliferation thereby providing a pathway for C. 
pneumoniae to aggravate vein graft failure (Cirillo 2005). Indeed, increased levels 
of CRP are independent predictors of late all-cause mortality after primary on-pump 
CABG (Kangasniemi 2006). C. pneumoniae is also able to stimulate SMC activation and 
proliferation through a wide range of soluble growth factors secreted from infected 
neighboring endothelial cells, representing an important paracrine mechanism sti-
mulating intimal hyperplasia (Coombes 1999, 2001).
Besides activation and proliferation the invasion of SMC as facilitated by matrix 
metalloproteinases (MMP’s) is an important event in the development of intimal 
hyperplasia in saphenous vein bypass grafts. Inhibition of MMP’s has been shown to 
reduce neointimal hyperplasia in human saphenous veins (Porter 1999, George 1998). 
Several studies delineate a relation between C. pneumoniae and MMP’s. For example 
presence of C. pneumoniae in coronary artery atherosclerotic lesions correlates with 
MMP-9 expression and infection of monocytes by C. pneumoniae directly induces MMP 
activity (Arno 2005, Schmidt 2006).
Additionally Kol et al. have shown that chlamydial heat shock protein-60 stimulates 
MMP-2 and MMP-9 production in atherosclerotic lesions hereby contributing to the 
breakdown of extracellular matrix and stimulating migration of SMC providing an 
additionally mechanism by which C. pneumoniae may be able to aggravate venous 
bypass graft failure in a similar fashion (Kol 1998). 
If C. pneumoniae indeed contributes to venous graft failure it would be tempting 
to intervene with antibiotic treatment trying to improve clinical outcome after bypass 
grafting. Several small clinical trials have indicated that antibiotic treatment of C. 
pneumoniae infection is associated with a better outcome in patients with coronary 
artery disease. However evidence available from large meta-analysis to date does 
not demonstrate an overall benefit of antibiotic therapy in reducing mortality or 
cardiovascular events (O’Conner 2003, Gupta 1997, Sinisalo 2002, Andrews 2005). 
Nonetheless antibiotic treatment prior to coronary artery bypass grafting could be 
an interesting therapeutic option clinical studies focusing on antibiotic treatment 
and primary prevention of vein graft failure as determined by visualization with 
intra vascular ultrasound, computer tomography or angiography are still lacking. 
However Berg et al. treated patients scheduled for CABG surgery with clarithromycin 
demonstrating no differences focusing on secondary endpoints as recurrence of 
cardiovascular events or mortality (Berg 2005). Although in this study antibiotic 
treatment prior to coronary artery bypass grafting did not seem to influence 
secondary endpoints it is questionable whether this therapeutic regime was effective 
in eradicating C. pneumoniae from the vascular tissue. In a study published by the 
same group they tested the presence of C. pneumoniae in vascular tissue specimens 
by immunohistochemistry after treatment with clarithromycin in a group of patients 
with coronary artery disease waiting for CABG. They found no differences in the 
presence of C. pneumoniae major outer membrane protein antigen in the specimens 
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from the group treated with clarithromycin in comparison with the specimens from 
the placebo-treated control group (Berg 2005). 
Summarizing, there is evidence that C. pneumoniae is present in occluded 
saphenous vein grafts but until now it is unclear whether C. pneumoniae substantially 
contributes to graft failure in the long run. Therefore, experimental (animal) 
studies are mandatory to shed light on the possible causal relationship between C. 
pneumoniae infection and vein graft failure. 
5 Cytomegalovirus and Chlamydia pneumoniae in transplantation 
 arteriosclerosis
5.1. Transplantation arteriosclerosis
Organ transplantation has become an increasingly successful medical treatment for 
patients with end-stage organ failure. However, despite improvements in immuno-
suppressive drug therapy and treatment of acute rejection, long-term survival of 
solid-organ transplants is limited as a result of chronic transplant dysfunction (CTD). 
The leading causes of death in the first year following cardiac transplantation 
include infection, rejection, and graft failure. After the first year, CTD is the second 
leading cause of death following cardiac transplantation and the incidence of CTD 
increases in the next years. This is illustrated by the International Society of Heart 
and Lung Transplantation registry, in which CTD is reported in only 7.0% of survivors 
at 1 year but in 32% and 46% of survivors at 5 and 8 years, respectively (International 
Society of Heart and Lung Transplantation (ISHLT) registry. http://www.ishlt.org/
registries). Furthermore, with the availability of intravascular ultrasonography, a 
sensitive imaging modality which allows excellent examination of the entire coronary 
arterial wall, it has become clear that up to 75% of all transplant patients have some 
form of transplantation arteriosclerosis already at 1 year post transplantation (Yeung 
1995). 
Cardiac allograft vasculopathy is thought to result from an initial injury to the 
endothelium of the allograft ensuing in a chronic inflammatory state. In the majority 
of organs and predominantly in the heart, this ultimately results in a persistent 
perivascular inflammation, diffuse multifocal myointimal hyperplasia and inadequate 
vascular remodeling with intimal narrowing of all the vessels in the graft, also named 
transplantation arteriosclerosis (TA) (Pethig 1998). In addition to the conventional 
risk factors for atherosclerosis, such as hyperlipidemia, hypertension and diabetes, 
determinants contributing to this inflammation include preservation injury, the 
frequency and intensity of acute rejection episodes, alloimmune response (cellular 
and humoral rejection), and cytomegalovirus infection (Cramer 1989, Tesi 1993, 
Winters 1990). 
5.2. Cytomegalovirus and transplantation arteriosclerosis
Evidence linking infections and acute or chronic solid organ transplant rejection was 
first presented in the early 1970s and primarily refers to the role of herpes viruses 
and cytomegalovirus in particular (Lopez 1974). Cytomegalovirus infection in solid 
organ transplant recipients mostly occurs through reactivation of latent virus from 
either the infected graft (primary infection) or the recipient and epidemiological 
data revealed that CMV infections occur in 30%-65% of transplantation recipients, 
of which 18%-40% developed a symptomatic infection mostly within 1 to 3 months 
after transplantation (Reischig 2006). In a prospective study of 218 liver transplant 
recipients Paya and coworkers showed that 55% of patients developed CMV infection 
during the 1st year post-transplantation. Of the 62 episodes of documented organ 
involvement, liver was the major site (38 episodes), followed by lung, gastrointestinal 
tract and retina (Paya 1993). In another study, Lautenschlager et al. showed that 
there was at least one episode of rejection early after transplantation in ten liver 
transplants whose graft was lost due to histologically confirmed chronic rejection. All 
patients had a history of CMV infection usually following acute rejection. Persistent 
CMV-DNA was found in all of those grafts examined by DNA-hybridization in situ, CMV-
DNA was strongly expressed in the remaining bile ducts and moderately expressed 
in endothelial cells of the vascular structures. Persistent CMV genome was found in 
those structures that were the major targets of chronic rejection process in the liver 
(Lautenschlager 1997, Arnold 1992). Besides, a study concerning the relation between 
cytomegalovirus infection status and first-year mortality among orthotopic liver 
transplantation recipients showed that donor and recipient CMV serologic status is 
a significant pre-transplantation determinant for death in liver transplant recipients 
(Falagas 1997). In addition, CMV infection in heart transplant recipients has been 
shown to augment plaque progression as determined by quantitative intra-coronary 
ultrasound. The CMV-positive group showed more advanced, calcified lesions and the 
maximal plaque thickness was significantly enhanced compared to the CMV-negative 
group. Thus CMV seropositivity is a predictor for the progression of CTD independent 
of other cardiovascular risk factors while a positive PCR test for CMV even further 
increases the risk for accelerated transplant arteriosclerosis and consecutively 
transplant failure (Fateh-Moghadam 2003). 
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The critical role of CMV infection in TA has also been demonstrated in experimental 
models. Compelling evidence for enhancing effect of CMV on transplantation 
arteriosclerosis comes from various transplantation models in rats using aortic, 
cardiac, kidney and liver allografts as well as a trachea model. Infection of the 
immune-competent recipients resulted in an early inflammatory response with an 
increased influx of monocytes/macrophages and T-lymphocytes in the aortic and 
cardiac allograft vascular adventitia and intima and in the airway wall of tracheal 
allografts (Koskinen 1994, Li 1996). This early inflammatory response leads to 
enhanced intimal thickness in vascular and cardiac allografts and enhanced luminal 
occlusion of tracheal allografts (Lemström 1993, 1995, 1996). Similar findings 
were reported using a rat kidney allograft in which CMV infection prolonged and 
increased graft inflammation and accelerated chronic rejection of renal allografts 
(Lautenschlager 1997). The role of CMV in TA is further corroborated by data 
demonstrating that antiviral drug treatment entirely abolished the enhanced intimal 
response and luminal occlusion in allografts (Lemström 1997, 1994, Tikkanan 2001).
Several mechanisms have been suggested to explain the association between CMV 
and transplant rejection. The findings in the studies mentioned before could partially 
be explained by the direct effects of CMV infection on the inflammatory response 
leading to the development of transplant arteriosclerosis and allograft rejection. 
CMV infection triggers an immune response by inducing MHC antigens and adhesion 
molecules on the cell surface making the cells a target for immunological attack. 
Indeed, CMV immediate early proteins (IE-1 and IE-2) increase the constitutive 
expression of several cell surface molecules by CMV-infected endothelial cells that 
are involved in the adhesion of leukocytes, such as intracellular adhesion molecule- 
1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), vascular adhesion protein-1 
(VAP-1), E-selectin and MHC class I antigens (van Dorp 1989, Kloover 2000, Martelius 
2000). Also, a cross-reaction between the viral protein and MHC molecules cannot 
be excluded because CMV has been shown to encode a protein homologous to MHC 
class I antigen, and a CMV IE-2 protein has been found to share an epitope with the 
HLA-DRβ chain (Beck 1988, Fujinami 1988). Furthermore, CMV infection has been 
shown to induce the production of chemokines, like CCL5 (earlier called Regulated 
upon Activation, Normal T-cell Expressed, and Secreted or RANTES) and monocyte 
chemotactic protein-1 (MCP-1), which subsequently induce the migration of the 
inflammatory cells to the sites of the chemokine production. It has been suggested that 
this results from generation of reactive oxygen species (ROS) following CMV infection 
of for example smooth muscle cells (SMC). This ROS production may subsequently 
result in the production of chemokines as well as pro-inflammatory cytokines (Speir 
1998). Apart from its effects of host chemokine production it has been demonstrated 
that CMV encodes several viral chemokines, like as US28, which have been implicated 
in vascular disease because of their ability to induce SMC migration (Streblow 1999). 
It has also been reported that immediate early gene products of HCMV increase SMC 
proliferation possibly by augmenting platelet derived growth factor-β (PDGF-β) 
receptor expression and enhancing migration of cells towards the PDGF-β receptor 
(Zhou 1999). Additionally, CMV might induce proliferation of SMC in the vascular wall 
by altering the SMC metabolism due to the production of an immediate early gene 
product of CMV, IE2-84, which has been shown to bind to and inactivate the tumor 
suppressor gene p53 (Speir 1994). CMV may also interfere with the endothelial nitric 
oxide system. This is supported by recent data showing that CMV infection accelerates 
CTD through its ability to diminish the vascular protective effects of the endothelium-
derived nitric oxide system (eNOS) (Speir 1998, Weis 2004). The importance of the 
eNOS system for TA has recently been demonstrated in eNOS deficient mice, in which 
aortic allograft failure was significantly accelerated (Lee 2000). Furthermore, gene 
delivery of eNOS to cardiac allografts at the time of transplantation, extended graft 
survival, and inhibited NFκB activation, adhesion molecule expression and leukocyte 
infiltration (Iwata 2001). 
Most of the molecular mechanisms mentioned above require infection of specific 
cells like SMC. However, although several studies have shown a stimulating effect 
of cytomegalovirus infection on CTD, in the rat aortic allograft model only a few 
RCMV-positive cells in allografts could be detected at any time point and the 
infected cells mainly appeared to be mononuclear inflammatory cells and not SMC 
(Lemström 1993). This suggests that aside from its effects in causing local disease, 
CMV is also recognized to have indirect effects, consistent with the induction of 
a pro-coagulant and pro-inflammatory state. Indeed, CMV is able to induce a pro-
coagulant environment on endothelial surfaces. This probably occurs because CMV 
surface molecules contain pro-coagulant phospholipids that promote the assembly of 
a complex between factors Xa and cofactor Va. Also, CMV has the ability to form pro-
thrombinase leading to thrombin generation (van Dam-Mieras 1992, Pryzdia 1994). 
In addition to its potential role in chronic allograft dysfunction, CMV is a marked 
risk factor for acute allograft rejection episodes and has been shown to actively boost 
the alloimmune response (Potena 2006, Lemström 1995). The latter is supported by 
earlier data demonstrating the efficacy of triple drug immunosuppression on RCMV-
induced allograft arteriosclerosis suggesting that CMV aggravates SMC proliferation 
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and CTD indirectly by stimulating the immune response (Lemström 1994). Never-
theless, there might be two sides on the coin of anti-rejection therapy, as it might 
also suppress CMV specific cytotoxic T-cell responses and result in prolonged viraemia, 
which in turn could cause a prolonged alloreactive cytotoxic response increasing the 
risk of allograft rejection and vascular disease (Tu 2006). Interesting in this respect 
would be the combination of an immunosuppressive drug with antiviral properties 
like the recently introduced synthetic malononitrilamide FK778 (Evers 2005). Taking 
all this in consideration, prophylaxis might be beneficial in preventing direct and 
indirect effects of CMV infection in transplant recipients, affecting both allograft 
and patient survival. If CMV infection is really an etiological factor for CTD, antiviral 
therapy would also be effective in decreasing incidence of the chronic rejection 
in clinical studies; indeed, this has been demonstrated in patients who underwent 
heart transplantation. In a prospective cohort study of 66 heart transplant recipients, 
aggressive CMV prophylaxis with CMV hyperimmune globulin and four weeks of 
intravenous ganciclovir followed by two months of valganciclovir was compared with 
the standard prophylaxis of four weeks intravenous ganciclovir. Aggressively treated 
patients had a lower incidence of CMV infection and reduced risk for acute rejection. 
Additionally they also showed a slower progression of CTD, in terms of coronary artery 
lumen loss at one year follow up (Potena 2006).
5.3. Chlamydia pneumoniae and transplantation arteriosclerosis
Since the original observation by Saikku and colleagues, demonstrating an increased 
incidence of myocardial infarction among C. pneumoniae positive coronary heart 
disease patients, the role of C. pneumoniae on the progress of atherosclerosis and 
coronary artery disease has been suggested by many others. The presence of C. 
pneumoniae DNA, C. pneumoniae antigen and viable C. pneumoniae in the vessel 
wall has further contributed to the mounting evidence of C. pneumoniae involvement 
in atherosclerosis (Saikku 1988, Ramirez 1996, Campbell 1995). This is supported by 
experimental studies which showed an acceleration of lesion development in several 
experimental animal models of mice and rabbits although an atherogenic diet seems 
to play a pivotal role for the C. pneumoniae induced effects in these models (Ezzahiri 
2002, Fong 1999).
Several mechanisms are held responsible for the C. pneumoniae accelerated 
atherosclerotic lesions so has C. pneumoniae been held responsible for impairing 
endothelial function and inducing a wide variety of pro-inflammatory cytokines such 
as IL-1β, IL-3, IL-4, IL-6, IL-8, IFN-γ and TNF-α. In addition after infection of human 
vascular endothelial cells an up-regulation of various adhesion molecules (VCAM-1, 
ICAM-1, P-selectin and E-selectin) has been reported (Liuba 2000, Quin 1999, Burian 
2003, Summersgill 2000).
Interestingly, most of the suggested mechanisms by which C. pneumoniae may 
affect atherosclerosis highly resemble those by which CMV has been suggested to 
affect the disease. Therefore, it is plausible that C. pneumoniae, similar to CMV, 
is also involved in other cardiovascular pathologies like CTD. This is supported by 
previous findings that chronic C. pneumoniae infection as evidenced by anti-IgG 
antibody titers has a significant effect on the development of cardiac allografts 
arteriosclerosis, which is considered as the most important indicator for a worsened 
long term prognosis after heart transplantation (Subramanian 2002). 
The impact of C. pneumoniae seropositivity on survival after transplantation 
has been confirmed by Pienazek et al. They found that C. peumoniae infection, as 
expressed through high IgA levels, seems to have adverse impact on the survival 
rate during one-year follow-up after heart transplantation. Although others were 
only able to demonstrate a significant trend toward lower actuarial freedom from 
transplant arteriosclerosis in patients with elevated IgA titers against C. pneumoniae 
after the period of 14 months postoperative (Pieniazek 2003, Wittwer 2000). Like-
wise, an association between the occurrence of C. pneumoniae detected by PCR 
and the presence of foam cell arteriopathy in liver transplant patients with chronic 
rejection has been suggested (Lotz 2004). Also in lung transplant complications 
C. pneumoniae might be involved. A common late complication in lung transplant 
recipients is bronchiolitis obliterans syndrome (BOS), a fibrotic process resulting 
in progressive narrowing of bronchiolar lumens and airflow obstruction, which is 
a manifestation of chronic allograft rejection. Based on the observation that BOS 
occurs more frequent and earlier in C. pneumoniae seropositive recipients it has been 
suggested that the presence of C. pneumoniae IgG antibodies in the lung transplant 
recipient is an independent risk factor for the development of BOS (Kotsimbos 2005). 
Similar results were published by Glanville et al. who showed an association between 
persistent infection with C. pneumoniae confirmed by nested PCR and deterioration 
of pulmonary allograft functioning, graft rejection and BOS (Glanville 2005). Along 
the same line, it has been shown previously that the presence of C. pneumoniae in 
peripheral blood leukocytes increased the risk of chronic kidney allograft rejection. 
Additionally seropositivity for IgG and IgA antibodies to C. pneumoniae was found 
to be associated with increased mortality as the result of cardiovascular disease in 
renal transplant recipients (Haubitz 2004, Kwiatkowski 2006). Nonetheless, not all 
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studies have confirmed a decrease in survival rate after heart transplantation of C. 
pneumoniae positive recipients. Also in a retrospective study involving 115 kidney 
transplant patients no correlation between CRP levels or C. pneumoniae seropositivity 
with respect to rejection rates or graft failure was found. However increased CRP 
levels were associated with all-cause and cardiovascular mortality indicating an 
inflammation mediated effect (Fang 1998, Varagunam 2004).
Summarizing, although there is some evidence that chronic infections with C. 
pneumoniae seem to be associated with post-transplant allograft vasculopathy, 
experimental evidence for this hypothesis is fairly absent. Also, no clinical trials 
of empiric antibiotic therapy for C. pneumoniae in transplant recipients have been 
performed so far. Therefore, one of the main topics of this thesis is to address the 
potential role of C. pneumoniae in TA in a rat aortic allograft model and an animal 
model of vein graft failure.
6 Therapeutic approach: Activin A and venous bypass failure
6.1. Gene therapy and venous bypass failure
Even with optimal pharmacotherapy, some forms of cardiovascular disease may 
be refractory to treatment and prognosis remains poor for a significant number of 
patients. Also, pharmacotherapy often requires long-term administration while rarely 
addressing the underlying pathophysiology. Alternatively, with the identification of a 
number of genes, which are key to neointimal formation, gene therapy aiming to alter 
their relative expression has been recognised as having the potential to be added to 
the therapeutic armamentarium available to treat patients after intervention thereby 
providing secondary prevention (Baker 2002). In particular, those genes involved 
in smooth muscle cell proliferation might be of special interest. For example, 
in the carotid artery model of balloon angioplasty, enhancing the local expression 
of inhibitors of cell cycle progression, like p21 protein, ribozymes against c-myb 
mRNA, light-type caldesmon or retinoblastoma significantly inhibited experimental 
neointimal hyperplasia (Chang 1995, Macejak 1999, Yokouchi 2006, Chen 1997). An 
ideal target for cell-cycle blockade would be E2F, a transcription factor that leads to 
up-regulation of 12 cell-cycle genes. Recently, a strategy has been developed to block 
E2F using a double stranded decoy oligodeoxynucleotide that bears the consensus 
E2F-binding site, and this approach has proven to be effective in reducing neointimal 
hyperplasia in different experimental animal models (Morishita 1995, Ehsan 2001, 
Cho 2005).
Yet, as already mentioned above, intimal hyperplasia is not only seen after 
balloon dilatation but also in venous graft failure and targeting similar genes may 
eventually preserve vein graft patency. However, until now no data have been 
presented regarding interference with genes associated with cell cycle progression in 
vein graft failure. Alternatively, West et al. demonstrated that adenoviral-mediated 
overexpression of neuronal NOS (nNOS) decreased SMC proliferation and intimal 
hyperplasia in a rabbit model of jugular vein to ipsilateral carotid artery grafting 
(West 2001). Furthermore, overexpression of nNOS during the early phase of vein 
graft remodelling resulted in intimal SMC with a more differentiated phenotype and 
reduced SMC-related superoxide production, thus protecting the vein graft from 
damage by reactive oxygen species. The importance of reactive oxygen species in 
modulating intima hyperplasia has recently been emphasized as N-acetylcysteine, a 
strong scavenger of oxygen-free radicals, significantly reduced the amount of intimal 
hyperplasia in rat venous graft model (de Graaf manuscript in preparation).
Besides inhibition of SMC proliferation, gene therapy offers other therapeutic 
approaches like modulation of SMC migration and regulation of SMC apoptosis. For 
example, over-expression of p53 has been shown to inhibit migration of SMC and to 
inhibit intimal thickening in an ex vivo human saphenous vein model (George 2001). 
Similar results were obtained in a porcine venous interposition graft model were 
induction of SMC apoptosis by transient p53 over-expression reduced neointimal 
proliferation by 28% resulting in a 68% less thicker neointima with a significant 
increase in lumen size (Wan 2004). Likewise, neointimal hyperplasia was also 
diminished by stimulating SMC apoptosis through Fas ligand gene transfer to the 
vessel wall (Sata 1998). Furthermore, decreased SMC migration has been achieved by 
preventing matrix degradation through over-expression of tissue inhibitors of matrix 
metalloproteinase’s (TIMP). Several studies demonstrated the effectiveness of TIMP-1 
and TIMP-2 overexpression in reducing neointimal hyperplasia in a rat balloon injury 
model and ex vivo culture models of human saphenous veins (Dollery 1999, George 
1998). Additionally, over-expression of TIMP-3, an extracellular matrix–associated 
MMP inhibitor which uniquely promotes apoptosis of isolated vascular smooth muscle 
cells, reduced neointima formation by 84% in human organ cultures and by 58% in pig 
vein grafts. The latter was confirmed by Akowauh et al. using the same model but in 
combination with a non-viral delivery system demonstrating that TIMP-3 is able to 
influence venous remodelling by increasing lumen size and total vessel area (Baker 
1998, George 2000, Akowuah 2005). Other approaches include successful attempts to 
downregulate the expression of chemotactic and mitogenic factors in the graft or to 
inhibit the signalling cascade responsible for neointimal hyperplasia (Wolff 2005).
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Direct access to the vein during surgery offers a major potential benefit as a 
target for gene therapy. The vein graft can be manipulated and therapeutic genes, 
which may prevent subsequent graft failure, can be applied ex vivo. Yet, only a few 
clinical studies have addressed this subject so far. In the single-centre, prospective, 
randomised controlled PREVENT phase I trial (“PRoject of Ex-vivo Vein graft 
ENgineering via Transfection”) E2F decoy oligodeoxynucleotides were applied ex-vivo 
to the saphenous vein graft resulting in a promising 24% decrease in early 30 day graft 
occlusion (Mann 1999). However, subsequent studies were less positive including 
recently published results of the PREVENT III phase 3, multicentre, randomised 
double-blinded, placebo-controlled trial including 1404 patients undergoing 
surgical bypass of peripheral arterial occlusive disease with autologous vein grafts. 
Unfortunately, in this large trial a protective role E2F decoy oligodeoxynucleotides 
in preserving graft patency rates at one year after surgery could not be confirmed 
(Conte 2006). Furthermore in a phase 3 randomized, double-blind, placebo-controlled 
trial of 3014 patients undergoing primary CABG, the PREVENT IV trial showed that E2F 
decoy oligodeoxynucleotide had no effect on angiographically determined vein graft 
failure compared to the placebo-treated group during a 12 to 18 month follow up 
period (Alexander 2005).
6.2. Activin A and vein graft failure
Experimental studies delineated above have mainly focused on adenovirus-mediated 
inhibition of neointimal hyperplasia through induction of cell cycle arrest or 
apoptosis of the activated SMC rather than on preventing the phenotypical change of 
SMC from quiescent to proliferating stage. Activin A, a member of the transforming 
growth factor-β super family, does enhance the expression level of SMC-specific 
alpha-actin markers, indicating that it promotes the contractile phenotype of these 
cells (Engelse 1999). Based on these observations Engelse et al. hypothesized that 
activin A might reduce neointima formation by preventing phenotypic modulation 
of vascular SMC. Indeed, they demonstrated in a femoral artery cuff mouse model 
that systemically induced elevated levels of activin A resulted in a 77% reduction of 
neointima formation. Similar results were obtained with local adenoviral expression 
of activin A in a human saphenous vein organ culture model (Engelse 2002). In this 
thesis we will address a similar approach − maintenance of the contractile phenotype 
of SMC through activin A overexpression − to prevent intimal hyperplasia in venous 
graft failure.
Aims and outline of the thesis
Intimal hyperplasia is considered to be the major determining factor limiting long 
term success after PTCA, venous bypass grafting and solid organ transplantation. 
Although the underlying cause is generally considered to be multifactorial, infections 
with C. pneumoniae and CMV have been proposed as pathogenic factors possibly 
aggravating intimal hyperplasia. 
However sero-epidemiological studies describing an association between C. 
pneumoniae, CMV and restenosis, venous graft failure and transplantation arterio-
sclerosis show conflicting results. Moreover animal models shedding light on a more 
causal relationship between these two pathogens and intimal hyperplasia if any 
are scarce and do not point in the same direction, thereby generating the need for 
additional evidence.
In this thesis we tried to shed a light and unravel the mechanisms of interplay 
between C. pneumoniae, CMV and intimal hyperplasia using different animal models. 
First we studied the effect of CMV infection on the process of restenosis (Chapter 
2). Hereby we tried to show the relationship between the time point of CMV 
infection and its effect on SMC proliferation using a well described animal model of 
photochemically induced endothelial denudation leading to intimal hyperplasia. As 
CMV showed to aggravate intimal hyperplasia as seen in the process of restenosis we 
hypothesized that similar effects might be present in intimal hyperplasia leading to 
venous bypass failure. In a study using an epigastric vein-to-common femoral artery 
interposition graft we evaluated the effect of CMV infection. Additionally we studied 
the potential effect of a new immunosuppressive, anti-viral and anti-proliferative 
agent FK778 to prevent intimal hyperplasia and its ability to diminish the CMV induced 
effects (Chapter 3). Today it is generally acknowledged that atherosclerosis can be 
considered as an inflammatory disease. Common chronic infections caused by viruses 
and bacteria may contribute to this inflammatory process and interact with classic 
cardiovascular risk factors. Most convincing evidence comes from data regarding the 
intracellular pathogen C. pneumoniae. We hypothesized that C. pneumoniae besides 
in atherosclerosis may also be involved in venous bypass failure. Using the epigastric 
vein-to-common femoral artery interposition graft rat model we studied the effect of 
C. pneumoniae infection on intimal hyperplasia in venous bypass failure. Additionally 
we studied the role of C-reactive protein and heat shock protein 60 in this process 
(Chapter 4).
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Given the well established relationship between CMV and transplantation 
arteriosclerosis we hypothesized that other pathogens like C. pneumoniae may also 
play a role in similarity with observations seen in the field of atherosclerosis. Using a 
well established rat allograft model of orthotopic abdominal aorta transplantations 
we studied the effect of C. pneumoniae infection on transplantation arteriosclerosis 
(Chapter 5).
Even with optimal pharmacotherapy some forms of cardiovascular disease may 
be refractory to treatment and prognosis remains poor for many patients. Gene 
therapy aiming at preventing intimal hyperplasia has been recognised as having the 
potential to add to the therapeutic armamentarium by treating patients during or 
after intervention providing secondary prevention. Maintaining the contractile SMC 
phenotype could prevent intimal hyperplasia and would represent a novel strategy to 
prevent venous graft failure (chapter 6).
Finally, in Chapter 7 the observations as presented in this thesis are discussed 
and related to the hypothesis that the pathogens C. pneumoniae and CMV contribute 
to intimal hyperplasia thereby compromising the long term results of intervention 
techniques used for salvation of atherosclerotic induced pathology.
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Abstract
Epidemiological and animal studies suggest a role for cytomegalovirus (CMV) in 
restenosis. Previously we demonstrated that proliferating smooth muscle cells in the 
injury arterial wall are particularly susceptible for CMV induced effects. Therefore, 
we hypothesized that, depending on the time point of infection after vascular injury, 
CMV infection may affect cell proliferation either in the media or in the neointima 
thereby aggravating the process of restenosis. In the present study we focused on the 
individual layers of the arterial wall by evaluating, besides neointima to media ratio, 
the medial and neointimal area and cellularity in the rat femoral artery. 
Vascular injury was photochemically induced in rat femoral arteries. Immediately 
or 14 days thereafter rats were infected with rat CMV (RCMV) or mock. The presence 
of RCMV in the vascular wall was determined at 3, 5, 14 and 35 days after infection by 
quantitative real time PCR.
When rats were infected immediately after injury a significant increase was only 
seen in the medial but not in the neointimal cross sectional area. On the other hand, 
when rats were infected 14 days after the initial injury, a significant increase was only 
seen in the neointimal area, thereby confirming our hypothesis that RCMV infection 
primary affect proliferating SMC’s. As the mean number of smooth muscles cells per 
μm2 in both cell layers was unchanged despite an increase in cross sectional area, 
this implies that RCMV stimulated smooth muscle cell proliferation. Furthermore, 
these vascular effects were observed without the virus being abundantly present in 
the vascular wall suggesting that inflammatory and immune mediated responses to 
RCMV infection are more important in aggravating the response to vascular injury 
than the virus itself.
Introduction
Arterial stenosis, resulting from advanced atherosclerosis, is commonly treated 
with angioplasty (PTCA). Nevertheless, since the introduction of PTCA more than 
20 years ago, the problem of renewed narrowing of the initially successful dilated 
lesion has plagued this procedure in 30-50% of all cases (Glagov 1994). Despite 
intensive investigation, the exact underlying mechanism still has to be elucidated 
and pharmacological therapy hasn’t been found yet to completely prevent 
restenosis. A hyperplastic smooth muscle cell (SMC) response is considered to be 
the main cause for limiting the long-term success of the angioplastic procedures 
(Tanaka 1995). Recent epidemiological studies indicated that infectious agents 
may increase the risk of restenosis after PTCA, although reported results have not 
always been consistent (Horne 2002, Anderson 1998, Patel 1995). These infectious 
agents, and cytomegalovirus (CMV) in particular, have been suggested to promote 
SMC proliferation by blocking the anti-proliferative effect of the tumour suppressor 
gene p53 and by doing so increase the risk for restenosis (Castillo 2000, Epstein 1996, 
Rodriguez-Campos 2001, Tanaka 1999, Zhou 1999a). Besides SMC proliferation, CMV-
induced immune activation may also contribute to the process of restenosis (Zhou 
1999b). 
To date, several experimental approaches have been used to induce intimal hyper-
plasia and thickening. Most of these techniques are based on endothelial denudation 
by a flexible wire (Lindner 1993), a balloon catheter (Clowes 1986), air-drying 
(Fishman 1975) or laser (Hanke 1991). Although all of these procedures are intended 
to induce intimal damage, which then results in neointima formation, they are 
relatively inaccurate regarding the extent of intimal damage and are mostly difficult 
to perform (Indolfi 1995). In regard of this imperfection, we used a simple and 
reproducible thrombosis model to induce intimal thickening in the rat femoral artery 
as described previously (Kikuchi 1996). This method is based on a photochemical 
reaction between green light and intravenously administered rose bengal (Saniabadi 
1995, Paczkowski 1985). The model represents a non-invasive and non-mechanical 
approach to induce endothelial damage and neointima formation. 
The aim of the current study was to elucidate in more detail the role of CMV in the 
process of restenosis, induced by the ‘rose bengal model’. Previous studies already 
delineated the stimulating effect of CMV on the hyperplastic response following 
balloon denudation (Zhou 1999b, 2000). Nonetheless, in these studies the main focus 
was on the neointima/media ratio and no attention has been paid to individual layers 
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of the vascular wall (i.e. media and neointima). Previously, we demonstrated that 
proliferating smooth muscle cells are particularly susceptible for CMV induced effects 
(Persoons 1997). Therefore, we hypothesized that, depending on the time point of 
infection, CMV may affect cell proliferation either in the media or in the neointima. 
For that reason, we evaluated, besides neointima to media ratio, the medial and 
neointimal area and cellularity in the rat femoral artery when rats were infected 
either immediately or 2 weeks after injury.
Although CMV may stimulate the hyperplastic response following endothelial 
injury, it still remains a matter of debate whether this results from a direct effect 
of CMV in the vascular wall or from an indirect effect resulting from an increased 
influx of inflammatory cells in the vascular wall of infected animals. Although CMV 
has been demonstrated in the vascular wall by sensitive PCR methods, we used the 
quantitative real time PCR technique to determine the exact number of CMV DNA 
copies in the vascular wall at various time points post infection.
Methods
Animals
Specific pathogen-free (SPF), inbred male Lewis rats were obtained from the 
Department of Experimental Animal Service of the University of Maastricht, the 
Netherlands. Experiments were carried out on animals aged 12 weeks, weighing 300 
to 400 gram. Housing and care of the animals, and all the procedures used in these 
studies were approved by the Ethical Committee for the Use of Experimental Animals 
of the institution, and conform with the Guide for the Care and the Use of Laboratory 
Animals, published by the US National Institute of Health (NIH Publication No. 85-23, 
revised 1985). Rats were fed standard rat chow and tap water at libitum. All surgical 
procedures were performed under general anaesthesia and using sterile technique. 
Experimental design
Vascular injury was photochemically induced in the rat femoral artery (Kikuchi 1996, 
Saniabadi 1985). The rats were anaesthetised with sodium pentobarbital (60 mg/
kg body weight, intraperitoneally (i.p.)), and the right femoral artery was carefully 
exposed. The exposed segment was proximally and distally covered with gauze 
soaked with physiological salt solution (PBS) to prevent the surrounding tissue from 
desiccation, leaving only 5-10 mm of the arterial segment uncovered. Thereafter, 
bengal rose (50 mg/kg, Sigma Chemical Co U.S.A.) was administered intravenously via 
the penile vein. Transillumination of the exposed segment during 13 minutes was done 
with a cold light source (KL 2500 LCD, SCHOTT) equipped with a halogen reflector 
lamp (Osram, type HLX 64653) and a green filter (540 nm). Transillumination time was 
chosen based on a pilot study, which indicated that 13 minutes was the most suitable 
exposure time for providing endothelial damage resulting in neointima formation 
without causing an occlusive thrombus. After exposure, the wound was closed and 
the animal was returned to its cage to recover from anaesthesia. Animals were kept 
warm by a heat-lamp during the time of surgery and during the recovery phase. 
Infection was established by inoculating rats i.p. with 1.25*106 plaque forming units 
(PFU) of homogenised salivary gland derived RCMV (Maastricht strain) (Bruggeman 
1982) immediately after surgery or 14 days after closure of the wound. Controls were 
injected i.p. with 1 ml mock solution (salivary gland homogenate). Animals (n=16 per 
group) were sacrificed 35 days post surgery.
Histological and morphometrical procedures
Five weeks after surgery, rats were anaesthetised, the chest and abdominal cavities 
were opened and a catheter was inserted into the apex of the heart. Vessels were 
initially flushed with physiological salt solution and then perfusion fixed with 3.7% 
formaldehyde in phosphate buffered saline, pH 7.4, at physiological pressure 
(100 mm Hg). Femoral arteries were removed and fixed overnight in the same fixative. 
Furthermore, tissue biopsies of liver, spleen, lung and salivary gland were collected. 
The fixed femoral artery was cut in three or four segments, routinely processed and 
paraffin embedded. Cross-sections (4 µm) were taken for morphometrical analysis 
at 200 µm intervals and mounted on glass slides for haematoxylin-eosin and Lawson 
staining. Medial, neointimal and luminal areas were determined in those cross-
sections of the femoral artery where a neointima was seen (average of 10 cross-
sections per artery) by using a computer-assisted morphometry system (analySIS®, 
Soft Imaging System, GmbH). The cross-sectional area of the media was defined as 
the area surrounded by the external and internal elastic lamina. The neointimal 
cross-sectional area was defined by the area surrounded by the internal elastic lamina 
and the arterial lumen. Final scores were given as percentage of the mock-injected 
group.
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Quantification of number of cells in the intima and media
The number of cells in the intima and media was quantified by counting the total 
number of nuclei using a microscope. All nuclei were counted in those haematoxylin-
eosin stained cross-sections in which a neointima was observed. Final scores were 
expressed as number of cells per area and values are given as median.
Detection of RCMV DNA after endothelial injury by real time PCR
Lewis rats (n=3 per time point) were used for the detection of RCMV. Surgical 
procedures were performed as described above. Rats were inoculated i.p. with 
1.25*106 plaque forming units RCMV (Maastricht strain, derived from homogenised 
salivary glands) immediately after surgery (group A) or 14 days (group B) after closure 
of the wound. Animals were sacrificed at various time points post infection (3, 5, 
14 and 35 days p.i.). This implicates that in group A animals were sacrificed 3, 5, 14 
and 35 days after surgery and in group B 17, 19, 28 and 35 days after surgery. Right 
(injured) and left (control) femoral arteries and tissue biopsies from the lung, spleen 
and salivary glands were collected and stored in liquid nitrogen. For the detection 
of viral DNA within the tissues, total genomic DNA was extracted from tissue using 
the WIZARD® method (Promega Corporation, Madison, WI). To determine the number 
of RCMV DNA copies in all tissues quantitative real time PCR was used as recently 
described (Kaptein 2003). 
Statistical Analysis
Morphological data were expressed as percentage of the data obtained in the mock-
injected group. Cell count numbers are expressed as mean ± SEM. Values were 
compared using the Mann Whitney U test and p<0.05 was considered as statistically 
significant.
Results
Animal conditions
No apparent clinical signs of illness were observed in any of the animals during the 
5- week follow-up period. Starting body weights ranged from 300g to 400g while at 
the end of the experiments animal weights ranged from 350 g to 445 g. There were no 
significant differences between the experimental groups.
Vascular remodelling
RCMV administration in the rats immediately after endothelial damage had no 
significant effect on the cross-sectional area of the neointima or the neointima to 
media ratio (figure 1A and C) at 35 days after surgery. However, at this time point a 
significant increase in the medial cross-sectional area was observed when rats were 
infected immediately after surgery (figure 1B). 
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Figure 1 | Effect of RCMV infection on neointimal and medial cross-sectional area.
Rats were infected with RCMV or mock immediately or 14 days after injury and vascular remodelling 
was determined 35 days after the initial injury. Data are expressed as percentage of mock. *P<0.05 
(RCMV compared to mock)
In contrast, a significant increase in neointimal cross-sectional area was observed 
in injured arteries from rats infected with RCMV 14 days after the initial injury while 
no significant effect was observed on the medial cross-sectional area (figure 1A and 
B). Consequently, administration of RCMV 14 days after injury did also result in a 
significant increase in neointimal/medial ratio (figure 1C). No differences were seen 
in luminal stenosis or luminal cross-sectional area (data not shown).
Cell numbers in the neointima and media
Although the medial cross-sectional area was significantly increased at 35 days when 
rats were infected immediately after surgery, average number of cells/µm2 was 
not different in the media (table 1). This implies that the total number of cells in 
the media is increased and suggests that cell proliferation in the media has been 
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stimulated by RCMV. Nevertheless, at the time of sacrifice this stimulating effect 
could not be detected anymore as the percentage of PCNA positive cells had returned 
to levels comparable to mock (Intima: 7.3 ± 0.03% (RCMV) vs. 12.0 ± 3.5% (mock), n.s. 
Media: 11.0 ± 4.5% (RCMV) vs. 12.0 ± 4.6% (mock), n.s.). In contrast, the mean number 
of cells/µm2 was significantly decreased in the neointima despite an unchanged cross-
sectional area.
Table 1 | Effect of RCMV infection on number of cells in intima and media.
Cells a
(×10-3) /µm2
RCMV b
t=0
MOCK
t=0
RCMV
t=14 
MOCK
t=14 
intima 11.1 ± 1.0* 19.6 ± 4.9 14.2 ± 4.0 20.2 ± 6.1
media 4.5 ± 1.0 4.7 ± 0.5 4.1 ± 0.7* 2.8 ± 0.1
a Cell count numbers in sections with neointima in rat femoral arteries 35 days after injury. 
b Rats injected with RCMV or mock immediately (t=0) or at 14 days (t=14) after injury. Data are 
expressed as mean ± SEM * P<0.05 (RCMV compared with mock at same time point).
When rats were infected 14 days after the initial injury, the mean cell number/µm2 
in the neointima was not significantly altered at 35 days post surgery notwithstanding 
the significant increase in neointimal cross-sectional area (table 1). This resembles 
the results seen in the media when rats were infected immediately after surgery 
and strengthens the idea that RCMV infection stimulates the proliferative response 
in SMC’s following arterial injury. On the other hand, however, the mean number of 
cells/µm2 in the media was significantly increased following RCMV infection without 
any increase in medial cross-sectional area. But, as in the early infection group, at 
the stage no difference in PCNA positive cells could be detected anymore in either 
the media or the intima (Intima: 7.7 ± 0.03% (RCMV) vs. 18.3 ± 5.8% (mock), n.s. 
Media: 10.8 ± 4.1% (RCMV) vs. 22.0 ± 5.0% (mock), n.s.)
Detection of RCMV DNA by real time PCR 
The number of RCMV DNA copies was determined in various organs (liver, lung, spleen) 
at different time points p.i. As expected, in group A (infection immediately after 
surgery) RCMV DNA could be detected in all organs at day 3, 5 and 14 pi, indicating 
that the RCMV infection was successful. The highest amount of RCMV DNA copies was 
found in the spleen at 5 days p.i. (6,9 * 103 copies of RCMV DNA per 1 µg total DNA). 
After 35 days no RCMV DNA could be detected anymore in these initially positive 
organs, indicating that the virus was cleared from these tissues. However, at this 
time point the highest amount of RCMV DNA was found in the salivary gland (7,6 * 105 
copies of RCMV DNA per 1 µg total DNA). In group B (infection 14 days post surgery), 
similar results were obtained with highest copy numbers in the spleen at 5 days p.i. 
(4,8 * 103 copies of RCMV DNA per 1 µg total DNA) and in the salivary gland at 21 days 
p.i (~35 days after surgery, 3,9 * 104 copies of RCMV DNA per 1 µg total DNA)
In the femoral arteries only limited number of RCMV DNA copies could be detected 
(table 2). Although RCMV DNA could be detected for a longer period of time in the 
arteries when rats were infected immediately after injury compared to infection 14 
days after injury, no significant differences in RCMV DNA copy numbers were observed 
either between injured or uninjured arteries or when rats were infected immediately 
or 14 days after injury. 
Cell numbers in the neointima and media
Although the medial cross-sectional area was significantly increased at 35 days when 
rats were infected immediately after surgery, average number of cells/µm2 was 
not different in the media (table 1). This implies that the total number of cells in 
the media is increased and suggests that cell proliferation in the media has been 
stimulated by RCMV. Nevertheless, at the time of sacrifice this stimulating effect 
could not be detected anymore as the percentage of PCNA positive cells had returned 
to levels comparable to mock (Intima: 7.3 ± 0.03% (RCMV) vs. 12.0 ± 3.5% (mock), n.s. 
Media: 11.0 ± 4.5% (RCMV) vs. 12.0 ± 4.6% (mock), n.s.). In contrast, the mean number 
of cells/µm2 was significantly decreased in the neointima despite an unchanged cross-
sectional area.
When rats were infected 14 days after the initial injury, the mean cell number/µm2 
in the neointima was not significantly altered at 35 days post surgery notwithstanding 
the significant increase in neointimal cross-sectional area (table 1). This resembles 
the results seen in the media when rats were infected immediately after surgery 
and strengthens the idea that RCMV infection stimulates the proliferative response 
in SMC’s following arterial injury. On the other hand, however, the mean number of 
cells/µm2 in the media was significantly increased following RCMV infection without 
any increase in medial cross-sectional area. But, as in the early infection group, at 
the stage no difference in PCNA positive cells could be detected anymore in either the 
media or the intima (Intima: 7.7 ± 0.03% (RCMV) vs 18.3 ± 5.8% (mock), n.s. Media: 
10.8 ± 4.1% (RCMV) vs. 22.0 ± 5.0% (mock), n.s.)
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Detection of RCMV DNA by real time PCR 
The number of RCMV DNA copies was determined in various organs (liver, lung, spleen) 
at different time points p.i. As expected, in group A (infection immediately after 
surgery) RCMV DNA could be detected in all organs at day 3, 5 and 14 pi, indicating 
that the RCMV infection was successful. The highest amount of RCMV DNA copies was 
found in the spleen at 5 days p.i. (6,9 * 103 copies of RCMV DNA per 1 µg total DNA). 
After 35 days no RCMV DNA could be detected anymore in these initially positive 
organs, indicating that the virus was cleared from these tissues. However, at this 
time point the highest amount of RCMV DNA was found in the salivary gland (7,6 * 105 
copies of RCMV DNA per 1 µg total DNA). In group B (infection 14 days post surgery), 
similar results were obtained with highest copy numbers in the spleen at 5 days p.i. 
(4,8 * 103 copies of RCMV DNA per 1 µg total DNA) and in the salivary gland at 21 days 
p.i (~35 days after surgery, 3,9 * 104 copies of RCMV DNA per 1 µg total DNA)
In the femoral arteries only limited number of RCMV DNA copies could be detected 
(table 2). Although RCMV DNA could be detected for a longer period of time in the 
arteries when rats were infected immediately after injury compared to infection 14 
days after injury, no significant differences in RCMV DNA copy numbers were observed 
either between injured or uninjured arteries or when rats were infected immediately 
or 14 days after injury. 
Table 2 | Presence of RCMV in rat femoral arteries.
Group A: Infection immediately after injury
days post infection left femoral artery a right femoral artery
3 28,1 ± 22,3 10,3 ± 10,3
5 62,8 ± 36,3 5,5 ± 5,5
14 21,8 ± 15,8 68,9 ±50,0
35 1,7 ± 1,7 0,0 ± 0,0
Group B: Infection 14 days after injury
days post infection left femoral artery a right femoral artery
3 170,1 ± 98,8 14,1 ± 8,7
5 0,0 ± 0,0 0,0 ± 0,0
14 0,0 ± 0,0 0,0 ± 0,0
21 0,0 ± 0,0 0,0 ± 0,0
a RCMV DNA is expressed as the number of copies per 1 µg total DNA. 
Data are expressed as mean ± SEM. 
Discussion
Restenosis is a common problem occurring in 30-50% of all cases after an initially 
successful PTCA. And although subject for research for several decades, the 
exact underlying mechanism for restenosis has not been elucidated yet. Here, we 
investigated the role of RCMV on the process of restenosis, thereby focusing on the 
effect of infection on the different layers of the vessel wall. Furthermore, as it is still 
a matter of debate whether the effect of RCMV is attributable to a direct effect of 
the virus on components of the vascular wall we decided to determine the number of 
RCMV DNA copies in the (injured) vascular wall at various time points post infection. 
In the current study, we used a different model for endothelial denudation than the 
classical balloon injury model. The present model is based on a photochemical reaction 
between green light and rose bengal, which causes endothelial injury followed by 
ICAM, VCAM, E/P-selectin expression and monocyte recruitment, as well as platelet 
adhesion, aggravation, and formation of a platelet- and fibrin-rich thrombus at the 
site of the reaction (Saniabadi 1995). This photochemical model is a simple, non-
invasive and non-mechanical animal model to study the neointimal formation after 
vascular injury as compared to flexible wire and balloon catheter injury. However, 
the morphological and proliferative changes observed after endothelial injury in this 
model, with respect to thrombus formation and SMC’s proliferation, still mimics the 
phenomenon seen after balloon angioplasty and flexible wire injury (Kikuchi 1998). In 
conformity with previous studies this model proved to be a reproducible, simple and 
practical approach to study SMC replication, migration and neointimal formation and 
to study possible risk factors on the process of restenosis.
After endothelial injury, platelets adhere to the denuded surface thereby 
releasing their granules, which contain vasoactive, thrombotic factors as well as 
several growth factors. Subsequently, the following cellular events can be described 
by three partially overlapping phases; (1) proliferation of SMC’s in the media; (2) 
migration of SMC’s from the media to luminal surface and (3) proliferation of SMC’s 
in the neointima (Schwartz 1995). We focused on the two proliferative phases since 
stimulatory effects of CMV infection on the proliferation and accumulation of SMC’s 
have been described in detail previously (Yonemitsu 1997, Castillo 2000, Tanaka 
1999).
Previously, we demonstrated that the smooth muscle phenotype determines 
the susceptibility for RCMV infection. When arterial SMC’s exhibit a contractile 
phenotype they seem rather resistant against RCMV infection as illustrated by the 
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absence of RMCV antigens in the normal media following RCMV infection (Persoons 
1994). However, it has been demonstrated that the arterial SMC phenotype changes 
from contractile to synthetic/proliferative shortly after injury of the vascular wall 
thereby rendering them more susceptible for infection. This is supported by the 
observation that RCMV antigens and DNA could be demonstrated in the neointima 
but not in the media when rats were infected 14 days post angioplasty when intimal 
but not medial SMC display the proliferative phenotype (Persoons 1997). Thus, we 
infected rats immediately after injury, when dedifferentiation of the medial smooth 
muscle layer is initiated. This resulted in a noticeable effect on medial cross sectional 
area, which was significantly enlarged compared to the medial area in mock-injected 
rats. Since the mean number of cells per µm2 did not alter, this implicates an increase 
in the total number of cells underlying the increase in medial cross-sectional area. 
However, no difference in the number of PCNA positive cells was observed anymore 
suggesting that the stimulating effect of RCMV on SMC proliferation had taken place 
in the early phase after infection. On the other hand, no effect was seen on the 
neointimal cross-sectional area. This suggests that RCMV is able to infect the vascular 
wall when dedifferentiated SMC’s are present and exert a transient effect, which 
is only reflected by the increase in the medial cross-sectional area. This concept is 
supported by the data obtained when rat were infected with RCMV 14 days after the 
initial injury. Previous data demonstrated that at this stage medial SMC proliferation 
has returned to control values but intimal SMC proliferation is still submaximal. 
Under these conditions, a significant increase in neointimal cross-sectional area was 
observed with no effect on the media. Consequently, the neointima-to-media ratio 
was significantly augmented. Furthermore, the absence of significant differences 
in the number of PCNA positive cells again suggest that the RCMV effect on SMC 
proliferation takes place at an early stage after infection.
The absence of an increase in neointima-to-media ratio, when rats were infected 
immediately after injury, is in contrast with earlier studies. Zhou and colleagues 
previously reported an increase in the neointima-to media ratio in a similar experiment 
(Zhou 1999b). Nevertheless, for various reasons, their results may differ from the 
ones in the present study. First of all, we used a different model as compared to Zhou 
et al. Since the degree of neointima formation is linearly correlated with the amount 
of damage to the vascular wall (Indolfi 1995) and as the model we used may result 
in less damage to the medial layer than a balloon catheter this may partially explain 
the observed differences. In particular when the stimulating effect of RCMV is mainly 
restricted to dedifferentiated SMC’s as suggested in the present study. Furthermore, 
Zhou et al. used a different RCMV stain as in the present study (Priscott vs. Maastricht 
strain). Studies in the mouse already pointed out that the cardiovascular effects of 
different CMV strains may differ (Fairweather 1998) thereby offering an alternative 
explanation, e.g. that vascular effects of RCMV are also strain-specific.
Interestingly, a significant increase in the neointima-to-media ratio was observed 
when rats were infected 14 days after the initial injury. These results are in conflict 
with data previously published by our group. When we infected rats at a similar time 
point after balloon injury no significant effects on this ratio were observed (Persoons 
1994). Nonetheless, the present study differs at several important aspects from the 
previous one. In these earlier experiments immuno-compromised rats were used 
to give the virus the chance to proliferate and initiate an infection (Stals 1990). 
Indeed, a large number of cells in the neointima of the common carotid arteries was 
positive for RCMV antigens and genome, as shown with immunohistochemical and in 
situ hybridisation techniques. This is in contrast with the present study where no 
RCMV antigens could be detected in the vascular wall (data not shown) and only a 
limited number of RCMV DNA copies per µg total DNA was found with the far more 
sensitive real time PCR technique. Nonetheless, in the earlier study no effect on SMC 
proliferation was found while in the present study the neointimal area as well as 
the neointima-to-media ratio was significantly increased following RCMV infection. 
These data suggest that the abundant presence of the virus in the vascular wall is not 
mandatory to exert an effect on SMC proliferation and indicates that indirect effects 
of RCMV infection may be of more importance. 
Indirect effects may result from the systemic production of various pro-
inflammatory cytokines such as IL-2, IL-4 or IFN-γ. Indeed, elevated serum levels of 
these cytokines have been described following RCMV infection (Zhou 2000). Also, the 
transient presence of RCMV in the vascular wall may result in an increased influx of 
immune cells such as macrophages and T-cells. These cells then may responsible for an 
increased local production of pro-inflammatory cytokines and growth factors thereby 
stimulating SMC proliferation and growth. Interestingly, we recently demonstrated 
an increased influx of T-cells in atherosclerotic plaques of apoE-/- mice following 
MCMV infection despite the absence of MCMV DNA in the vascular wall (Vliegen 2002). 
The importance of a functional immune system in the hyperplastic response was also 
emphasized by Lemström and colleagues, who demonstrated that RCMV infection 
increased SMC proliferation and neointimal thickness of aortic allografts, even 
though there was no evidence of active viral infection in the graft tissue (Lemström 
1993). When systemic and/or local immune responses are indeed more important 
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for stimulation of SMC proliferation than the actual presence of the virus, this may 
explain our previous results showing a lack of effect of RCMV infection on neointima 
formation in immuno-compromised rats. 
In de novo atherosclerosis as well as in restenosis two factors are related to 
the severity of luminal stenosis: plaque mass or intimal hyperplasia and arterial 
remodelling. Nevertheless, we did not observe an increase in the neointima/lumen 
ratio in rats, which were infected 14 days after initial surgery despite a significant 
increase in the neointimal area. This suggests that the observed increase in intimal 
area is followed by compensatory outward remodelling. Such compensatory enlarge-
ment, in particular of coronary arteries partly occluded by atherosclerotic plaques, has 
previously been described (Glagov 1987, Hernmiller 1986, Isner 1986). Furthermore, 
a positive correlation has been observed between vessel enlargement and intimal 
area so that the lumen cross-sectional area tends to be maintained at a near normal 
level for extended periods of time (Masawa 1994). This compensatory enlargement 
ensures that adequate amounts of nutrients and oxygen can still be transported to 
tissues, which are supplied by post stenotic arteries and may result from an increase 
in shear stress sensed by the regenerating endothelium on the intimal smooth muscle 
cell layer. Such augmentation in shear stress has been demonstrated to be a powerful 
stimulus for outward remodelling (Pouradeaud 1997).
We also found a decrease in the number of cells per µm2 in the intima at 35 days 
after injury when rats were RCMV infected immediately after endothelial injury. 
This observation suggests that either the cells in the intima in the infected group 
became hypertrophic or that extracellular matrix proteins take a larger proportion 
of the neointimal area. Unfortunately, due to technical imperfections we were 
unable to quantify the amount of extracellular matrix by using a Sirius red staining. 
Nevertheless, RCMV is not present in the arterial wall at this time point and the link 
between prior infection and cellular hypertrophy or extracellular matrix production 
in the intima 35 days after infection remains subject for further study.
In summary, we demonstrated that RCMV infection stimulates arterial SMC 
proliferation when vascular injury is induced by a photochemical reaction resulting 
in endothelial damage and neointima formation. Furthermore, we showed that the 
increase in the medial or intimal cross-sectional area was dependent on the time 
point of infection. Importantly, this RCMV induced effect occurs even when there are 
only low amounts of virus present in the arterial wall, suggesting that inflammatory 
and immune responses to RCMV infection are more important in exaggerating the 
response to vascular injury than the virus itself.
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Abstract
Venous grafts are commonly used to treat drug resistant coronary artery disease 
although long term functionality is limited because of proliferation and migration of 
smooth muscle cells (SMC). As proliferating SMC are particularly susceptible for the 
stimulating effects of cytomegalovirus (CMV), we hypothesized that CMV infection 
may enhance cell proliferation and graft failure. Furthermore, we evaluated the 
potential of FK778 to prevent intimal hyperplasia. Apart from its antiviral properties, 
FK778 is a new immunosuppressive agent which may also affect SMC proliferation 
making it an interesting drug to prevent (CMV-enhanced) venous graft intimal 
hyperplasia.
In 4 groups (n=10 rats/group), epigastric vein-to-common femoral artery 
interposition grafts were placed. Rats received either FK778 (oral treatment, 15mg/
kg), were infected with CMV (1,25 × 106 PFU) or were both treated and infected. 
CMV infection resulted in a significant increase in intimal and medial cross-
sectional area and medial wall thickness of the vein grafts. This effect was diminished 
by administration of FK778. Moreover, FK778 treatment alone resulted in a significant 
decrease in neointimal area and percentage of stenosis vs. the control group. 
These data suggest a role of CMV in venous graft failure. Also, our results suggest 
a prospective role for the new immunosuppressive drug FK778 in the prevention of 
(CMV-mediated) vein graft initimal hyperplasia.
Introduction
Autologus vein grafts are commonly used for coronary artery bypass grafting, 
along with angioplasty, for the treatment of advanced arterial stenosis and drug-
resistent angina pectoris. Although the initial results of venous grafts are successful, 
the symptoms tend to recur due to degeneration and occlusion of the graft. Early 
thrombosis and neointimal hyperplasia are thought to be the primary causes of graft 
failure. Intimal hyperplasia (IH), defined as the accumulation of smooth muscle cells 
(SMC) and extracellular matrix in the intimal component of the vein, is the major 
disease process in the venous graft within the first year. It has been strongly suggested 
that IH is associated with extensive endothelial denudation and destruction of venous 
grafts, resembling a response to injury as seen after PTCA often leading to restenosis 
of the denuded artery (LoGerfo 1983). Previous studies indicated that infectious 
agents, and in particular cytomegalovirus (CMV), increase the risk of restenosis after 
PTCA (Horne 2002, Mueller 2003) and coronary atherectomy (Zhou 1996). In addition, 
we recently showed that CMV aggravates intimal hyperplasia in rats by stimulating 
SMC proliferation in an arterial injury model (Kloppenburg 2005). 
Although multiple studies demonstrated a role for CMV in IH, a possible 
contribution of CMV in venous bypass failure received only limited attention so 
far and results have been inconclusive hitherto (Bartels 1999, 2000, Ibrahim 2005, 
Limnell 2004). Therefore, we decided to elucidate the role of CMV on vein graft IH 
in an experimental animal model. Moreover, we evaluated whether treatment with 
FK778 i) could restrain vein graft stenosis, ii) reduced the aggravating effects of CMV 
on IH due to its antiviral properties. The synthetic malononitrilamide FK778 (MNA 
715) is one of the most interesting new immunosuppressive/anti-proliferative drugs 
(Vincenti 2002). It is a derivative of A77 1726, the active metabolite of leflunomide, 
which already has been shown to be effective in reducing rat aortic SMC proliferation 
(Czech 1999). FK778 binds specifically to the enzyme dihydro-orotate dehydrogenase 
thereby inhibiting the de novo pyrimidine biosynthesis (Silva 1997) and consequently 
cell proliferation. Besides its effect on pyrimidine synthesis FK778 may also affect 
other processes potentially involved in IH. E.g., FK778 has been shown to reduce 
endothelial adhesion molecule up-regulation and to attenuate lymphocyte-
endothelium interaction (Deuse 2004). In addition FK778 effectively attenuated 
vascular response to injury by diminishing neointima formation through the inhibition 
of receptor tyrosine kinase activity in vascular SMC or their progenitors (Savikko 
2003). Furthermore, despite different modes of action, antiviral properties have 
74
Chapter 3
75
FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model
been attributed to both FK778 and A77 1726 (Evers 2005, Waldman 1999a, 1999b). 
These vasculoprotective and antiviral properties of FK778 make it a potentially 
interesting drug to prevent not only venous graft intimal hyperplasia, but also inhibit 
the aggravating effects of CMV infections on this process. In the present study both 
issues were addressed.
Materials and Methods
Animal Conditions and Vein Grafting Procedure
Male inbred specific pathogen free (SPF) Lewis (LEW) rats were obtained from the 
Department of Experimental Animal service of the University of Maastricht, the 
Netherlands. Experiments were carried out on animals aged 12 weeks weighing 
250-350 gram. Housing and care of the animals, and all the procedures used in this 
study were approved by the Ethical Committee for the Use of Experimental Animals 
of the institution, and conform the Guide for the Care and the Use of Laboratory 
Animals, published by the US National Institute of Health (NIH Publication No. 85-23, 
revised 1985). Rats were fed standard rat chow and tap water at libitum. All surgical 
procedures were performed under general anesthesia and using sterile technique. 
Epigastric vein-to-common femoral artery interposition grafts were placed in rats by 
the use of a method similar to that described earlier by Hoch et al. (Hoch 1994). 
In brief, each animal was anesthetized with an intraperitoneal (i.p.) injection of 
pentobarbital sodium (60mg/kg). An 8mm segment of the ipsilateral epigastric vein 
was carefully harvested, gently irrigated with heparinized saline solution (100 U/ml), 
and placed as reverse interposition graft into a segmental 3mm defect of the common 
femoral artery with 8 to 10 interrupted sutures of 11-0 nylon (Ethicon). The entire 
procedure was carried out with standard microsurgical techniques. The total ischemic 
time was kept to less than 30min. Graft patency, defined as a condition of flow 
through the graft, was verified by visual inspection. 
Experimental Design
The whole experiment consisted of a total of four experimental groups (n=10 animals/
group) which all underwent surgery. Furthermore, rats were either infected with 
CMV, treated with FK778 or both. A control group only received the FK778 solvent 
(1ml of a 1% carboxymethyl cellulose solution in water). Infection was established 
by inoculating rats i.p. with 1,25 × 106 plaque forming units (PFU) of homogenized 
salivary gland-derived rat CMV (RCMV, Maastricht strain) (Bruggeman 1982) imme-
diately after surgery. 
FK778 was supplied by Fujisawa Healthcare Inc. (Osaka, Japan). For oral 
administration, FK778 powder was suspended in 1% carboxymethyl cellulose solution 
in water, until a final concentration of 5mg/ml was reached. Animals received an oral 
dose of 15mg/kg body weight per day from one day prior to the operation till the day 
of tissue harvest.
Histological and Morphometrical Procedures
Three weeks after surgery, rats were anaesthetized and graft patency was verified 
by visual inspection. Then, the chest and abdominal cavities were opened and a 
catheter was inserted into the apex of the heart. Vasculature was initially flushed 
with physiological salt solution and then perfusion fixed with 3.7% formaldehyde in 
phosphate-buffered saline, pH 7.4, at physiological pressure (100 mmHg). Vein grafts 
were removed and fixed overnight in the same fixative and routinely processed for 
paraffin embedding. Cross-sections (4 μm) were taken for morphometrical analysis 
and haematoxylin-eosin or Lawson stained (average of three cross-sections per graft). 
Intimal and medial areas were quantified using a computer assisted morphometry 
system (analySIS®, Soft Imaging System, GmbH). The cross-sectional area of the 
media was defined as the area surrounded by the external and internal elastic 
lamina. The neointimal cross-sectional area was defined by the area surrounded by 
the internal elastic lamina and the arterial lumen. Next, the percentage of stenosis 
was calculated which is defined as the percentage of cross-sectional area of the 
former lumen occluded by the neointima. Final scores were given as percentage of 
the control group.
Quantification of number of cells in the intima and media
The number of cells in the intima and media was quantified by counting the total 
number of nuclei using a microscope. All nuclei were counted in haematoxylin-eosin 
stained cross-sections taken from patent grafts in which a neointima was observed. 
Final scores were expressed as number of cells per µm2 and values are given as 
mean.
Immunohistochemistry 
Paraffin sections (4μm), taken from vein grafts three weeks after surgery, were 
routinely processed and stained with the two-layer indirect immunoperoxidase 
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technique using monoclonal antibodies (mAb). The following mAbs were used in this 
study: anti-rat CD3 (Sera-lab, Crawley Down, UK); anti-α smooth muscle actin (Sigma, 
Missouri, USA); ED-1, a mouse mAb to monocytes/macrophages was kindly supplied by 
Dr. A.M. Duijvestijn (Dept. of Immunology, University Maastricht, the Netherlands). 
Sections were incubated with 2% BSA in phosphate-buffered saline (PBS) (ED-1 and 
α-actin) for 15min at room temperature and treated with antigen retrieval buffer 
(CD3) for 25min at 95°C (McKechnie 1997). Monoclonal antibodies were diluted 
(ED-1 1/20, α-actin 1/1500 and CD3 1/400) in PBS and applied to the slides for 60 
min at 37°C. After three washes with PBS for 5 min, a biotinylated goat anti-mouse 
secondary antibody (1/1200, DAKO Glostrup Denmark) was applied for 30 min at room 
temperature. Finally, sections were incubated with alkaline phosphatase-coupled 
streptavidin (ABC reagent, Vector Laboratories), followed by immunodetection 
using fast red as a substrate. Then, the presence of positive cells was analyzed by 
microscopy and scored semi-quantitatively (0=no staining, 1=positive staining and 
2=extensive positive staining) by an observer blinded to the specimen group.
Statistical analysis 
All data were expressed as mean ± S.E.M. To analyze differences for statistical 
significance, a Mann-Whitney U test was performed using SPSS 11.0 for Windows 
(SPSS, Chicago IL, USA). Differences were considered to be statistical significant 
when P values were less than 0.05. 
Results
Animal condition and grafts
No apparent clinical signs of illness were observed in any of the animals during the 
follow-up period. Starting body weight ranged from 250 g to 350 g; at the end of the 
experiments animal weight ranged from 325 g to 405 g. The overall graft patency was 
90%. There were no significant differences in body weights or graft patency between 
the experimental groups (data not shown). There were no structural abnormalities at 
the anastomotic regions of the grafts. The gross appearance of the veins and adjoining 
arteries was normal.
Table 1 | Summary of morphological alterations found in CMV-infected rats.
Intimal area  Medial area  Stenosis % Wall
thickness
CMV   = 
CMV + FK778 =   
FK778  =  =
FK778-treated rats or CM-infected/FK778 –treated animals three weeks after vein grafting. All data 
were compared to data obtained in control rats.  : significant increase,  : significant decrease, 
= : no significant change.
FK778 attenuates CMV aggravated intimal hyperplasia
Three weeks after bypass grafting, medial cross-sectional area was increased and a 
pronounced neointimal thickening was observed in all grafted veins (figure 1 and 2A). 
CMV  infection immediately after vein grafting resulted in a significant increase in 
intimal  cross-sectional area, medial cross-sectional area and medial wall thickness 
at three weeks  after surgery as compared to the control group (figure 1 and 2B). This 
effect was partially  reversed by FK778 treatment, resulting in a significant decrease 
of the CMV aggravated  neointimal cross-sectional area as well as percentage of 
stenosis but not medial cross-sectional area or medial thickness. Furthermore, FK778 
treatment alone resulted in a significant decrease in neointimal area and percentage 
of stenosis as compared to the control group although no effects were seen on medial 
cross-sectional area or medial thickness (figure 1, table 1).
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Figure 1 | Effect of FK778, CMV or co administration of CMV and FK778 on neointimal (A) 
and medial (B) cross sectional areas three weeks after vein grafting.*: P<0.05 vs. controls.
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Quantification of number of cells in the intima and media
Although the medial and intimal cross-sectional area was significantly increased at 
3 weeks when rats were infected immediately after surgery, the average number of 
cells/µm2 was not different as compared to the control group (table 2). This implies 
that the total number of cells in the intima and media is increased and suggests that 
CMV predominantly stimulated cell proliferation. FK778 treatment resulted in a 
decrease of intimal cross-sectional area but again average number of cells/µm2 was 
not different as compared to the control group (table 2). This implies that the total 
number of cells in the intima is decreased and suggests that cell proliferation has 
been attenuated by FK778.
Table 2 | Cellular density in both media and neointima of all groups.
Control CMV FK778 CMV+FK778
media 4,4 ± 0,7 4,9 ± 0,6 4,3 ± 0,6 4,7 ± 0,3
neointima 16,4 ± 3,5 15,4 ± 3,6 18,1 ± 2,1 16,5 ± 3,1
Data are expressed as x10-3 cells/µm2. No significant differences were observed between groups
Figure 2 | Showing typical examples of venous grafts cross-sections 21 days after grafting. 
A) Lawson staining venous graft control group, B) Lawson staining venous graft CMV infected 
group, C) ED-1 monocyte macrophage staining. I = Intima, M = Media, A = Adventitia. (see page 
166 for color picture)
Immunohistochemistry
The number of T-cells in the venous graft  three weeks after surgery was minimal with 
an average of one to three T-cells per cross-section. No difference in T cell number/
section was observed between groups. Presence of macro- phages was abun-dant and 
cells were most frequently detected in the subendothelial space as well as in  the 
intima (figure 2C). However, when stainings were analyzed in a semi-quantitative 
way, no significant differences were noted between groups  (data not shown). Alpha-
actin staining showed SMC to be the main content of the intima and media with little 
extra-cellular matrix accumulation in all groups.
Discussion
Venous graft failure is a common problem, occurring in 10-15 % of grafts during the 
first year increasing up to 40% within 10 years (Fitzgibbon 1996). Early thrombosis 
and neointimal hyperplasia are considered to be the primary causes of graft failure. 
Nonetheless, although a research subject for several decades, the exact underlying 
mechanism of venous graft failure has not been elucidated yet. As CMV infections 
have been shown to accelerate arterial restenosis, we hypothesized that the virus 
may also contribute to venous graft failure. This was addressed in the present study 
in which we investigated whether CMV contributes to venous graft failure in a rat 
epigastric vein-to-common femoral artery graft model. In addition, we studied the 
therapeutic potential of the immunosuppressive/anti-proliferate drug FK778 in 
preventing intimal hyperplasia (IH) with or without a concomitant CMV infection. 
Here we present for the first time evidence that CMV contributes to the process of 
venous graft failure. Furthermore, we demonstrate that FK778 is able to partially 
prevent IH in a venous bypass graft in non-infected animals, while the drug was also 
able to reverse the additional effect of a concomitant CMV infection on IH (table 2).
Neointimal hyperplasia, defined as the accumulation of SMC and extracellular 
matrix in the intimal compartment of blood vessels, is the major disease process 
in venous grafts within the first year. Nearly all veins implanted into an arterial 
circulation develop intimal wall thickening thereby reducing the lumen size. This is 
confirmed by our results in the rat venous graft model. In the epigastric vein-to-
common femoral artery interposition grafts a significant enlargement of the vascular 
wall was observed at 3 weeks post transplantation, which is in agreement with earlier 
data presented by others (Hoch 1994).
This intimal wall thickening predominantly results from excessive SMC prolife-
ration in response to injury. Under normal conditions SMC in the media of blood 
vessels proliferate at very low rates, but can switch very rapidly from quiescence 
to a proliferative state in response to appropriate stimuli like bypass grafting 
or angioplasty (Majesky 1987). Previously it has been shown that CMV accelerates 
cellular proliferation (Speir 1994). This suggestion is supported by the present 
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data. Although the total intimal area was significantly increased following CMV 
infection, the average number of cells per μm2 was unchanged, indicating that CMV 
stimulates SMC proliferation but not cellular hypertrophy or extensive accumulation 
of extracellular matrix ultimately resulting in an enlarged medial and intimal area. 
The latter was confirmed by α-actin immunostaining showing that the majority of the 
intima and media consisted of SMC. These results are in accordance with earlier data 
from our group, in which we demonstrated that CMV stimulates SMC proliferation 
in the thrombosis-induced intimal thickening in the rat femoral artery (Kloppenburg 
2005). Although the exact mechanism is unclear until now, it has previously been 
suggested that inhibition of the p53 suppressor effects are the predominant cause of 
CMV-induced stimulation of SMC proliferation (Speir 1994). Nevertheless, additional 
research is required to further clarify the effect of CMV on cellular proliferation.
The new malononitrilamide FK778 is currently being evaluated as an immuno-
suppressant for organ transplantations as it effectively inhibits T-cell proliferation 
and alloantibody synthesis by B cells (Kurrle 1996). Furthermore, besides being 
immunosuppressive, vasculoprotective properties have also been attributed to FK778. 
More precisely, it has been shown that FK778 may inhibit SMC proliferation. In various 
experimental models it has been demonstrated that FK778 effectively attenuates 
vascular responses to injury by diminishing neointima formation and fibrointimal 
hyperplasia, perhaps through inhibition of the receptor tyrosine kinase activity in 
vascular SMC or their progenitors (Savikko 2003, Hoch 1994, Janhke 2005). Also in 
our rat model of epigastric vein-to-common femoral artery interposition grafts a 
daily regimen of 15 mg/kg FK778 significantly reduced intimal hyperplasia resulting 
in a lower percentage stenosis as compared to the control group. Quantification of 
the number of cells per μm2 revealed no significant differences between groups, 
indicating that the reduction in cross-sectional intimal area caused by FK778 is due to 
a decrease in SMC proliferation. 
Along with its antiproliferative activity, antiviral properties against cytome-
galovirus have been assigned to FK778 (Waldman 1997, 1999). FK778 is a potent 
and effective inhibitor of CMV and its mode of antiviral action appears to mirror 
the biochemical mechanism described to be responsible for its immunosuppressive 
properties: inhibition of protein tyrosine phosphorylation and inhibition of cellular 
de novo pyrimidine biosynthesis (Evers 2005). Here we demonstrate that FK778 is 
able to partially prevent the CMV-mediated enhancement of IH in the venous graft. 
Treatment with FK778 significantly reduced the effect of CMV on intimal area as 
well as on the percentage stenosis. In contrast, no effects of FK778 treatment were 
observed on the medial cross-sectional area. 
It remains to be established whether the antiviral or the anti-proliferative 
properties of FK778 are predominantly responsible for its inhibitory effect on the 
CMV-mediated enhancement of intima formation in infected animals. Previously, 
we demonstrated that CMV aggravates intimal hyperplasia in a thrombosis-induced 
intimal thickening model mainly by stimulating SMC proliferation (Zhou 1996). 
As hardly any virus could be detected in the vascular wall at various stages of the 
hyperplastic process, it was suggested that inflammatory and immune responses are 
more important in the CMV-mediated augmentation of the hyperplasic response than 
the virus itself. Based on these findings we assume that the effects of FK778 in our 
venous graft model should not be ascribed to its antiviral characteristics. 
Although inhibition of the cellular and humoral immune response is of great 
importance in preventing acute rejection and also chronic allograft dysfunction 
in transplantation, it is questionable whether it plays a significant role in venous 
graft failure. Hoch et al. showed the relative absence of CD4+ and CD8+ cells in the 
epigastric vein-to-common femoral artery interposition grafts in the rat model (Hoch 
1994). Likewise, we also found only a limited number of CD3+ cells in the grafts at 
three weeks after surgery with no clear difference between the infected, treated 
and the control group. This also suggests that it is unlikely that the effect of FK778 
on intima hyperplasia is due to its immunosuppressive activity. Alternatively, it has 
recently been shown that FK778 directly reduces ICAM-1 and VCAM-1 up regulation 
and attenuates lymphocyte-endothelium interaction (Deuse 2004). We therefore 
speculated that administration of FK778 might result in a decreased influx of 
macrophages in our venous grafts. However, immunological staining showed no clear 
differences in the influx of macrophages in the grafts at three weeks after surgery. 
In conclusion, the majority of our data suggest that the effect of FK778 on intima 
hyperplasia has mainly to be attributed to its effect on SMC proliferation.
In conclusion, in a well defined animal model, we present for the first time 
evidence for a possible role of CMV in the process of venous graft failure, which could 
partially be inhibited by the new immunosuppressive agent FK778. These data suggest 
that FK778 might be a potential candidate to prevent intimal hyperplasia following 
venous bypass surgery.
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Abstract
Along with angioplasty, autologus vein grafts are commonly used for artery bypass 
grafting in patients with advanced arterial stenosis and drug-resistant angina pectoris. 
Although initially a successful procedure, long-term functionality is limited due to 
proliferation and migration of smooth muscle cells. Like in atherosclerosis, common 
chronic infections caused by viruses and bacteria may contribute to this process of 
vein graft failure. Here we investigated the possible role of Chlamydia pneumoniae 
(C. pneumoniae) in the pathogenesis of venous graft failure in an experimental animal 
model. 
In 2 groups (n=10 rats/group), an epigastric vein-to-common femoral artery 
interposition graft was placed. Immediately thereafter, rats were infected with 
C. pneumoniae (5*108 IFU) or injected with control solutions. Rats were sacrificed 
three weeks after surgery and the grafts were harvested for morphometrical and 
immunohistochemical analysis.
C. pneumoniae administration immediately after vein grafting resulted in a 
significant increase in medial cross-sectional area, wall thickness and total wall 
area. There were no significant differences in T-cell or macrophage influx. Likewise, 
although positive immunostaining for both HSP60 and CRP could be detected, no 
differences were found between groups. Based on the observation that the number of 
cells/µm2 was also not altered, we conclude that C. pneumoniae infection stimulates 
smooth muscle cell proliferation by hereunto unknown molecular mechanisms, 
resulting in a significant increase in intimal hyperplasia.
In conclusion, in a well defined animal model we present here for the first time 
evidence for a role of Chlamydia pneumoniae in the process of venous graft failure.
Introduction
Besides internal mammary arteries, autologus saphenous vein grafts are commonly 
used for coronary artery bypass grafting (CABG) in angina pectoris patients, resistant 
to aggressive medical therapy or patients with advanced coronary artery stenosis 
not suitable for percutaneous transluminal coronary angioplasty (PTCA). Although 
the initial results of venous grafts are excellent, the symptoms tend to recur due to 
vein graft degeneration and stenosis greatly limiting the long term success of bypass 
surgery. Early failure occurs within the first 1 to 2 months probably from primary 
thrombosis often due to technical failure or poor runoff in severely stenotic distal 
coronary arteries (Cox 1991). Late failure occurs from several months to years 
after bypass surgery and is caused by neointimal hyperplasia (NIH) with subsequent 
atherosclerosis in the saphenous vein graft (Nwasokwa 1995). NIH, defined as 
the accumulation of phenotypically altered medial smooth muscle cells (SMC) 
and extracellular matrix in the intimal component of the vein, is most prominent 
in the venous graft within the first year. Several factors interact to influence the 
development of NIH mostly initiated by ischemia of the venous wall, mechanical 
trauma and hemodynamic stress. Moreover, convincing evidence suggested that 
NIH is associated with extensive endothelial denudation and destruction of venous 
grafts (Logerfo 1983), resembling a response to injury as seen after angioplasty often 
leading to restenosis of the denuded artery. 
Today it is generally accepted that atherosclerosis is an inflammatory diseases 
and that atherogenesis as well as disease progression result from inflammation and 
immune responses towards various stimuli. Common chronic infections caused by 
viruses and bacteria have been suggested to contribute to this inflammatory process. 
Most compelling evidence comes from data concerning the intracellular pathogen 
Chlamydia pneumonia (C. pneumoniae). Although this bacterium was initially 
identified as a causative factor in (a-)symptomatic inflammation of the airways, 
clinical studies demonstrated that patients with high titers of antibody against C. 
pneumoniae have an increased risk for cardiovascular complications (Wimmer 1996, 
Saikku 1988). This is supported by studies revealing significant accelerations of 
lesion development in animals and a large variety of pro-atherogenic effects in vitro 
(Ezzahiri 2002, Mahony 2001, Campbell 2004). In addition, recent studies have shown 
that C. pneumoniae infection promotes a proliferative phenotype in the vasculature, 
which makes C. pneumoniae also a likely risk factor for vein graft failure (Rupp 
2005, Hirono 2003). This is supported by the work of Bartels et al., who observed a 
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strong correlation between elevated C. pneumoniae IgG titers and the detection of 
C. pneumoniae in occluded vein grafts (Bartels 2000). Similar data were shown by 
Zorc et al., implicating a possible relationship between C. pneumoniae presence and 
occluded arterial bypass grafts (Zorc 2005). These studies suggest that C. pneumoniae 
is present in occluded grafts, however, experimental evidence for this is currently 
lacking. In the present paper we addressed this by examining the contribution of C. 
pneumoniae to neointimal hyperplasia in a well defined animal model for autologous 
vein grafting. To our knowledge this is the first paper which addresses the possible 
contribution of C. pneumoniae infection to the pathogenesis of venous graft failure in 
an experimental model.
Methods
Animals and vein grafting procedure
Male inbred specific pathogen free (SPF) male Lewis (LEW) rats were obtained form 
the Department of Experimental Animal service of the University of Maastricht, 
the Netherlands. Experiments were carried out on animals aged 12 weeks weighing 
250-350 gram. Housing and care of the animals, and all the procedures used in this 
study were approved by the Ethical Committee for the Use of Experimental Animals 
of the institution, and conform the Guide for the Care and the Use of Laboratory 
Animals, published by the US National Institute of Health (NIH Publication No. 85-23, 
revised 1985). Rats were fed standard rat chow and tap water at libitum. All surgical 
procedures were performed under general anesthesia and using sterile techniques. 
Epigastric vein-to-common femoral artery interposition grafts were placed in rats in a 
similar way as previously described by Hoch et al. (Hoch 1994). In brief, each animal 
was anaesthetized with an intraperitoneal (i.p.) injection of pentobarbital sodium 
(60mg/kg). An 8mm segment of ipsilateral epigastric vein was carefully harvested, 
gently irrigated with heparinized saline solution (100 U/ml), and placed as reverse 
interposition graft into a segmental 3mm defect of the common femoral artery with 
8 to 10 interrupted sutures of 11-0 nylon (Ethicon). The entire procedure was carried 
out with standard microsurgical techniques. The total ischemic time was kept to less 
than 30min. Graft patency, defined as a condition of flow through the graft, was 
verified by visual inspection at the end of the surgical procedure.
Experimental design 
Two experimental groups were used. Directly after the grafting procedure, rats 
(n=10 animals/group) were either C. pneumoniae-infected by i.p. injection (1 ml 
of 5 x 108 inclusion forming units (IFU) dissolved in a sucrose-phosphate-glucose 
solution) or received a 1 ml i.p. injection of a sucrose-phosphate-glucose solution. 
The i.p. inoculation route instead of the intranasal route was used because of the 
high infectious dosage required in rat experiments. Previous experiments done in our 
laboratory have demonstrated no significant differences in systemic dissemination 
of C. pneumoniae between intranasal and i.p. injection (Ezzahiri, personal commu-
nication). 
Histological and morphometrical procedures
Three weeks after surgery, rats were anaesthetized, the chest and abdominal cavities 
were opened and a catheter was inserted into the apex of the heart. Vessels were 
initially flushed with physiological salt solution and then perfusion fixed with 3,7% 
formaldehyde in phosphate-buffered saline (PBS, pH 7.4) at physiological pressure 
(100 mmHg). Vein grafts were removed and fixed overnight in the same fixative and 
routinely processed for paraffin embedding. Cross-sections (4 μm) were haema-
toxylin-eosin or Lawson stained for morphometrical analysis (average of three 
cross-sections per graft). Intimal and medial areas were quantified using a computer-
assisted morphometry system (analySIS®, Soft Imaging System, GmbH). The cross-
sectional area of the media was defined as the area surrounded by the external and 
internal elastic lamina. The neointimal cross-sectional area was defined by the area 
surrounded by the internal elastic lamina and the arterial lumen. Final scores were 
given as means ± SEM.
Quantification of cell number in the intima and media
The number of cells in the intima and media was quantified by counting the total 
number of nuclei using a microscope. All nuclei were counted in haematoxylin-eosin 
stained cross-sections. Final scores were expressed as number of cells per area and 
values are given as means ± S.E.M.
Immunohistochemistry 
Paraffin sections (4 μm), taken from vein grafts three weeks after surgery, were 
routinely processed and stained with the two-layer indirect immunoperoxidase 
technique using monoclonal antibodies (mAb).
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The following mAbs were used in this study: Anti-rat CD3 (Sera-lab, Crawley 
Down, UK), a mouse mAb against T-cells; anti-α smooth muscle actin (ASMA, Sigma, 
Missouri, USA), ED-1, a mouse mAb to monocytes/macrophages (kindly supplied by 
Dr. A.M. Duijvestijn Dept. of Immunology, University Maastricht, the Netherlands), a 
rabbit anti-HSP60 (CST, Danvers, USA) and anti-CRP (R&D systems, Minneapolis, USA) 
a mouse mAb against C-reactive protein. 
Sections were incubated with 2% BSA/PBS (ED-1, CRP and ASMA) for 15min at 
room temperature and treated with antigen retrieval buffer (CD3) for 25 min at 95°C 
[13]. Sections for HSP60 staining were incubated with 10mM sodium citrate buffer 
pH 6.0 and microwave boiled for 10 min at 95-99°C. Monoclonals were diluted (ED-1 
1/20, ASMA 1/1500, CD3 1/400, CRP 1/100) in PBS and applied to the slides for 
60 min at 37°C. HSP60 monoclonals were diluted 1/100 in PBS and applied to the 
slides overnight at 4°C. After three wash steps with PBS for 5 min, a biotinylated 
goat anti-mouse secondary antibody (1/1200, DAKO Glostrup Denmark) was applied 
for 30 min at room temperature. Finally, sections were incubated with alkaline 
phosphatase-coupled streptavidin (ABC reagent, Vector Laboratories), followed by 
immunodetection using fast red as a substrate. To visualize nuclei, sections were 
counterstained with haematoxylin. Then, the presence of positive cells was analyzed 
by microscopy and scored semi-quantitatively, using a zero to four scale with zero 
meaning no positive signal and 4 extremely positive, by an observer blinded to the 
experimental groups. Final values were expressed as mean ± S.E.M.
Statistical analysis 
Morphometrical data and cell count numbers are expressed as means ± S.E.M. 
Values were compared using the Mann Whitney U test and p<0.05 was considered as 
statistically significant.
Results
Animal condition and grafts
Starting body weight ranged from 250 g to 350 g, while at the end of the experimental 
period animal weight ranged from 320 g to 400 g. No differences in body weight were 
observed between experimental groups. During the experimental phase no apparent 
clinical signs of illness were observed in any of the animals. The overall graft patency 
after three weeks was 90%. Early thrombosis seemed the underlying cause of the 
failed grafts. No structural anomalies at the anastomotic regions of the grafts were 
observed.
Chlamydia pneumoniae aggravates intimal hyperplasia through 
stimulation of SMC proliferation
Three weeks after bypass grafting in all veins a significant increase in medial 
thickness was observed (medial thickness in normal, non-grafted vein: 10 ± 2 μm vs. 
36 ± 3 μm in grafted vein of the control group) and showed neointimal thickening, 
which is principally absent in non-grafted control veins. C. pneumoniae administration 
immediately after vein grafting resulted in a significant increase in the medial 
thickness (C. pneumoniae-group: 50 ± 3 μm vs. control group: 36 ± 3 μm, p<0.05), 
total wall cross-sectional area (C. pneumoniae-group: 184200 ± 57932 μm2 vs. control 
group: 75359 ± 15473 μm2, p<0.05) and medial cross-sectional area (C. pneumoniae-
group: 101731 ± 22984 μm2 vs. control group: 54149 ± 13960 μm2, p<0.05) at 3 weeks 
post surgery (figure 1). 
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Figure 1 | Effect of Cpn administration on total wall (A) cross-sectional area, medial cross-
sectional area (B) and wall thickness (C) three weeks after vein grafting. * P<0.05 (values 
compared with control)
Next, we tried to determine whether the increase in cross-sectional area results 
from a concomitant increase in cell number or whether the increase is due to cellular 
hypertrophy, interstitial oedema or an increase in extracellular matrix components. 
Therefore, we determined cellular density. Our finding that the average number of 
cells/μm2 was not significantly different between groups (C. pneumoniae-group: 
5.0 ± 0.7 × 10-3 cells/μm2 vs. control group: 4.1 ± 0.5 × 10-3 cells/μm2), suggests that 
C. pneumoniae infection stimulates cell proliferation but not cellular hypertrophy 
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or interstitial oedema or an increase in extracellular matrix components. After all, 
the latter are expected to reduce cellular density, a phenomenon which was not 
observed. 
Influx of inflammatory cells
Staining for inflammatory cells in the venous graft showed a minimal influx of T-cells 
at three weeks after surgery with an average of one to three T-cells per cross-section. 
No significant differences between experimental groups were observed. On the other 
hand, macrophages were notably present in the subendothelial area and in the media, 
however with a wide variance. Therefore, no significant differences between groups 
were found. Moreover, alpha-actin staining showed SMC to be the main content of 
the intima and media with little extra-cellular matrix accumulation in both groups, 
confirming that the increase in wall mass is predominantly due to smooth muscle cell 
proliferation. 
C-reactive protein
We also performed an immunostaining to reveal the presence of C-reactive protein 
(CRP) in the venous graft. Although predominantly produced by the liver, local 
production of CRP by SMC in response to inflammatory cytokines has also been 
demonstrated recently (Calabro 2003). Also, evidence suggests that CRP is involved in 
smooth muscle cell migration and proliferation (Jialal 2004). Truly, positive staining 
for CRP could be detected mainly in the subendothelial area (typical example shown 
in figure 2A). Nonetheless, when stainings were quantified in a semi-quantitative 
manner, no significant differences were observed between groups (C. pneumoniae-
infected: 2.5 ± 0.8 vs. control group 2.4 ± 0.5, n.s.).
Heat shock protein 60
Previously we demonstrated the noticeable presence of heat shock protein 60 (HSP60) 
in occluded veins (de Graaf 2006). Furthermore, we were able to demonstrate that 
HSP60 is able to stimulate SMC proliferation in a TLR2/4 dependent way (de Graaf 
2006). To determine whether HSP60 also plays a role in graft failure in the present 
model and whether C. pneumoniae affects the presence of HSP60 in the grafts, we 
stained HSP60 in grafts from both the control group and the C. pneumoniae-infected 
group. Indeed, HSP60 positive staining could be revealed in both groups (typical 
example shown in figure 2C). Also, semi-quantitative analysis showed a trend towards 
a more intense HSP60 signal in the C. pneumoniae-infected group (C. pneumoniae-
group: 3.3 ± 0.5 vs. control group: 2.8 ± 0.7, n.s.), although the difference was not 
statistically significant.
Figure 2| Photomicrographs showing subsequent immunolabeling of a venous bypass graft 
3 weeks after surgery (A: CRP, C:HSP60) as well as their representative negative controls 
(B,D). (see page 167 for color figure)
Discussion
Saphenous vein graft failure is a common problem after CABG. Approximately 15% to 
30% of vein grafts occlude during the first year increasing up to 50% within 10 years 
(Fitzgibbon 1996). Graft failure occurring within one month after surgery is almost 
always caused by thrombosis. Neointimal hyperplasia as defined as the accumulation 
of SMC and extracellular matrix in the intimal layer follows a similar pattern in the 
balloon injured artery or vein graft and is the major disease process in the vein graft 
resulting in failure during the first year (Motwani 1998). Nearly all veins implanted 
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into the arterial circulation develop intimal wall thickening thereby reducing the 
lumen size. This is confirmed by our results in the rat venous graft model. At 3 weeks 
post transplantation, a significant increase in both total and medial cross-sectional 
area as well as media thickness was observed in the epigastric vein grafts, which is in 
agreement with earlier data from Hoch and colleagues (Hoch 1999). 
To unravel the underlying molecular mechanisms contributing to the pathology of 
vein graft failure a large variety of studies have been carried out of the past decades 
in order to find an effective intervention. However, until now these mechanisms 
haven’t been completely elucidated yet. Recently, sero-epidemiologic studies 
have suggested a role for C. pneumoniae the development of vascular disease. C. 
pneumoniae is an obligatory intracellular Gram-negative bacterium that was first 
isolated as a respiratory pathogen. This micro-organism has also been isolated from 
coronary arteries of patients with acute coronary syndrome (Zorc 2005), as well as 
from carotid arteries (Johnston 2005), the aorta and peripheral arteries (Gutierrez 
2001). These observations in combination with multiple in vitro findings (Mahony 
2001) demonstrating a stimulating effect of C. pneumoniae on SMC proliferation, 
supported a role for C. pneumoniae in obstructive vascular disease. Nonetheless, in 
contrast to atherosclerosis, a possible role of C. pneumoniae in venous bypass failure 
has been less subject of study. Bartels et al. (Bartels 1999) studied the prevalence of 
C. pneumoniae in occluded vein grafts and native saphenous veins and showed that 
C. pneumoniae was frequently present in occluded CABG but not in normal veins. 
C. pneumoniae DNA could be detected by PCR in 25% of the cases, while viable C. 
pneumoniae was recovered from 16% of occluded vein grafts. In this study we present 
for the first time evidence for a role for C. pneumoniae in venous graft failure. 
When rats were infected with C. pneumoniae immediately after surgery, a 
significant increase in media thickness and total wall cross-sectional area was 
observed in the epigastric vein-to-common femoral artery graft. To unravel a 
potential mechanism which might explain the effect of C. pneumoniae on intima 
hyperplasia, we first evaluated the presence of inflammatory cells in the graft. 
Focal endothelial disruption, occurring during all vein graft harvesting, leads to 
adherence of platelets and monocytes. Several lines of evidence suggest that C. 
pneumoniae replicate within alveolar cells and can make its way into the wall of the 
healing graft by using macrophages and monocytes as vectors (Kaukoranta-Tolvanen 
1996). Once present in the vascular wall, C. pneumoniae may further enhance the 
influx of monocytes through the release of monocyte chemoattractant protein 1 
by VSMC’s. Chronic macrophage infection contributes to local inflammation but it 
remains unclear whether this aggravates intimal hyperplasia and bypass failure. Hoch 
et al. demonstrated that depletion of macrophages suppresses intimal hyperplasia 
indicating the importance of the amount of macrophages present in the graft 
(Hoch 1999). However immunostaining of the venous graft in our model showed no 
differences in influx of inflammatory cells between the C. pneumoniae infected and 
the control group, suggesting a different mechanism of action. 
C. pneumoniae infection of vascular smooth muscle cells increases interleukin-6 
(IL-6) secretion in vitro (Yang 2005). In vivo, IL-6 is a strong inducer of liver C-reactive 
protein (CRP) production which is able to stimulate endothelial and smooth muscle 
cell proliferation providing a pathway for C. pneumoniae to aggravate vein graft 
failure (Cirillo 2005). In addition, evidence is accumulating suggesting that SMC are 
able to produce CRP and stimulate SMC migration and proliferation in an autocrine 
fashion (Jialal 2004). Indeed, we were able to demonstrate the presence of CRP in 
particular in the sub-endothelial layer thereby providing further evidence for a role 
for CRP in intima hyperplasia. Nonetheless, no significant difference between the two 
groups was observed indicating that C. pneumoniae infection does not have an effect 
on the presence of CRP in the vascular wall at the time point examined. Nevertheless, 
this does not exclude that C. pneumoniae may affect the production of CRP at earlier 
time points post surgery and contribute as such to the process already at an earlier 
stage. Further studies are required to unravel this aspect in more detail.
C. pneumoniae is also known to produces large amounts of heat shock protein 60 
(HSP 60) during chronic, persistent infections (Costa 2002). C. pneumoniae HSP60, 
which is well conserved during evolution and shows a high degree of homology with 
mammalian HSP60, is able to activate vascular endothelium, smooth muscle cells, 
and macrophages (Kol 1999). HSP60 is also able to stimulate SMC proliferation 
(de Graaf 2006, Sasu 2001) and may hereby aggravate a hyperplastic response 
as seen in our model. Therefore, we decided to determine the presence of HSP60 
by immunohistochemistry. Actually we were well able to visualize the presence 
of HSP60 in the grafts of both groups; however, despite the fact that there was a 
trend towards an increase in the presence of HSP 60 in the venous grafts of the C. 
pneumonia-infected group as compared to the controls, this failed to reach statistical 
significance.
Conclusion
Summarizing, we present here for the first time evidence for a possible role of 
Chlamydia pneumoniae in the process of venous graft failure. In a well defined animal 
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model, a significant increase in total and media cross-sectional area as well as media 
thickness was observed in vein grafts obtained from C. pneumoniae-infected rats, 
suggesting that C. pneumoniae is able to promote the process of intima hyperplasia. 
Furthermore, cellular density in the vascular wall remained constant indicating that 
C. pneumoniae stimulates cell proliferation but not hypertrophy nor the formation of 
institial oedema or the deposition of extracellular matrix components. In addition, 
we analyzed in more details some of the possible molecular mechanisms which may 
contribute to the observed C. pneumoniae-mediated effects. However, none of the 
suggested mechanisms (enhanced influx of inflammatory cells, augmented production 
of CRP or HSP60) seemed primarily responsible for the observed effects and further 
research is warranted to elucidate in more detail how C. pneumoniae affects vein 
graft failure.
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Abstract 
Long-term survival of solid-organ transplants is limited as a result of chronic transplant 
dysfunction (CTD), which is characterized by occlusion of intragraft vascular tissue 
due to myointimal hyperplasia. Recent studies showed a role for infections in vascular 
pathologies. For example, Chlamydia pneumoniae (C. pneumoniae) has been shown 
to aggravate atherosclerosis and C. pneumoniae IgG titers correlate with severity of 
allograft atherosclerosis after cardiac transplantation. In this study we evaluated the 
effect of C. pneumoniae infection on CTD by using a rat aortic allograft model.
Orthotopic abdominal aorta transplantations (Tx) were performed with BN rats as 
donors and Lewis rats as recipients. Rats were sacrificed 1 or 8 weeks after surgery 
and the graft was processed for DNA isolation and histological examination. Influx of 
macrophages and T-cells was assessed by immunohistochemistry.
At 1 week after Tx, the perivascular influx of inflammatory cells in the graft was 
not affected by C. pneumoniae infection. Furthermore, only limited numbers of C. 
pneumoniae DNA copies were found in the graft at 1 week after Tx. In addition, C. 
pneumoniae did not alter the severity of myointimal hyperplasia in the rat aortic 
allograft model at 8 weeks after surgery.
Our data suggest that in the rat aortic allograft model C. pneumoniae infection 
does not influence the influx of inflammatory cells or the severity of CTD.
Introduction
 
Organ transplantation has become an increasingly successful medical treatment 
for patients with end-stage organ failure. However, despite improvements in 
immunosuppressive drug therapy and treatment of acute rejection, long-term survival 
of solid-organ transplants is limited as a result of chronic transplant dysfunction 
(CTD). In the majority of organs, CTD is characterized by a persistent perivascular 
inflammation which results in a diffuse multifocal myointimal hyperplasia and 
inadequate vascular remodeling resulting in intimal narrowing of all the vessels in 
the graft (Pethig 1998). Major risk factors for CTD are humoral and cellular immune 
responses, hyperlipidemia and viral infections. Regarding the latter, cytomegalovirus 
(CMV) in particular has been associated with CTD. Multiple experimental as well 
as clinical data support a detrimental effect of CMV infections on long term graft 
survival (Lemstrom 1993, 1994, Potena 2003, Arnold 1992, Fitzgerald 2004, Fateh-
Moghadam 2003). 
Apart from its effect on CTD, it’s becoming increasingly clear that CMV has an 
effect on other vascular pathologies, like atherosclerosis or restenosis (Vliegen 
2002, Bason 2003, Sorlie 2000). Moreover seropositivity for other organisms, like 
Helicobacter pylori, herpes simplex or hepatitis A virus, has also been shown to be 
associated with the atherosclerosis (Mayr 2003, Kotronias 2005, Zhu 2000). Most 
convincing evidence comes from data regarding the intracellular pathogen Chlamydia 
pneumonia (C. pneumoniae). Although this bacterium was initially identified as 
a causative factor in (a-) symptomatic inflammation of the airways, numerous 
clinical studies demonstrated that patients with high titers of antibody against C. 
pneumoniae have an increased risk for cardiovascular complications (Wimmer 1996, 
Saikku 1988). This is supported by experimental studies which showed an acceleration 
of lesion development in experimental animals and a large variety of pro-atherogenic 
effects in vitro (Ezzahiri 2002, Liu 2000, Blessing 2001). Interestingly, recent studies 
also show a strong correlation between C. pneumoniae IgG titer and severity of 
allograft arteriosclerosis after cardiac transplantation as well as early graft failure 
(Subramanian 2002, Pieniazek 2003, Wittwer 2000), although results have not been 
consistent (Fang 1998). Also, an association between the occurrence of C. pneumoniae 
and the presence of foam cell arteriopathy in liver transplant patients with chronic 
rejection has been suggested (Lotz 2004).
These data suggest that C. pneumoniae, apart from its effect on atherosclerosis, 
may also play a role in CTD. However, until now no studies have been published 
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regarding such a role for C. pneumoniae in the progression of CTD. For this purpose 
we used a well established animal model to study the effect of C. pneumoniae on 
transplant related neointima formation which characterizes CTD. The rat aorta 
transplantation model is easy to perform, has a low post-operative mortality and 
alterations in the aorta graft are virtually identical with the vascular lesion of 
chronically rejecting parenchymal organ transplants in human subjects (Mannander 
1991, Lemstrom 1993).
Materials and Methods
Animal conditions
Male inbred specific pathogen free Lewis (LEW) (Department of Experimental Animal 
Service of the University of Maastricht, the Netherlands) and BN (Charles river, 
Maastricht, the Netherlands) rats, weighing 200-300 gram, were used as donors and/
or recipients. Housing and care of the animals and all the procedures used in this 
study were approved by the Ethical Committee for the Use of Experimental Animals 
of the institution, and conform the Guide for the Care and the Use of Laboratory 
Animals, published by the US National Institute of Health (NIH Publication No. 85-23, 
revised 1985). Rats were fed standard rat chow and tap water at libitum. All surgical 
procedures were performed under general anesthesia and sterile conditions. 
Experimental design
Aortic grafts from BN rats were transplanted to LEW recipients (allogeneic) or to 
BN recipients (syngeneic). Aortic allografting was performed as described previously 
(Mennander 1991). Briefly, the rats were anaesthetized by intraperitoneal 
injection of pentobarbital (60 mg/kg). The abdominal aorta from the renal artery 
to the bifurcation (about 1.8 cm) was harvested from Brown Norway (BN) rats 
after intravenous injection of 50 U of heparin. The aorta grafts were transplanted 
orthotopically into recipients with the end-to-end anastomosis technique, using 
non-interrupted 9-0 nylon sutures. Total ischemic time varied from 20 to 25 minutes 
during which the grafts were kept cold using phosphate buffered saline (4°C). After 
transplantation, the animals were randomly divided into several groups (Table 1). 
C. pneumoniae infection (1 ml of 5 x 108 inclusion forming units (IFU)/ml 
sucrose phosphate-glucose solution) was performed by i.p. injection 24 hours after 
transplantation. The i.p. inoculation route instead of the intranasal route was use 
because of the high infectious dosage required in rat experiments.
Table 1 | Summary of experimental groups.
Group Transplantation Number of rats C. pneumoniae infection1 Day of sacrifice
1 Syngeneic  5 -  7
2 Syngeneic  5 - 56
3 Allogeneic 10 -  7
4 Allogeneic 10 +  7
5 Allogeneic 10 - 56
6 Allogeneic 10 + 56
1 C. pneumoniae infection (1 ml of 5 x 108 inclusion forming units)/ml sucrose phosphate-glucose 
solution) was performed by i.p. injection 24 hours after transplantation. 
Histological and morphometrical procedures
The recipients were sacrificed either at 1 or 8 weeks post-surgery. Vessels were 
initially flushed with physiological salt solution and then perfusion fixed with 3.7% 
formaldehyde in phosphate-buffered saline (pH 7.4) at physiological pressure 
(100 mm Hg). Aortic grafts were removed and cut in three sections for paraffin 
embedding, frozen sections and isolation of C. pneumoniae DNA. For histology, 
a segment of the graft was fixated overnight in 3.7% formaldehyde in phosphate-
buffered saline (pH 7.4) and embedded in paraffin. Four-micron thick cross-
sections from the middle part of the graft were stained with haematoxylin-eosin 
and Lawson. The perimeters of the external elastic lamina, internal elastic lamina 
and lumen were measured in those cross-sections of the graft, by using a computer-
assisted morphometry system (analySIS®, Soft Imaging System, GmbH). The cross- 
sectional area of the media was defined as the area surrounded by the external and 
internal elastic lamina. The neointimal cross-sectional area was defined by the area 
surrounded by the internal elastic lamina and the arterial lumen. Luminal stenosis 
was defined as percentage of lumen area occluded by neointimal area. Final scores 
were given as mean ± SEM.
Immunohistochemistry
Frozen sections (4 μm thick), taken from aortic grafts 1 week after Tx, were fixed 
in acetone (-20°C) for 15 min for immunohistochemistry and stained with the two-
layer indirect immunoperoxidase technique using monoclonal antibodies (mAb). After 
fixation, the sections were air-dried for 30 min. 
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The following mAbs used in this study were purchased from Sera-lab (Crawley 
Down, UK): W3/13, a mouse IgG1 mAb to CD3+ cells, W3/25, a mouse IgG1 mAb to 
rat CD4+ cells and Ox-8, a mouse IgG1 mAb to rat CD8+ cells. ED-1, a mouse mAb to 
monocytes/macrophages was kindly supplied by Dr. A.M. Duijvestijn (department of 
Immunology, Universiteit Maastricht, the Netherlands). Monoclonals were diluted in 
TBS and applied to the slides for 60 min at room temperature. After three washes with 
TBS for 5 min, a biotinylated horse anti-mouse secondary antibody (1:400 dilution 
Dako) was applied for 30 min at room temperature. Finally, sections were incubated 
with alkaline phosphatase-coupled streptavidin (ABC reagent, Vector Laboratories), 
followed by immunodetection using fast red as a substrate and finally counterstained 
with haematoxylin. Then, the presence of positive cells was analyzed by microscopy 
and scored semi-quantitatively by an observer blinded to the specimen group.
Detection of C. pneumoniae DNA by real-time PCR 
At 1 week post-surgery, a small part of the aorta grafts was processed for DNA 
isolation and detection of C. pneumoniae DNA in the tissues by real time PCR. In 
addition, a part of the recipient’s spleen was processed to confirm dissemination of 
C. pneumoniae throughout the animal. Total genomic DNA was extracted from tissue 
using the WIZARD® method (Promega Corporation, Madison, WI). DNA content of each 
sample was measured using the The NanoDrop® ND-1000, a full-spectrum (220-750 nm) 
spectrophotometer. Next, real-time PCR (ABI Prism 7000, Applied Biosystems, Foster 
City, USA) was applied to detect and quantify C. pneumoniae DNA copy numbers. 
The sequences of the primers and probes were based on a variable domain of the 
ompA gene, VD4, as described before (Tondella 2002). PCR was performed with a 
total volume of 25 µl; consisting of 12.5 µl TaqMan Universal Master Mix (Applied 
Biosystems, 2x concentrated), 300 nM forward primer (5’TCCGCATTGCTCAGCC3’), 
900 nM reverse primer (5’AAACAATTTGCATGAAGTCTGAGAA3’), 200 mM probe (5’-FAM-
TAAACTTAACTGCATGGAACCCTTCTTTACTAGG3’-TAMRA), 3.5 µl NASBA water and 1 µg 
DNA (5 µl of the sample). Serial dilutions of the plasmid, containing the VD4 part of 
the C. pneumoniae ompA gene (GenBank, accession number AY426607) and a negative 
control, containing reagents only were applied to create the standard curve. The 
concentrations of the plasmid dilutions were: 106, 105, 104, 103, 102, 101 copies of 
ompA plasmid. For the quantification of C. pneumoniae DNA in the samples, ABI Prism 
7000 SDS software was applied. Thermal cycling started with UNG activation for 2 
min at 50°C, followed by HotStarTaq activation during 10 min at 95°C. Afterwards 42 
cycles of amplification were run consisting of 15 seconds at 95°C and 1 min at 60°C.
Statistical analysis 
Morphometrical data were expressed as mean ± S.E.M. Values were compared using 
the Mann-Whitney U-test and p<0.05 was considered to be statistically significant.
Results
Animal conditions 
No apparent clinical signs of illness were observed in any of the animals during the 
follow-up period. Starting body weight ranged from 200 g to 300 g; at the end of the 
experiments animal weight ranged from 325 g to 405 g. There were no significant 
differences between the experimental groups.
Detection of C. pneumoniae DNA by real-time PCR 
The number of C. pneumoniae DNA copies was determined in aorta graft and 
recipient’s spleen at 1 week post-surgery. Although substantial levels of C. 
pneumoniae DNA were found in the recipient’s spleen (464 ± 163 copies of Cpn DNA 
per µg total DNA) only a limited amount of C. pneumoniae DNA was detected in 4 out 
of 10 samples taken from the transplanted aorta (3 ± 1 copies of C. pneumoniae DNA 
per µg total DNA). 
Figure 1 | Photomicrographs of rat aortic allograft 1 week after transplantation. ED-1 
immunoperoxidase staining against monocytes/macrophages. A) Allogeneic group with 
C. pneumoniae infection 24 hours after transplantation. B) Allogeneic control group. No 
statistical significant differences were observed. (see page 166 for color picture)
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Inflammatory infiltrate in the graft
At 1 week post Tx an abundant influx of monocyte/macrophages and T-cells was 
observed in the perivascular area in contrast to only limited amounts (less than 5 
per section) of inflammatory cells seen in the intima and media of the vessel wall 
(figure 1). Nevertheless, no differences were observed between the C. pneumoniae-
infected and control allogeneic group, either for the amount of influx of monocyte/
macrphages or the amount of T-cells in the perivascular area, media or intima. In 
contrast, significantly less perivascular inflammation was seen in the syngeneic 
group. 
Figure 2 | Representative photomicrographs of rat aortic grafts weeks after transplantation. 
Lawson staining. A) syngeneic group B) allogeneic control group C) allogeneic group with C. 
pneumoniae infection 24 hours after transplantation. (see page 170 for color picture)
Vascular remodeling 
C. pneumoniae administration in the rats 24 hours after aortic Tx had no significant 
effect on the mean neointimal cross-sectional area or the percentage of luminal 
stenosis at 8 weeks post surgery as compared to the control group (figure 2). In 
addition, no differences in medial cross-sectional area, luminal cross-sectional area, 
neointimal/medial ratio or neointimal/lumen ratio were seen (data not shown). As 
expected, no neointima formation was seen in the syngeneic group at 8 weeks after 
Tx (figure 3). No neointima was observed in the rats sacrificed 1 week after Tx in 
either of the groups.
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Figure 3 | Effect of C. pneumoniae infection on neointimal cross-sectional area and 
percentage stenosis. Rats were infected with C. pneumoniae 24 hours after aortic 
transplantation and vascular remodeling was determined 56 days after surgery. A) neointimal 
cross-sectional area B) percentage stenosis. No significant differences between allogeneic 
groups.
Discussion
Previous data compellingly demonstrated that cytomegalovirus affects cardiovascular 
disorders such as atherosclerosis, restenosis and transplant arteriosclerosis. Like-
wise, C. pneumoniae has been suggested to aggravate atherosclerosis by similar 
mechanisms. Nonetheless, to our knowledge it has not yet been determined whether 
C. pneumoniae also affects CTD. Here, we demonstrate that C. pneumoniae has no 
108
Chapter 5 Chlamydia pneumoniae infection is not associated with chronic transplant dysfunction
109
effect on neointima formation following allogeneic aorta transplantation in a well 
established rat model. 
Transplantation associated arteriosclerosis is the most important cause of 
graft failure after the first post-transplant year (Paul 1993). Although the exact 
pathogenesis of CTD remains to be established, several risk factors, like humoral 
and cellular immune responses, hyperlipidema and frequency and intensity of acute 
rejection episodes have been described to contribute to the development of CTD 
(Cramer 1989, Tesi 1993, Winters 1990). Evidence linking infections and acute or 
chronic solid organ transplant rejection was first presented in the early 1970s and 
primarily refer to the role of herpes viruses (Lopez 1974). Also, based on sero-
epidemiologic surveys, an acute rejection-causing effect of the influenza B virus and 
the adenoviruses has been suggested (Gabriel 1976). Nevertheless, cytomegalovirus 
shows the strongest epidemiological connection with CTD. Several clinical studies 
demonstrated a role for cytomegalovirus infection in chronic hepatic allograft 
dysfunction (Arnold 1992, O’Grady 1988). In addition, clinically relevant CMV infection 
has been shown to negatively influence the coronary remodeling modalities during 
the first follow up year after heart transplantation (Potena 2003). Also, pre-transplant 
CMV seropositivity is associated with decreased patient and allograft survival after 
kidney transplantation (Fitzgerald 2004). Furthermore, the association between CMV 
and CTD is supported by various experimental studies. For example, Lemström et 
al. demonstrated the stimulating effect of cytomegalovirus infection on CTD in the 
rat aortic allograft model (Lemstrom 1993, 1994). Likewise, Lautenschlager et al. 
showed that CMV prolonged and increased the graft inflammation and accelerated 
chronic rejection of rat renal allografts under triple-drug treatment (Lautenschlager 
1997). 
As CMV also affects other cardiovascular diseases and atherosclerosis in particular, 
it may be hypothesized that other micro-organisms, similarly affecting athero-
sclerosis, may also have an impact on CTD. In this respect, C. pneumoniae might be 
the most promising candidate. The pathogenic role of C. pneumonia in cardiovascular 
pathologies is widely supported. Since the original observation by Saikku and 
colleagues, demonstrating an increased incidence of myocardial infarction among C. 
pneumoniae positive coronary heart disease patients (Saikku 1992), the role of C. 
pneumoniae in atherosclerosis has been confirmed by many others (Jaremo 2004, 
Mitusch 2005). Most of the suggested mechanisms by which C. pneumoniae may 
affect atherosclerosis highly resemble those by which CMV has been suggested to 
affect the disease. Therefore, it is plausible that C. pneumoniae, similar to CMV, 
is also involved in other cardiovascular pathologies like CTD. This is supported by 
the observation that C. pneumoniae is a potential risk factor for cardiac allograft 
vasculopathy (Wittwer 2000) and that C. pneumoniae IgG titers correlate with 
severity of allograft atherosclerosis after cardiac transplantation as well as early 
graft failure (Subramanian 2002). 
Nevertheless, a direct cause-effect relationship between C. pneumoniae and 
CTD has not yet been demonstrated. Thus, we studied the effect of C. pneumoniae 
infection on CTD by using a rat aortic allograft model. However, when we evaluated 
various morphological parameters at 8 weeks post-transplantation no effect of C. 
pneumoniae could be observed. While no intima hyperplasia could be observed 
following syngeneic transplantation, a significant neointima could be observed in the 
allogeneic group. However, neither the amount of neointima nor the percentage of 
stenosis was significantly affected by concomitant C. pneumoniae infection.
Despite the fact that significant amounts of C. pneumoniae could be detected in 
the spleen of infected rats, indicating that the bacteria was disseminated throughout 
the body, only a few C. pneumoniae DNA copies could be detected in some graft 
early after infection. This may partially explain the lack of effect of the infection on 
intimal thickening. On the other hand, CMV, which also can be hardly detected in the 
graft, has been shown to exert a prominent effect on intimal thickening despite the 
relative absence of the virus in the vascular wall. Similarly, we recently demonstrated 
a marked effect of CMV infection on intima hyperplasia following arterial injury even 
in the absence of large amounts of virus in the vascular wall (Kloppenburg 2005). 
Therefore, to affect the remodeling process the presence of the microbes in the graft 
may not be a pre-requisite. 
Thus, alternative routes have been suggested for the CMV-enhanced graft arterio-
sclerosis. Interestingly, CMV infection enhances the early, prominent inflammatory 
episode in the allograft adventitia with a pronounced influx of macrophages and T-cells. 
This enhanced inflammatory response is accompanied by a significant up-regulation 
of PDGF and TGF-β mRNA expression in the graft following CMV infection. However, 
following C. pneumoniae infection no clear difference in perivascular inflammation 
could be observed between infected and control rats, thereby providing an additional 
reason for the lack of effect of C. pneumoniae on intimal thickening. Nevertheless, C. 
pneumoniae is able to promote a proliferative phenotype as the post-infectious mRNA 
expression of Egr-1, an angiogenic transcription factor, was significantly up-regulated 
both in vitro (coronary artery smooth muscle cells) and ex vivo in a rat aortic ring 
model of focal vascular chlamydial infection (Mitusch 2005). Therefore, it remains to 
be established why C. pneumoniae has no effect on intimal thickening in vivo.
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Although ample literature is available concerning C. pneumoniae infection, 
dissemination and subsequent immune responses in mice, less is known about C. 
pneumoniae infections in rats. Although a few papers demonstrated that rats can 
be infected with C. pneumoniae (Damy 2003) and that C. pneumoniae infection 
may result in vascular alterations (Chrapusta 2002, Herrera 2003) the exact course 
of infection as well as the immunological response of rats towards C. pneumoniae 
is, at least to our knowledge, unknown. Although we demonstrated the systemic 
dissemination of C. pneumoniae early after infection, we were unable to detect IgG 
antibodies directed against C. pneumoniae in the majority of the infected rats at 8 
weeks post infection (data not shown). This suggests that the early immune response 
is able to eliminate the microbe rapidly. Interestingly, pronounced vascular effects of 
C. pneumoniae are seen in mice, which mount a strong IgG antibody response against 
C. pneumoniae. Yet, further research is required to elucidate the exact role of the 
different parts of the immune system in C. pneumoniae-mediated vascular effects.
In summary, we demonstrated that C. pneumoniae is able to disseminate in 
rats following i.p. infection. However, hardly any C. pneumoniae DNA was found in 
the transplanted graft and no enhancement of the perivascular inflammation was 
observed. To some extent, this may explain the lack of effect of C. pneumoniae 
infection on the intimal thickening in the allogeneic aortic graft model. In conclusion, 
our data suggest that C. pneumoniae infection may be of minor importance for the 
severity of CTD as seen in the rat aortic allograft model.
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Abstract
Autologus vein grafts are commonly used for coronary artery bypass grafting and 
infrainguinal bypass procedures. Although initially a successful procedure long term 
patency rates are limited due to proliferation and migration of smooth muscle cells 
leading to the formation of a neointima occluding the lumen. Gene therapy aiming at 
preventing smooth muscle cell proliferation responsible for intimal hyperplasia has 
been a subject of many studies although none of them have seemed to be entirely 
successful. Activin A, a member of the transforming growth factor-β super family, 
does enhance the expression level of SMC-specific alpha-actin markers, indicating 
that it promotes the contractile phenotype of these cells. Maintaining the contractile 
SMC phenotype would represent a novel strategy to prevent intimal hyperplasia as 
seen in venous graft failure.
Epigastric vein-to-common femoral artery interposition grafts were placed in 
rats. Two experimental groups (n=10 animals/group) were used. In the Activin A group 
adenoviral activin A (1×109 Plaque Forming Units) was i.v. injected immediately after 
grafting. Animals in the control group were injected with a solution containing an 
empty Adenoviral vector (1×109 Plaque Forming Units). All animals were sacrificed 
three weeks after surgery and the grafts were harvested for morphometrical and 
immunohistochemical analysis.
Activin A overexpression immediately after surgery resulted in a significant 
decrease in intimal cross-sectional area and percentage stenosis as compared to the 
control group. BrdU staining indicated a much lower proliferation rate of the smooth 
muscle cells in the experimental group treated with activin A as compared to the 
control group.
We here show for the first time evidence of the ability of activin A to diminish 
vein graft failure in a rat model of epigastric to common femoral artery vein grafting, 
implying a novel strategy to prevent intimal hyperplasia as seen in venous graft 
failure.
Introduction
Over the last forty years autologus saphenous vein grafts have become common 
practice for coronary artery bypass grafting (CABG). Apart from its use in CABG, 
saphenous vein grafts are also used in infrainguinal bypass procedures in patient 
with critical limb ischemia. Although the initial results of these procedures are 
successful, the symptoms tend to recur due to degeneration and occlusion of the 
graft giving rise to 15-30% graft failure within one year and up to 50% of all grafts 
being occluded 10 years after surgery. Usually, early thrombosis occurs within the 
first month after implantation and is thought to be responsible for ~20% of all failed 
grafts. Subsequently, intimal hyperplasia (IH), defined as the accumulation of smooth 
muscle cells (SMC) and extracellular matrix in the intimal component of the vein, is 
the major disease process in the venous graft within the first year. This process of 
graft occlusion involves the migration of medial vascular smooth muscle cells to the 
lumen of the graft were they transform into a more synthetic phenotype. Then, these 
cells will start proliferating as well as secreting extra-cellular matrix proteins. These 
processes will ultimately result in the formation of a neointima. It has been strongly 
suggested that IH is associated with extensive endothelial denudation and destruction 
of venous grafts, resembling the response to injury as seen after PTCA often leading 
to restenosis of the denuded artery (Logerfo 1983).
Gene therapy aiming to prevent processes contributing to IH, like smooth muscle 
cell proliferation, has been a subject of many studies. Nonetheless, none of the 
approaches attempted so far gave acceptable results. A novel mechanism to reduce 
IH may be provided by the protein Activin A.
Activin A belongs to the transforming growth factor-β super family and was initially 
identified as a protein that induced the release of follicle-stimulating hormone by 
pituitary cells (Ling 1986, Vale 1986). Next, it has been demonstrated that the protein 
is involved in growth and differentiation of various cell types including endothelial 
cells, macrophages and SMC (McCarthy 1993, Kozaki 1997, Kojima 1993). In separate 
studies, activin A has been shown to be expressed in atherosclerotic lesions of 
hyperlipidaemic rabbits as well as in human atherosclerotic lesions (Inoue 1994). In 
addition, enhanced activin expression was observed in the rat carotid artery after 
balloon injury Pawlowski (1997). 
Even though activin A has been shown to inhibit the growth of endothelial cells, 
its effect on SMC proliferation is more controversial. Although some demonstrated 
that activin A enhances rat SMC DNA synthesis, others found no effect of activin A on 
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rat SMC growth (Kojima 1993, Nakaoka 1997). The latter is supported by findings of 
Engelse and colleagues, who demonstrated that activin A augments the expression 
level of SMC-specific markers, indicating that it promotes the contractile phenotype 
of these cells (Engelse 1999).
Maintaining the contractile SMC phenotype would represent a novel strategy to 
prevent intimal hyperplasia as seen in venous graft failure. In this study we show the 
ability of activin A to prevent venous graft failure in an experimental animal model.
Materials and Methods
Animal conditions and vein grafting procedure
Male inbred specific pathogen free (SPF) male Lewis (LEW) rats were obtained form 
the Department of Experimental Animal service of the University of Maastricht, the 
Netherlands. Experiments were carried out on animals aged 12 weeks weighing 250-
350 gram. Housing and care of the animals, and all the procedures used in this study 
were approved by the Ethical Committee for the Use of Experimental Animals of 
the institution, and are in accordance with the Guide for the Care and the Use of 
Laboratory Animals, published by the US National Institute of Health (NIH Publication 
No. 85-23, revised 1985). Rats were fed standard rat chow and tap water at libitum. 
All surgical procedures were performed under general anesthesia and using sterile 
techniques. Epigastric vein-to-common femoral artery interposition grafts were 
placed in rats by the use of a method similar to that described earlier by Hoch et 
al. (Hoch 1994). In brief each animal was anesthetized with an intraperitoneal 
(i.p.) injection of sodium pentobarbital (60 mg/kg). An 8 mm segment of relaxed 
ipsilateral epigastric vein was carefully harvested, gently irrigated with heparinized 
saline solution (100 U/ml), and placed as reverse interposition graft into a segmental 
3mm defect of the common femoral artery with 8 to 10 interrupted sutures of 11-0 
nylon (Ethicon). The entire procedure was carried out with standard microsurgical 
techniques. The total ischemic time was kept to less than 30 min. Patency was 
verified by visual inspection. 
Experimental design 
An activin A–expressing adenovirus (Ad.activin) as well as an adenoviral construct 
carrying no insert (Ad.mock) were kindly provided by Dr. Paul Quax, (Gaubius 
Laboratory, TNO-PG, Leiden, the Netherlands). For further details regarding 
construction see Engelse et al. (Engelse 2002). Two experimental groups (n=10 
animals/group) were used. Ad.activin (1×109 PFU) was i.v. injected immediately after 
grafting. Controls were injected with Ad. mock (1×109 PFU).
Histological and morphometrical procedures
Three weeks after surgery, rats were anaesthetized, the chest and abdominal cavities 
were opened and a catheter was inserted into the apex of the heart. Vessels were 
initially flushed with physiological salt solution and then perfusion fixed with 3,7% 
formaldehyde in phosphate-buffered saline, pH 7.4, at physiological pressure (100 
mmHg). Vein grafts were removed and fixed overnight in the same fixative and 
routinely processed for paraffin embedding. Cross-sections (4 μm) were taken for 
morphometrical analysis and haematoxylin-eosin or Lawson stained (average of three 
cross-sections per graft). Intimal and medial areas were quantified using a computer 
assisted morphometry system (analySIS®, Soft Imaging System GmbH, Muenster, 
Germany). The cross-sectional area of the media was defined as the area surrounded 
by the external and internal elastic lamina. The neointimal cross-sectional area was 
defined by the area surrounded by the internal elastic lamina and the arterial lumen. 
Percentage stenosis was defined as the percentage of cross-sectional area surrounded 
by the internal elastic lamina covered by neointima. Final scores were given as mean 
± SEM.
Immunohistochemistry
Paraffin-embedded sections (4μm), taken from vein grafts three weeks after surgery, 
were routinely processed and stained with the two-layer indirect immunoperoxidase 
technique using monoclonal antibodies (mAb). BrdU was injected intraperitoneally 
one day before sacrifice. 
The following mAbs were used in this study: anti-α smooth muscle actin (ASMA, 
Sigma, Missouri, USA); and anti-BrdU (Sigma, Missouri, USA). To visualize smooth 
muscle cells, sections were pre-incubated with 2% bovine serum albumin (BSA) in 
phosphate-buffered saline (PBS) for 15min at room temperature and treated with 
antigen retrieval buffer. To reveal cell proliferation sections were pretreated with 3% 
H202 in PBS for 15 min at 37°C, followed by HCl 2N for 30min at 37°C and 0.4% pepsin 
in 0.01N HCl for 30 min at 37°C. Monoclonals were diluted (ASMA 1/1500, anti-BrdU 
1/500) in PBS and applied to the slides for 60 min at 37°C. After three wash steps 
with PBS for 5 min, a biotinylated goat anti-mouse secondary antibody (1/1200, DAKO 
Glostrup Denmark) was applied for 30 min at room temperature. Finally, sections 
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were incubated with alkaline phosphatase-coupled streptavidin (ABC reagent, Vector 
Laboratories), followed by immunodetection using fast red as a substrate. Finally, 
sections were counterstained with haematoxylin to visualize nuclei. Then, the 
presence of positive cells was analyzed by microscopy and scored semi-quantitatively 
by an observer blinded to the experimental groups. Representative cross-sections 
of the graft were analyzed and amount of proliferation was indicated by zero (<10 
positive signals per section), ⊕ (10-50 positive signals per section), ⊕⊕ (50-100 
positive signals per section), ⊕⊕⊕ (>100 positive signals per section).
Statistical analysis 
Morphometrical data and cell count numbers are expressed as mean ± S.E.M. Values 
were compared using the Mann-Whitney U test and p<0.05 was considered as 
statistically significant.
Results
Animals and grafts
None of the animals had apparent clinical signs of illness during the follow-up period. 
Starting body weight ranged from 250 g to 350 g; at the end of the experiments 
animal weight ranged from 300 g to 375 g. The overall graft patency rate was 90%. 
Failures seemed related to early thrombosis. There were no significant differences 
in body weights or graft patency between the experimental groups (data not shown). 
There were no structural anomalies at the anastomotic regions of the grafts. The 
gross appearance of the veins and adjoining arteries was normal.
Activin A prevents neo intimal hyperplasia
Three weeks after bypass grafting all veins developed an increase in medial thickness 
(10 ± 2 µm none grafted control vs. 36 ± 3 µm grafted control group) and showed 
neointimal thickening as compared to non-grafted controls. Activin A administration 
immediately after vein grafting resulted in a significant decrease in intimal cross-
sectional area and percentage stenosis at three weeks after surgery as compared to 
the control group (figure 1). 
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Figure1 | Effect of activin A administration on intimal cross-sectional area (A) and 
percentage stenosis (B) three weeks after vein grafting. * P<0.05 (values compared with 
control)
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Figure 2 | (A) Alpha-actin smooth muscle cell staining of cross-section of the vein graft 
three weeks after surgery, activin A group. (B). Semiquantative analysis of proliferation 
measured by BrdU staining. Bars stand for number of sections representing indicated 
amount of proliferation. (see page 171 for color picture)
ASMA and BrdU staining
Alpha-actin smooth muscle cell staining revealed that the medial and neointimal layer 
in both activin A-treated and control rats predominantly consisted of smooth muscle 
cells (figure 2A). Furthermore, the result of the BrdU staining indicated a significantly 
lower proliferation rate of the smooth muscle cells in de experimental group treated 
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with activin A as compared to the non-treated control group suggesting that the over-
expression of activin A prevents excessive proliferation of smooth muscle cells and in 
that way intimal hyperplasia (figure 2B).
Discussion
Although used for several decades, autologous saphenous vein grafts have a reduced 
long term patency as compared to arterial revascularisation with internal thoracic 
artery grafts. Nonetheless, as saphenous veins are usually more accessible than 
arterial segments, the availability of an easy to apply intervention to improve the 
long-term patency rates of vein grafts would be a major advance for cardiac and 
vascular surgery and its patients. Saphenous graft failure can be considered as 
a trimodel disease. Early graft failure occurs within the first months after surgery 
and is predominantly caused by thrombotic events often due to mechanical trauma 
during vein harvesting. Late graft failure tends to occur after several years and is 
caused by accelerated atherosclerosis. These causes may be treated with currently 
available antiplatelet and lipid lowering drug therapy which has been proven to be 
successful in several clinical studies (Christenson 2001, Paz 1993). Intermediate 
failure of saphenous vein grafts is due to neointimal hyperplasia which is most 
prominent in the first year after surgery but can occur up to three years after CABG 
(Barboriak 1978). Excessive proliferation and migration of several vascular cell 
types (e.g. vascular smooth muscle cells, endothelial cells, myofibroblasts) are 
important components in vascular remodeling and associated pathologies, including 
angiogenesis, atherosclerosis, and restenosis following percutaneous transluminal 
coronary angioplasty (PTCA) (Schwartz 1990, Ross 1993, Schwartz 1997). In this study 
we show for the first time evidence of the ability of activin A to diminish excessive 
SMC hyperplasia in a rat model of epigastric to common femoral artery vein grafting. 
Along with transforming growth factor (TGF)-β and bone morphogenetic protein, 
activin A is a member of the TGF-β super family (Chen 2002). Although initially 
identified as a protein that induces the release of follicle-stimulating hormone 
by pituitary cells, recent studies suggest that this cytokine is also involved in 
atherogenesis. For example, it has been revealed that activin A promotes plaque 
stability by regulating the expression of scavenger receptor mRNA, thereby inhibiting 
foam cell formation, or by inducing a contractile, non-proliferative smooth muscle 
cell phenotype in culture (Engelse 1999).
This latter effect of activin A might be of importance as a new therapeutic 
strategy towards enhanced long term patency rates in venous grafts. After all, the 
process of vein graft occlusion involves the transition of vascular smooth muscle 
cells from a contractile to a more synthetic phenotype, a phenotype which is 
characterized by proliferation and secretion of various extra-cellular matrix proteins 
ultimately resulting in the formation of a neointima. Thus, maintaining VSMC in a 
more contractile phenotype by over-expressing activin A might be an attractive novel 
strategy to prevent intimal hyperplasia as seen in venous graft failure.
Indeed, we were able to demonstrate that in the vein grafts of rats, injected with 
an activin A expressing adenovirus, smooth muscle cell proliferation was significantly 
diminished. Furthermore, and more importantly, intimal cross-section area and 
%-stenosis were significantly reduced in activin A treated rats. These data suggest 
that activin A plays a role in controlling smooth muscle cell (de-)differentiation and 
proliferation, which is in accordance with data published earlier. In the rat carotid 
injury model, activin A expression increased already a few hours after injury and 
activin A immunoreactivity could be found in the developing neointimal (Pawlowski 
1997). Also, enhanced expression of activin A strongly reduced the formation of a 
neointima in cultured human saphenous vein segments or in mice with cuffed femoral 
arteries (Engelse 2002).
Therapeutic potential
Taken together, our results suggest that activin A might be an attractive candidate 
for new therapeutic avenues to prevent vein graft failure. Administration of activin 
in the early period after surgery might be a useful treatment to prevent neointimal 
formation and subsequent graft failure. Nevertheless, there might be some draw-
backs in this strategy. Despite the reported beneficial effects in cardiovascular 
disease, recent studies provided compelling evidence for important roles of activin 
in inflammation, tissue repair and fibrosis (Werner 2006). In particular, the findings 
that activin A may promote liver, kidney and lung fibrosis when abundantly present, 
suggests that we should consider some restraint with respect to the therapeutic 
applicability of the protein. 
Limitations of the study
It is generally assumed that the major target for adenoviruses is the hepatic tissue. 
This results in high expression mRNA levels and protein in the liver as well as enhanced 
plasma concentration. Although Engelse et al. demonstrated that the adenovirus used 
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in the present study had indeed these characteristics in mice, we didn’t examine the 
presence of the protein in either plasma or liver tissue (Engelse 2002). Therefore, 
the evidence that the observed effect can be fully attributed to enhanced activin 
A levels is circumstantial. Furthermore, additional experiments are required before 
the observed effects can be entirely accredited to an increased production of activin. 
For example, simultaneous injections with follistatin, which sequesters activin A and 
thus inhibits its biological activity, should prevent the beneficial effects of activin A 
on intima hyperplasia. 
In conclusion, we here show for the first time evidence for the ability of activin A 
to diminish vein graft failure in a rat model of epigastric to common femoral artery 
vein grafting. However, due to the possible side effects of high activin concentrations, 
in particular in tissue fibrosis, additional studies are required to further determine 
the therapeutic potential of this protein.
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General discussion
Evidence linking ubiquitous viruses, like members of the human herpes virus family, 
to cardiovascular diseases has been mounting since the late 1970’s observation that 
an avian herpes virus is able to initiate and aggravate atherosclerosis in chickens 
(Fabricant 1978). Since this original observation, multiple pathogens have been linked 
to coronary and peripheral artery disease as well as myocardial infarction and solid 
organ transplant dysfunction (Ellis 1997, Mattila 1998, Rubin 2001).
Next to the herpes virus cytomegalovirus (CMV), whose role in cardiovascular 
disease is fairly established, Chlamydia pneumoniae is the best characterized micro-
organism associated with cardiovascular diseases. This association was initially 
described by Saikku et al. (Saikku 1988) in the late 1980’s and since then confirmed 
by many others (recently reviewed by Watson and Alp) (Watson 2008). 
Apart from their suggested contribution to “naïve” atherosclerosis, sero-
epidemiological evidence also points towards a role for CMV and C. pneumoniae 
in other cardiovascular complications, like restenosis, venous graft failure or 
transplantation arteriosclerosis, which to predominantly result from surgical 
interventions. As intimal hyperplasia, which is considered to be the major determining 
factor in limiting the long term success rate of these interventions, is a general factor 
in all these different pathologies, it may be speculated that pathogens stimulate the 
processes underlying the formation of a neointima. Nonetheless, a causal relationship 
between these microorganisms and intima hyperplasia is still a matter of debate. 
Moreover, animal models shedding light on a more causal relationship between these 
two pathogens and intimal hyperplasia, if any, are scarce and do not all point in the 
same direction. Therefore, one of the main objectives of the present thesis was to 
elucidate and unravel the mechanisms of interplay between C. pneumoniae, CMV and 
intimal hyperplasia. Additionally, we tried a novel approach to diminishing intimal 
hyperplasia as seen in vein graft failure. 
CMV aggravates restenosis and venous graft failure
Data presented in this thesis confirm the hypothesis that CMV is able to aggravate 
both restenosis and venous bypass failure and offers additional insights in the 
relationship between CMV infection and intimal hyperplasia (chapter 2 and 3). 
Regarding restenosis, this process can be considered as a tri-phase disease 
consisting of: (1) proliferation of SMC’s in the media, (2) migration of SMC’s from 
the media to luminal surface and (3) proliferation of SMC’s in the neointima. To 
study the effect of CMV on this process, we used a rat model of photochemically-
induced endothelial injury to mimic thrombus formation and SMC’s proliferation 
as seen after balloon angioplasty (chapter 2). Inspired by previous findings which 
showed an enhanced susceptibility of proliferating SMC’s for CMV (Persoons 1997), 
we infected the animals at two different time points, i.e. prior to the stage when 
medial SMC proliferation is maximal or preceding the phase of maximal proliferation 
in the intima. Our data indicated that proliferating SMC are indeed predominantly 
susceptible for CMV infection and that the effect of CMV on these cells is primarily 
responsible for the observed effect of the virus on the process of restenosis. When 
rats were infected immediately after injury, medial but not neointimal cross-sectional 
areas were significantly increased in infected rats. Alternatively, infection prior to 
the second wave of proliferation enhanced the neointimal but not the medial area 
suggesting that CMV infection indeed primarily affects SMC cell proliferation. This is 
supported by the results concerning cellularity of the different layers which revealed 
that the increase in cross-sectional area was due to smooth muscle cell hyperplasia 
instead of hypertrophy. Whether this effect is due to a direct effect of the virus on the 
vessel wall or to an indirect effect through activation of the immune system following 
infection remains to be established. We addressed this question to some extent by 
determining the presence of CMV DNA in the injured vessel at various time points post 
infection. Only limited amounts of CMV DNA could be detected in the injured vessel. 
In contrast, high amounts were found in liver, spleen and salivary gland indicating 
that the infection procedure had been successful. These findings are in accordance 
with earlier results by Zhou et al., who also demonstrated an increased neointimal 
response in the rat carotid artery following balloon injury without significant amounts 
of virus present in the vessel wall and suggest that immune activation following CMV 
infection may be more important than direct effects of the virus (Zhou 1999, 2000). 
This will be discussed in more detail later in this section.
Taken into account the effects of CMV infection on the process of restenosis we 
hypothesized that CMV might also aggravate intimal hyperplasia in other vascular 
pathologies like venous bypass failure. Although this hypothesis is supported by some 
sero-epidemiological studies, experimental data demonstrating a causal relationship 
between CMV infection and venous bypass graft failure are lacking (Westphal 2006, 
Ibrahim 2005). We addressed this issue in chapter 3 in which we used the well-defined 
rat epigastric vein-to-common femoral artery graft model to investigate to possible 
role of CMV in venous graft failure. This model is characterized by a marked increase 
in the medial cross-sectional area of the venous wall when compared to a naïve veins 
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(Hoch 1994). Also in our hands a pronounced neointimal thickening was observed in all 
grafted veins at three weeks after surgery. Moreover, CMV infection immediately after 
vein grafting resulted in a significant increase in intimal cross-sectional area, medial 
cross-sectional area and medial wall thickness further supporting the hypothesis that 
CMV affects intimal hyperplasia
C. pneumoniae infections affects venous bypass failure, but not 
transplant arteriosclerosis
So, in both models we were able to demonstrate that CMV enhances the formation 
of a neoinitima. The issue we addressed next was whether C. pneumoniae was 
likewise able to affect this process. Previously, it has been shown that this obligate 
intracellular micro-organism, like CMV, is able to enhance or even initiate plaque 
formation in (atherosclerotic) animal models (Ezzahiri 2002). Yet, apart from some 
sero-epidemiological studies, little is known on the possible effects of C. pneumoniae 
on intima hyperplasia (Rupp 2005, Bartels 200). In chapter 4 we present for the first 
time direct experimental evidence for a role of C. pneumoniae in the process of 
venous graft failure. Using the epigastric vein-to-common femoral artery interposition 
graft rat model we demonstrated that C. pneumoniae administration immediately 
after vein grafting resulted in a significant increase in medial cross-sectional area, 
wall thickness and total wall area at three weeks after surgery as compared to the 
control group. Interestingly, and in accordance with our observations in the CMV 
experiments, C. pneumoniae infections also induced smooth muscle hyperplasia but 
not hypertrophy or edema as the total number of cells/µm2 in the graft remained 
constant. In line with this is the recent observation that C. pneumoniae infection 
promotes a proliferative phenotype in the vasculature which makes C. pneumoniae 
also a likely risk factor for vein graft failure (Rupp 2005, Hirono 2003).
Remarkably however, and in contrast to our expectations, our results do not point 
towards an effect of C. pneumoniae on chronic transplant dysfunction. Previously, it 
has been demonstrated convincingly by us and by others that CMV is well capable to 
affect the viability of solid organ transplants in a negative way (for review see Streblow 
2007). Likewise, it has been shown that CMV enhances transplant arteriosclerosis 
in a rat aortic allograft model (Bruning 1994, Lemström 1993). We used this latter 
model to study the effect of C. pneumoniae on transplant arteriosclerosis. However, 
no clear effects of C. pneumoniae on either myointimal hyperplasia or vascular 
inflammation were observed despite the fact that the infection had been successful 
and C. pneumoniae DNA copies could even be demonstrated in some grafts. Thus, 
although C. pneumoniae infection did augment the formation of the neointima in vein 
grafts, no effects were observed in arterial grafts. The reason for this discrepancy is 
still unclear.
Molecular mechanisms involved in pathogen-associated enhancement of 
intima hyperplasia 
Previously, various molecular mechanisms have been associated with infection-related 
enhancement of neointima formation. Nevertheless, most of these mechanisms 
have been established in isolated cells or other in vitro models. Yet, in our intact 
rat models only very limited amounts of either CMV or C.pneumoniae DNA copies 
could be detected in both arterial and venous grafts. This may limit the importance 
of previously reported direct effects of CMV or C. pneumoniae on vascular cells. In 
contrast, indirect immune-related mechanisms may be more important, which is in 
agreement with findings by Vliegen et al., who demonstrated in a mouse model of 
atherosclerosis that injection of non-infectious (UV-inactivated) virus was able to 
increase atherosclerotic lesion size (Vliegen 2005). Indeed, CMV-induced immune 
activation may also contribute to the process of restenosis as shown by the ability 
of CMV to increase intimal hyperplasia in the absence of detectable virus at the 
site of injury. This is supported by the observation in in-vitro infected cell cultures 
that up-regulation of adhesion molecules occurs on the surface of non-infected 
neighbouring cells (Dengler 2000). The same phenomenon is seen in response to 
supernatant from infected cultures, suggesting a paracrine mechanism of activation. 
In addition, infection induces production of pro-inflammatory cytokines such as IL-12, 
IL-18, TNF-α and IFN-γ by several cell-types including monocytes, SMC and endothelial 
cells. Although the exact role of IL-12 and IL-18 in the formation of a neointima has to 
be established, it is well known that these cytokines play a crucial role in activating 
NK- and T-cells with subsequent production of IFN-γ (Smith 1992, Woodroffe 1993, 
Whitman 2002). This will ultimately result in activation of macrophages which play 
an important role in aggravating vein graft intimal hyperplasia as was demonstrated 
earlier by Hoch et al. (Hoch 1999). Furthermore, additional support for a role for 
IL-18 comes from studies demonstrating that IL-18 affects smooth muscle cell 
proliferation and, most importantly, neutralization of IL-18 reduces restenosis in a 
rat carotid artery balloon model (Maffia 2006). Additionally, infections in patients 
with coronary disease are associated with increased serum concentrations of IL-6, a 
pro-inflammatory cytokine which has been implicated in the development of vascular 
diseases with high levels of IL-6 expression observed in atherosclerotic lesions of 
venous bypass grafts (Almeida 1994, Gredmark 2007). 
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Together with direct effects induced by presence of microbes in the vascular 
wall and indirect effects involving systemic cytokine induction, autoimmunity may 
contribute to the aggravated intimal hyperplasia after infection. For example, 
antibodies directed against CMV modulate the expression of genes coding for 
molecules involved in activation and apoptosis of endothelial cells (Lunardi 2007). 
Also, inactivated virus is able to induce T cell influx and increase plaque formation in 
mouse model of atherosclerosis (Vliegen 2005). A persistent C. pneumoniae infection 
is accompanied by an increased production of chlamydial Heat Shock Protein 
60 (cHSP60), which may induce antigenic mimicry (Mayr 1999). Also, persistent 
production of cHSP60 may result in chronic immune stimulation in the vascular 
wall and the release of local and systemic cascades of inflammatory cytokines (Kol 
1999). Alternatively, host-derived HSP60 may also play a role in neointima formation. 
HSP60 is expressed in the normal vessel wall and can be up-regulated under stressed 
conditions such as infection. Autoantibodies directed against expressed HSP60 may 
cause endothelial cell lysis (Schett 1995). Furthermore, it has been demonstrated 
that HSP60 is a potent inducer of SMC proliferation (de Graaf 2006, Sasu 2001). Similar 
effects have been attributed to C-reactive protein (CRP) (Kuji 2007). In Chapter 4, we 
addressed such a possible role for HSP60 and CRP in our venous bypass graft model. 
Although we were able to demonstrate the presence of both CRP and HSP60 in venous 
graft, difference between experimental and control groups never reached statistical 
significance.
In summary, we were able to show a persistent effect of infection on neointima 
formation in the models we used. As only limited amounts of either viral or bacterial 
DNA could be detected in either arterial or venous grafts questions whether microbes 
affect the process at a local levels and points towards a role for systemic immune 
activation. Nonetheless the hypothesis that infection-induced activation of the 
immune reaction is responsible for aggravating restenosis and venous bypass failure 
as seen in our studies remains to be established and further research is required 
challenging this hypothesis.
Treatment 
The synthetic malononitrilamide FK778
Since it is known that CMV infection plays a role in intimal hyperplasia it would be 
interesting to have a drug able to prevent not only intimal hyperplasia, but also 
inhibit the aggravating effects of CMV infections on this process. Previous studies 
reported that the immunosuppressive drug FK778, similar to the active metabolite 
of leflunomide but with a clinically relevant shorter serum half-life, exerts 
antiviral activity against CMV (Evers 2005, Zeng 2005). Furthermore, besides being 
immunosuppressive and antiviral, vasculoprotective properties have also been 
attributed to FK778. More precisely, it has been shown that FK778 is able to inhibit 
SMC proliferation. In various experimental models it has been demonstrated that 
FK778 effectively attenuates vascular responses to injury by diminishing neointima 
formation and fibrointimal hyperplasia, perhaps through inhibition of the receptor 
tyrosine kinase activity in vascular SMC or their progenitors (Jahnke 2005, Pan 2003). 
All this inspired us to study the therapeutic potential of the immunosuppressive/
anti-proliferate drug FK778 in preventing intimal hyperplasia with or without a 
concomitant CMV infection. We demonstrated that FK778 is able to partially prevent 
intimal hyperplasia in a venous bypass graft in non-infected animals, while the 
drug was also able to reverse the additional effect of a concomitant CMV infection 
on intimal hyperplasia (chapter 3). Unfortunately, the effect of FK778 on CMV 
dissemination was not established in this study. Therefore, additional studies are 
required to determine in more detail whether the effect of FK778 was predominantly 
due to its anti-proliferative effect or to its antiviral effect. Nevertheless, from 
these results and recent data from other animals studies as well as clinical trials it 
appears that FK778 is a promising therapeutic to prevent acute allograft rejection 
and vascular remodelling after mechanical intimal injury.
Activin A prevents vein graft failure
Intimal hyperplasia due to SMC proliferation is considered to be the main reason of 
graft failure. Therefore, gene therapy aiming at the prevention of SMC proliferation 
could potentially increase graft patency rates. Based on the observation that it 
modulates smooth muscle cell and macrophage proliferation and differentiation, 
it has been suggested that enhanced expression of activin A, a member of the 
transforming growth factor-β super family, might be a potential therapeutic avenue 
to treat vascular pathologies characterized by prominent smooth muscle proliferation 
(Engelse 1999). Indeed, in a femoral artery cuff model the formation of a smooth 
muscle cell-rich neointima was dramatically reduced in mice that were injected with 
adenoviral vehicles encoding activin A (Ad.activin A) (Engelse 2002). In chapter 6 we 
used a similar approach to study whether overexepression of activin A prevents intima 
hyperplasia in the epigastric vein-to-common femoral artery interposition graft. 
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Ad.activin A administration immediately after vein grafting resulted in a significant 
decrease in intimal cross-sectional area and percentage stenosis as compared to the 
control group. Alpha-actin smooth muscle cell staining revealed that the medial and 
neointimal layer predominantly consisted of smooth muscle cells. Furthermore, the 
result of BrdU staining indicated a significantly lower proliferation rate of the smooth 
muscle cells in de experimental group treated with activin A. Thus, in accordance with 
previously published data, our results suggest that activin A counteracts neointima 
formation and might accordingly help to maintain the integrity of venous bypass 
grafts. Nevertheless, although the role of activin A in diminishing intimal hyperplasia 
seems promising, care should be taken in clinical use as many other functions have 
been attributed to activin, including its involvement in apoptosis, metabolism, 
homeostasis, immune response, wound repair and endocrine function (Chen 2006, 
Sulyok 2005).
Concluding remarks and perspectives
Intimal hyperplasia is considered to be the major determining factor limiting long 
term success after PTCA, venous bypass grafting and solid organ transplantation. In 
this thesis we provide data that although the underlying cause may be multifactorial, 
infections with C. pneumoniae and CMV certainly aggravate intimal hyperplasia in 
experimental animal models of restenosis and venous graft failure. In contrast to 
the established relation between CMV and transplantation arteriosclerosis, our data 
suggest that C. pneumoniae infection may be of minor importance for the severity of 
transplantation arteriosclerosis as seen in the rat aortic allograft model.
Furthermore we were able to demonstrate the C. pneumoniae and CMV infection 
are able to stimulate SMC proliferation in vivo. Importantly, these induced effects 
even occur when there are only low amounts of pathogen present in the vessel wall, 
suggesting that inflammatory and immune responses to infections are more important 
in exaggerating the response to vascular injury than the pathogen itself. However 
further studies are required to unravel these exact underlying mechanisms.
Additionally we proved the potential effect of a new immunosuppressive, anti-
viral and anti-proliferative agent FK778 to prevent intimal hyperplasia and its ability 
to diminish the CMV induced effects rendering it a possible therapeutic candidate in 
the field of transplantation. In this thesis we also demonstrated gene therapy aiming 
at preventing intimal hyperplasia to be effective in reducing intimal hyperplasia as 
seen in venous graft failure. 
To conclude we and others demonstrated a causal role for infections in 
cardiovascular pathologies initiated by intimal hyperplasia and suggest that therapies 
aimed against these pathogens may diminish disease progression, unfortunately 
evidence arising from sero-epidemiologic and experimental studies still largely have 
to be proven in clinical trials.
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Summary
Intimal hyperplasia is considered to be the major determining factor limiting long 
term success after PTCA, venous bypass grafting and solid organ transplantation. 
Although the underlying cause is generally considered to be multifactorial, infections 
with C. pneumoniae and cytomegalovirus (CMV) have been proposed to be associated 
with intimal hyperplasia, especially in stimulating an already going process. 
Yet, sero-epidemiological studies demonstrating an association between C. 
pneumoniae or CMV and restenosis, venous graft failure and transplant arteriosclerosis 
show conflicting results. Moreover, the number of studies in which animal models 
have been used in order to investigate a more causal relationship between these 
two pathogens and intimal hyperplasia are scarce and results do not point in the 
same direction, thereby generating the need for additional research. In this thesis 
we tested the hypothesis that infections with C. pneumoniae and CMV affect the 
process of intimal hyperplasia and aimed to unravel the underlying mechanisms. For 
this purpose several animal models were used.
First we studied the effect of CMV infection on restenosis (Chapter 2). Using a 
well defined animal model of photochemically-induced endothelial denudation 
leading to intimal hyperplasia, a relationship was detected between the time point 
of CMV infection and its effect on SMC proliferation either in the media or in the 
neointima. When rats were infected immediately after injury a significant increase 
was observed on medial but not on neointimal cross sectional area. On the other 
hand, when rats were infected fourteen days after the initial injury, a significant 
increase was observed in the neointimal area. Also, the mean number of smooth 
muscle cells per μm2 in both cell layers was unchanged despite an increase in cross-
sectional area, which implies that CMV stimulated smooth muscle cell proliferation 
but not hypertrophy. Furthermore, these vascular effects were observed with only 
a few DNA copies of virus being present in the vascular wall as demonstrated by 
real time PCR. This suggests that indirect factors like inflammatory and immune-
mediated responses to CMV infection are more important in aggravating the response 
than direct vascular injury by the virus itself.
Thus, inspired by the observation that CMV aggravated intimal hyperplasia as 
seen in the process of restenosis, we hypothesized that similar effects might occur 
in intimal hyperplasia leading to venous bypass failure. In a study using an epigastric 
vein-to-common femoral artery interposition graft model, we evaluated the effect of 
CMV infection on intimal hyperplasia. Additionally we studied the potential effect of 
a new immunosuppressive, anti-viral and anti-proliferative agent FK778 to prevent 
intimal hyperplasia and its ability to diminish the CMV induced effects (Chapter 3). 
The results of this study revealed that CMV infection induced a significant increase 
in intimal cross-sectional area, medial cross-sectional area and medial wall thickness 
of the vein grafts, while this effect was diminished by administration of FK778. 
Moreover, FK778 treatment alone resulted in a significant decrease in neointimal 
area and stenosis rate vs. the control group but had no effect on medial cross-
sectional area or medial thickness. Interestingly, no significant differences in T-cell or 
macrophage influx observed. Likewise, cell counts revealed no significant differences 
in number of cells/µm2 between groups. Overall, these data suggested a role of CMV 
in venous graft failure as well as a role for the new immunosuppressive drug FK778 in 
the prevention of not only CMV-mediated vein graft intimal hyperplasia, but intima 
hyperplasia in general.
Next, we examined whether C. pneumoniae had an effect on venous bypass failure 
(Chapter 4). C. pneumoniae is an obligate intracellular Gram-negative bacterium 
which, like CMV, has frequently been associated with atherosclerosis. Using the 
epigastric vein-to-common femoral artery interposition graft rat model we were 
able to demonstrate that C. pneumoniae infection immediately after vein grafting 
resulted in a significant increase in medial cross-sectional area, wall thickness 
and total wall area. As with CMV, the mean number of cells/µm2 was not altered 
indicating that also in the case of C. pneumoniae the increase in area was caused by 
an increase in total cell number and not by cellular hypertrophy. This implicates that 
C. pneumoniae infection stimulated smooth muscle cell proliferation resulting in a 
significant increase in intimal hyperplasia hereby aggravating venous graft failure. 
We also tried to unravel the underlying mechanisms which may be responsible for 
this effect of C. pneumoniae. In vitro studies previously delineated an increased 
secretion of C-reactive protein (CRP) and heat shock protein 60 (HSP60) after 
infection of SMC with C. pneumoniae. These secreted proteins in turn may stimulate 
SMC proliferation. In our in vivo study we tried to confirm such relationship between 
C. pneumoniae, intimal hyperplasia, and presence of CRP and HSP60 in the venous 
graft. Also, the number of T-cells and macrophages were determined in the graft at 3 
weeks after surgery. Nonetheless, no significant differences in T-cell or macrophage 
influx were detected. Likewise, although positive immunostaining for both CRP and 
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HSP60 could be detected, no differences were found between groups. Thus, we were 
unable to confirm that either CRP or HSP60 plays a prominent role in the effects 
of C. pneumoniae on venous graft failure. Indicating that C. pneumoniae stimulates 
smooth muscle cell proliferation thereby aggravating intimal hyperplasia in venous 
grafts by hereunto unknown molecular mechanisms. 
Given the well established relationship between CMV and transplant 
arteriosclerosis we hypothesized that C. pneumoniae may also play a role in this 
process. To study this hypothesis we used the rat allograft model of orthotopic 
abdominal aorta transplantations (Chapter 5). Orthotopic abdominal aorta 
transplantations were performed with BN rats as donors and Lewis rats as recipients. 
Rats were sacrificed one or eight weeks after surgery to assess the presence of C. 
pneumoniae DNA, monocytes/macrophages and T-cells in the graft. Eight weeks 
after surgery grafts were also processed for morphometrical examination. One week 
after transplantation, the peri-vascular influx of inflammatory cells in the graft was 
not affected by C. pneumoniae infection. Furthermore, only limited numbers of C. 
pneumoniae DNA copies were found in the graft one week after transplantation. In 
addition, C. pneumoniae did not alter the severity of myointimal hyperplasia eight 
weeks after surgery. C. pneumoniae DNA was not present in the grafts at eight weeks 
after surgery. These data suggest that, in contrast to earlier observation with CMV, 
C. pneumoniae infection does not influence the influx of inflammatory cells or the 
severity of transplantation arteriosclerosis in the rat aortic allograft model.
Although with currently available pharmacotherapy a lot of cardiovascular 
diseases may be prevented and/or treated, some forms of cardiovascular disease are 
still difficult to prevent and/or treat. And despite some drawbacks in some early 
clinical trials, gene therapy is still accepted as being attractive and may open new 
ways for treatment and prevention. In our study we applied gene therapy in order to 
prevent intimal hyperplasia (chapter 6). Activin A is a member of the transforming 
growth factor-b superfamily and able to promote the contractile phenotype of smooth 
muscle cells. Maintaining the contractile SMC phenotype by adenoviral activin A over-
expression could prevent intimal hyperplasia and would represent a novel strategy 
to prevent venous graft failure. To examine the potential therapeutic of activin A in 
preventing venous graft failure we used the epigastric vein-to-common femoral artery 
interposition graft model in the rat. One group of rats was injected immediately 
after surgery with an adenoviral construct carrying the activin A gene resulting in 
an systemic over-expression of liver derived activin A. The other group was injected 
with an adenovirus carrying no insert. All animals were sacrificed three weeks after 
surgery and the grafts were harvested for morphometrical and immunohistochemical 
analysis for the presence of SMC. The amount of SMC proliferation was quantified 
using BrdU staining. Adenoviral activin A over-expression resulted in a significant 
decrease in intimal cross-sectional area and percentage stenosis as compared to the 
control group, Moreover, BrdU staining identified lower proliferation rates of the 
smooth muscle cells in the group treated with activin A indicating that overexpression 
of activin A may promote the contractile phenotype of these cells. This study shows 
for the first time evidence that activin A can diminish vein graft failure in a rat model 
supporting a novel strategy to prevent intimal hyperplasia.
In summary, in this thesis we provide supporting evidence that, besides multiple 
other factors, C. pneumoniae and CMV affect intimal hyperplasia in experimental 
animal models of restenosis and venous graft failure. On the other hand, in contrast 
to the established relation between CMV and transplant arteriosclerosis, our data 
suggest that C. pneumoniae is of no importance in the latter pathology. Furthermore, 
we were able to demonstrate the C. pneumoniae and CMV infections are able to 
stimulate SMC proliferation in vivo. Importantly, these infection-induced effects 
even occur when there are only low amounts of pathogen present in the vessel 
wall, suggesting that inflammatory and immune responses to micro-organisms are 
more important in exaggerating the response to vascular injury than the presence 
of pathogens itself. Nevertheless, additional studies are still needed to further 
elucidate the underlying mechanisms. Additionally we demonstrated that the new 
immunosuppressive, anti-viral and anti-proliferative agent FK778 may be useful in 
preventing intimal hyperplasia, rendering it a possible therapeutic candidate in the 
field of transplantation. Finally, we also demonstrated the feasibility of gene therapy 
in preventing intimal hyperplasia, as adenovirus-mediated overexpression of activin A 
significantly reduced intimal hyperplasia in our rat model of venous graft failure.
Samenvatting
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Samenvatting
Intima hyperplasie wordt beschouwd als de belangrijkste factor verantwoordelijk 
voor het limiteren van het lange termijn succes van PTCA, plaatsing van een veneuze 
bypass en orgaan transplantatie. Naast een groot aantal andere oorzaken welke 
gedurende de laatste decennia ontdekt zijn, wordt gesuggereerd dat bepaalde micro-
organismen, en met name cytomegalovirus (CMV) en Chlamydia pneumoniae, een 
rol spelen bij de verergering van intima hyperplasie. Echter, alhoewel verscheidene 
sero-epidemiologische studies een associatie beschrijven tussen C. pneumoniae en 
CMV enerzijds en restenose, veneuze bypass falen en transplantatie arteriosclerose 
anderzijds, zijn de resultaten niet eenduidend. Daarnaast zijn er slechts enkele 
dierexperimentele studies gepubliceerd waarin gekeken is naar een meer oorzakelijk 
verband tussen deze twee pathogenen en intima hyperplasia. Ook hier zijn de 
resultaten niet conclusief en zijn verdere studies noodzakelijk om meer duidelijkheid 
te krijgen omtrent de rol van micro-organismen binnen deze aandoening(-en). In deze 
thesis hebben we getracht met behulp van verschillende diermodellen de rol die C. 
pneumoniae en CMV spelen in intima hyperplasie te verhelderen en de onderliggende 
mechanismen te bestuderen.
 
Onderwerp van de eerste studie (Hoofdstuk 2) was de hypothese dat CMV infectie 
in staat is de mate van restenose te verergeren. In deze dierexperimentele studie werd 
in de grote beenslagader van de rat endotheelschade geïnduceerd wat vervolgens 
resulteerde in intima hyperplasie. Vervolgens werd het effect van een CMV infectie 
op de gladde spiercel proliferatie in de intima en media bestudeerd. Opmerkelijk 
was dat met name het moment van infecteren in belangrijke mate het effect van de 
infectie bepaalde. Wanneer ratten onmiddellijk na de ingreep werden geïnfecteerd 
werd er een significante toename gezien van de media oppervlakte maar niet van 
de intima oppervlakte. Anderzijds werd er een significante toename van alleen de 
intima oppervlakte gezien wanneer de ratten veertien dagen na de initiële endotheel 
beschadiging geïnfecteerd werden. In beide situaties bleef het totale aantal gladde 
spiercellen per μm2 in de vaatwand wel ongewijzigd hetgeen impliceert dat CMV de 
vermeerdering (”proliferatie”) van gladde spiercellen stimuleert maar niet de groei 
qua grootte (“hypertrofie”). Opvallend was dat deze vasculaire effecten werden 
waargenomen terwijl er maar enkele CMV DNA kopieën in de vaatwand konden 
worden aangetoond ondanks het feit dat gebruik gemaakt werd van een bijzonder 
gevoelige detectiemethode (real time PCR). Dit suggereert dat indirecte factoren 
zoals ontsteking en immuungemediëerde processen gericht tegen CMV belangrijker 
zijn voor het verergeren van de vaatwandschade dan de directe lokale aanwezigheid 
van het virus zelf. 
Geïnspireerd door de waarneming dat CMV intima hyperplasie verergert bij 
restenose ontstond de hypothese dat soortgelijke effecten wellicht ook een rol 
zouden kunnen spelen bij intima hyperplasie leidend tot het falen van een veneuze 
bypass. Gebruikmakend van een model waarbij we een stukje van een vene plaatsten 
in de beenslagader van de rat hebben we het effect van CMV infectie op intima 
hyperplasie in een veneuze bypass bestudeerd. Daarnaast hebben we gekeken in 
hoeverre een nieuw medicijn (FK778), waarvan de werking verondersteld wordt 
3-voudig te zijn (onderdrukking van het immuunsysteem, antiviraal en remming van 
de vermeerdering van gladde spiercellen in de vaatwand), in staat was om intima 
hyperplasie te voorkomen en de door CMV geïnduceerde effecten te verminderen 
(Hoofdstuk 3). Resultaten van deze studie gaven aan dat infecties met CMV leiden tot 
een significante toename van intima oppervlakte, media oppervlakte en media dikte 
hetgeen grotendeels tenietgedaan werd door behandeling met FK778. Behandeling 
met enkel FK778 gaf reeds een significante vermindering van de intima oppervlakte 
maar had geen effect op media oppervlakte en media dikte. Opmerkelijk was dat 
er geen verschil in de hoeveelheid T-cellen of macrofagen in de vaatwand werd 
gezien. Ook werden er geen significante verschillen tussen de groepen gevonden met 
betrekking tot het aantal cellen per µm2 vaatwandoppervlakte. Op basis van deze 
resultaten kan geconcludeerd worden dat CMV mogelijk ook een rol speelt bij het 
falen van een veneuze bypass. Daarnaast tonen ze aan dat FK778 een veelbelovend 
nieuw middel kan zijn bij het voorkomen intima hyperplasie in het algemeen.
Vervolgens hebben we gekeken of C. pneumoniae het falen van een veneuze 
bypass kan beïnvloeden (Hoofdstuk 4). C. pneumoniae is een intracellulaire Gram-
negatieve bacterie die evenals CMV frequent geassocieerd wordt met atherosclerose. 
Gebruikmakend van het eerder beschreven ratmodel, waarbij een klein stukje vene 
in de grote beenslagader werd gehecht, konden we aantonen dat een infectie met 
C. pneumoniae onmiddellijk na de operatie resulteerde in een significante toename 
van media oppervlakte, totale vaatwand oppervlakte en vaatwand dikte. Ook in deze 
experimenten bleef het totale aantal cellen per µm2 ongewijzigd. Dit wijst erop dat 
ook in het geval van C. pneumoniae de toename in oppervlakte veroorzaakt wordt 
door een toename van het aantal cellen (hyperplasie) en niet door een toename van 
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de celgrootte (hypertrofie). We hebben ook gekeken naar mogelijke mechanismen 
waardoor C. pneumoniae het falen van een veneuze bypass kan beïnvloeden. Eerdere 
in vitro studies wezen op een toegenomen productie ven het zogenaamde C-reactive 
proteïne (CRP) en heat shock proteïne 60 (HSP60) na infectie van gladde spiercellen 
met C. pneumoniae. Deze eiwitten kunnen op zichzelf gladde spiercel proliferatie 
stimuleren. In onze in vivo studie hebben we geprobeerd om deze mogelijke relatie 
tussen C. pneumoniae, intima hyperplasie en aanwezigheid van CRP of HSP60 in de 
veneuze bypass aan te tonen. Tevens hebben we gekeken naar de aanwezigheid van 
T-cellen en macrofagen in the veneuze bypass drie weken na de ingreep. Hierbij 
werden echter geen significante verschillen gevonden in het aantal T-cellen of 
macrofagen. Evenmin werden er verschillen gevonden tussen de groepen wat betreft 
de aanwezigheid van CRP of HSP60, ondanks het feit dat er aanwijzingen gevonden 
werden dat beide eiwitten daadwerkelijk aanwezig waren in de vaatwand. Derhalve 
hebben we in vivo niet kunnen bevestigen dat CRP danwel HSP60 een prominente rol 
speelt bij de effecten van C. pneumoniae op veneuze bypass falen. Concluderend 
kunnen we zeggen dat C. pneumoniae de poliferatie van gladde spiercellen stimuleert 
wat vervolgens kan bijdragen aan het falen van een veneuze bypass door tot nu toe 
onbekende moleculaire mechanismen. 
In het licht van deze resultaten en gebaseerd op de bekende relatie tussen 
CMV en transplantatie arteriosclerose is de hypothese ontstaan dat C. pneumoniae 
ook bij deze vasculaire aandoening wel eens een rol zou kunnen spelen. Om dit te 
bestuderen hebben we gebruik gemaakt van een diermodel waarbij een stukje van 
de aorta (‘graft”) van een donor rat getransplanteerd werd naar een ontvanger. 
(Hoofdstuk 5). Aorta transplantaties werden verricht met Brown Norway ratten als 
donor en Lewis ratten als ontvanger, waarbij als gevolg van weefselincompatibiliteit 
na enige tijd in de getransplanteerde graft intima hyperplasia zal ontstaan. Deze 
ratten werden op een of acht weken na de operaties ge-euthaniseerd waarna er werd 
gekeken naar de aanwezigheid van C. pneumoniae DNA, monocyten/macrofagen en 
T-cellen in de graft. Tevens werden de grafts acht weken na transplantatie verwerkt 
voor morfometrisch onderzoek. Een week na transplantatie was er geen effect van 
C. pneumoniae infectie op de perivasculaire aanwezigheid van ontstekingscellen. 
Daarnaast werd er slechts een geringe hoeveelheid C. pneumoniae DNA kopieën terug 
gevonden in de graft een week na transplantatie. Evenmin had een C. pneumoniae 
infectie een effect op de ernst van myointimale hyperplasie acht weken na chirurgie. 
C. pneumoniae DNA was op dat moment niet meer aanwezig in de grafts. Deze data 
suggereren dat in tegenstelling tot CMV, C. pneumoniae infectie geen invloed heeft 
op de instroom van ontstekingscellen in de graft noch op de ernst van transplantatie 
arteriosclerose in het rat aorta transplantatie model.
 
Alhoewel er met de huidige beschikbare medicijnen reeds vele cardiovasculaire 
aandoeningen voorkomen of behandeld kunnen worden, zijn er nog altijd 
verschillende “therapie-resistente” hart- en vaataandoeningen. Gen therapie wordt 
ondanks wat tegenslagen in vroegere klinische studies nog altijd beschouwd als een 
nieuwe en aantrekkelijke therapeutische strategie in behandeling en preventie 
van ziekten. In onze studie hebben we dan ook gentherapie gebruikt om intima 
hyperplasie te voorkomen (Hoofdstuk 6). Activin A is lid van de transforming growth 
factor-b superfamilie en is in staat om gladde spiercellen in een gedifferentieerd, 
contractiel fenotype te houden. Het voorkomen van intima hyperplasie middels het 
voorkomen van gladde spiercel de-differentiatie zou een nieuwe methode kunnen 
zijn om veneuze bypass falen te verhinderen. Om het therapeutisch vermogen van 
activin A te testen hebben we gebruik gemaakt van het eerder genoemde rat model 
waarbij we een stukje vene plaatsten in de beenslagader. Eén groep ratten werd 
direct na de operatie geïnjecteerd met een adenoviraal construct welke het activin 
A gen met zich meedroeg. Dit resulteert in systemische overexpressie van het in de 
lever gemaakte activin A. De andere groep werd geïnjecteerd met een adenovirus 
zonder construct. Alle dieren werden drie weken na chirurgie ge-euthaniseerd en 
grafts werden verwerkt voor morfometrisch onderzoek en immunohistochemische 
kleuringen voor de aanwezigheid van gladde spiercellen. De mate van gladde spiercel 
proliferatie werd bepaald door BrdU kleuring. Adenovirale over-expressie van activin 
A resulteerde in een significante afname van intima oppervlakte en percentage 
stenose ten opzichte van de controle groep. Tevens toonde BrdU kleuring aan dat de 
mate van gladde spiercel proliferatie lager was in de met activin A behandelde groep, 
hetgeen er op wijst dat activin A in staat is gladde spiercellen in hun contractiele fase 
te houden. Deze studie toont dan ook voor het eerst aan dat gen therapie met activin 
A een mogelijke nieuwe strategie kan zijn om intima hyperplasie en veneuze graft 
falen te verminderen. 
Samenvattend hebben we in deze thesis aangetoond dat, naast meerdere 
andere factoren, C. pneumoniae en CMV een rol spelen bij intima hyperplasie in 
experimentele diermodellen van restenose en veneuze graft falen. Aan de ander kant 
geven onze data, in tegenstelling tot de bekende relatie tussen CMV en transplantatie 
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arteriosclerose, geen bewijs voor een link tussen C. pneumoniae en deze pathologie. 
Daarnaast hebben we aangetoond dat C. pneumoniae en CMV infecties in staat zijn 
gladde spiercel proliferatie te stimuleren in vivo. Belangrijk hierbij is dat de infectie 
geïnduceerde effecten optreden terwijl er slechts geringe hoeveelheden pathogenen 
in de vaatwand aanwezig zijn. Dit suggereert dat onstekings en immunologische 
reacties gericht tegen de micro-organismen belangrijker zijn voor het stimuleren van 
intima hyperplasie dan de lokale aanwezigheid van het pathogeen zelf. Aanvullende 
studies naar de mogelijke onderliggende mechanismen zijn echter nog noodzakelijk. 
Tevens hebben we aangetoond dat het nieuwe immunosuppressieve, antivirale 
en antiproliferatieve medicijn FK778 functioneel is in het voorkomen van intima 
hyperplasie, hetgeen het een aantrekkelijke kandidaat maakt voor gebruik op het 
gebied van transplantatie. Tot slotte hebben we aangetoond dat gen therapie met 
activin A werkt ter vermindering van intima hyperplasie in ons rat model van veneuze 
graft falen.
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Figure 3.2 | Showing typical examples of venous grafts cross-sections 21 days after grafting. 
A) Lawson staining venous graft control group, B) Lawson staining venous graft CMV infected 
group, C) ED-1 monocyte macrophage staining. I = Intima, M = Media, A = Adventitia. (see page 
78 for gray picture)
Figure 4.2| Photomicrographs showing subsequent immunolabeling of a venous bypass 
graft 3 weeks after surgery (A: CRP, C:HSP60) as well as their representative negative 
controls (B,D). (see page 93 for gray picture)
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Figure 5.1 | Photomicrographs of rat aortic allograft 1 week after transplantation. ED-1 
immunoperoxidase staining against monocytes/macrophages. A) Allogeneic group with 
C. pneumoniae infection 24 hours after transplantation. B) Allogeneic control group. No 
statistical significant differences were observed. (see page 105 for gray picture)
Figure 5.2 | Representative photomicrographs of 
rat aortic grafts weeks after transplantation. Lawson 
staining. A) syngeneic group B) allogeneic control group 
C) allogeneic group with C. pneumoniae infection 24 
hours after transplantation. (see page 106 for gray 
picture)
Figure 6.2 | (A) Alpha-actin smooth muscle cell staining of cross-section of the vein graft 
three weeks after surgery, activin A group. (B). Semiquantative analysis of proliferation 
measured by BrdU staining. Bars stand for number of sections representing indicated 
amount of proliferation. (see page 121 for gray picture)
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